

## TITLE

Clinical Practice Guideline: Benign Paroxysmal Positional Vertigo (Update)

## AUTHORS

Neil Bhattacharyya, MD, FACS<sup>1</sup>, Samuel P. Gubbels, MD, FACS<sup>2</sup>, Seth R. Schwartz, MD, MPH<sup>3</sup>, Jonathan A. Edlow, MD<sup>4</sup>, Hussam El-Kashlan, MD<sup>5</sup>, Terry Fife, MD<sup>6</sup>, Janene M. Holmberg, PT, DPT, NCS<sup>7</sup>, Kathryn Mahoney<sup>8</sup>, Deena B. Hollingsworth, MSN, FNP-BC, CORLN<sup>9</sup>; Richard Roberts, PhD<sup>10</sup>, Michael D. Seidman, MD, FACS<sup>11</sup>, Robert Wm. Prasaad Steiner, MD, PhD, FAAFP<sup>12</sup>, Betty Tsai-Do, MD<sup>13</sup>, Courtney C. J. Voelker, MD, PhD<sup>14</sup>, Richard W. Waguespack, MD<sup>15</sup>, Maureen D. Corrigan<sup>16</sup>

## AUTHOR INFORMATION

<sup>1</sup> Harvard Medical School, Brigham & Women's Hospital, Department of Otolaryngology; <sup>2</sup> University of Colorado School of Medicine and Public Health, Department of Otolaryngology; <sup>3</sup> Virginia Mason Medical Center, Department of Otolaryngology; <sup>4</sup> Department of Emergency Medicine, Beth Israel Deaconess Medical Center; <sup>5</sup> University of Michigan Department of Otolaryngology; <sup>6</sup> Barrow Neurological Institute & University of Arizona College of Medicine; <sup>7</sup> Intermountain Hearing and Balance Center; <sup>8</sup> Vestibular Disorders Association; <sup>9</sup> Ear, Nose & Throat Specialists of Northern Virginia, P.C.; <sup>10</sup> Alabama Hearing and Balance Associates, Inc.; <sup>11</sup> University of Central Florida College of Medicine, Department of Otolaryngology—Head and Neck Surgery; <sup>12</sup> University of Louisville School of Public Health and Information Science, Department of Health Management and Systems Science & Department of Family and Geriatric Medicine; <sup>13</sup> University of Oklahoma Health Sciences Center, Department of Otorhinolaryngology; <sup>14</sup> Northwestern University Feinberg School of Medicine, Department of Otolaryngology—Head and Neck Surgery; <sup>15</sup> University of Alabama Birmingham,

Department of Otolaryngology; <sup>16</sup> American Academy of Otolaryngology—Head and Neck  
Surgery

## **AUTHOR CONTRIBUTIONS**

**Neil Bhattacharyya**, writer, chair; **Samuel P. Gubbels**, writer, assistant chair; **Seth R. Schwartz**, writer, methodologist; **Jonathan A. Edlow**, writer; **Hussam El-Kashlan**, writer; **Terry Fife**, writer; **Janene M. Holmberg**, writer; **Kathryn Mahoney**, writer; **Deena B. Hollingsworth**, writer; **Richard Roberts**, writer; **Michael D. Seidman**, writer; **Robert Wm. Prasaad Steiner**, writer; **Betty Tsai-Do**, writer; **Courtney C. J. Voelker**, writer; **Richard W. Waguespack**, writer; **Maureen D. Corrigan**, writer, AAO-HNSF staff liaison.

## **Differences from Prior Guideline**

This clinical practice guideline is as an update, and replacement, for an earlier guideline published in 2008 by the American Academy of Otolaryngology – Head and Neck Surgery Foundation. (Bhattacharyya et al, 2008)) An update was necessitated by new primary studies and systematic reviews that might suggest a need for modifying clinically important recommendations. Changes in content and methodology from the prior guideline include:

- Addition of a patient advocate to the guideline development group
- New evidence from 2 clinical practice guidelines, 20 systematic reviews, and 27 randomized controlled trials
- Emphasis on patient education and shared decision-making
- Expanded action statement profiles to explicitly state quality improvement opportunities, confidence in the evidence, intentional vagueness, and differences of opinion

- Enhanced external review process to include public comment and journal peer review
- New algorithm to clarify decision making and action statement relationships
- New recommendation regarding canalith repositioning post-procedural restrictions.
- Expansion of the recommendations regarding radiographic and vestibular testing.
- Removal of the “no recommendation” for audiometric testing.
- A diagnostic and treatment visual algorithm was added.

## INTRODUCTION

A primary complaint of dizziness accounts for 5.6 million clinic visits in the United States per year and between 17 and 42% of patients with vertigo ultimately receive a diagnosis of benign paroxysmal positional vertigo (Shappert 1992; Katsarkas 1999; Hanley et al., 2001).

Benign paroxysmal positional vertigo (BPPV) is a form of positional vertigo.

- *Vertigo* is defined as an illusory sensation of motion of either the self or the surroundings in the absence of true motion.
- *Positional vertigo* is defined as a spinning sensation produced by changes in head position relative to gravity.
- *Benign paroxysmal positional vertigo* is defined as a disorder of the inner ear characterized by repeated episodes of positional vertigo (Table 1).

Traditionally, the terms "benign" and "paroxysmal" have been used to characterize this particular form of positional vertigo. In this context, the descriptor *benign* historically implies that BPPV was a form of positional vertigo not due to any serious central nervous system (CNS) disorder and that there was an overall favorable prognosis for recovery. (Baloh et al 1987). This favorable prognosis is based in part on the fact that BPPV can recover spontaneously in

approximately 20% of patients by one month of follow up and up to 50% at 3 months (Lynn 1995; Burton et al, 2012) However, the clinical and quality-of-life impacts of undiagnosed and untreated BPPV may be far from "benign", as patients with BPPV are at increased risk for falls and impairment in the performance of daily activities (Lopez-Escamez et al, 2005). Furthermore, patients with BPPV experience effects on individual health-related quality of life and utility measures demonstrate that treatment of BPPV results in improvement in quality of life. (Roberts, et al, 2009). The term *paroxysmal* in this context describes the rapid and sudden onset of the vertigo initiated at any time by a change of position thus resulting in BPPV. BPPV has also been termed: benign positional vertigo, paroxysmal positional vertigo, positional vertigo, benign paroxysmal nystagmus, and paroxysmal positional nystagmus. In this guideline, the panel chose to continue to retain the terminology of BPPV as it is the most common terminology encountered in the literature and in clinical practice (Lopez-Escamez et al, 2005).

BPPV is most commonly clinically encountered as one of two variants: BPPV of the posterior semicircular canal (posterior canal BPPV) or BPPV of the lateral semicircular canal (also known as horizontal canal BPPV). (White et al 2005; Cakir et al 2006; Parnes et al 2003) Posterior canal BPPV is more common than horizontal canal BPPV, constituting approximately 85-95% of BPPV cases. (Parnes et al, 2003) Although debated, posterior canal BPPV is most commonly thought to be due to canalithiasis, wherein fragmented otolith particles (otoconia) entering the posterior canal become displaced and cause inertial changes to the cupula in the posterior canal and thereby resulting in abnormal nystagmus and vertigo when the head encounters motion in the plane of the affected semicircular canal.( Parnes et al, 2003; Parnes & McClure, 1992) Lateral (horizontal) canal BPPV accounts for between 5% and 15% of BPPV cases. (Cakir et al, 2006; Parnes et al, 2003) The etiology of lateral canal BPPV is also felt to be

due to the presence of abnormal debris within the lateral canal, but the pathophysiology is not as well understood as that of posterior canal BPPV. Other rare variations include anterior canal BPPV, multi-canal BPPV, and bilateral multi-canal BPPV.

**Table 1. Definitions of common terms**

| Term  | Definition   |
|---|--|
| Vertigo                                     | An illusory sensation of motion of either the self or the surroundings in the absence of true motion.  |
| Nystagmus                                   | A rapid, involuntary, oscillatory movement of the eyeball.   |
| Vestibular system/apparatus                 | The sensory system within the inner ear that together with the vestibular nerve and its connections in the brain provides the fundamental input to the brain regarding balance and spatial orientation.      |
| Positional vertigo                          | Vertigo produced by changes in the head position relative to gravity   |
| Benign paroxysmal positional vertigo (BPPV) | A disorder of the inner ear characterized by repeated episodes of positional vertigo.  |
| Posterior canal BPPV                        | A form of BPPV in which dislodged inner ear particles in the posterior semicircular canal abnormally influence the balance system producing the vertigo, most commonly diagnosed with the Dix-Hallpike test. |
| Lateral canal BPPV                          | A form of BPPV in which dislodged inner ear particles in the lateral semicircular canal abnormally influence the balance system producing the vertigo, most commonly diagnosed by the supine roll test.      |

|   |   |
|---|---|
| Canalithiasis                           | A theory for the pathogenesis of BPPV that proposes that there are free-floating particles (otoconia) that have moved from the utricle and collect near the cupula of the affected canal, causing forces in the canal leading to abnormal stimulation of the vestibular apparatus.  |
| Cupulolithiasis                         | A theory for the pathogenesis of BPPV that proposes that otoconial debris attached to the cupula of the affected semicircular canal cause abnormal stimulation of the vestibular apparatus.   |
| Canalith repositioning procedures (CRP) | A group of procedures in which the patient moves through specific body positions designed to relocate dislodged particles within the inner ear for the purpose of relieving symptoms of BPPV. The specific CRP chosen relates to the type of BPPV diagnosed. These have also been termed canalith repositioning maneuvers or canalith repositioning techniques. |

## GUIDELINE PURPOSE

The primary purposes of this guideline are to improve quality of care and outcomes for BPPV by improving the accurate and efficient diagnosis of BPPV, reducing the inappropriate use of vestibular suppressant medications, decreasing the inappropriate use of ancillary testing such as radiographic imaging and increasing the use of appropriate therapeutic repositioning maneuvers. The guideline is intended for all clinicians who are likely to diagnose and manage patients with BPPV, and applies to any setting in which BPPV would be identified, monitored, or managed. The target patient for the guideline is aged 18 years or older with a suspected or potential diagnosis of BPPV. The pediatric population was not included in the target population in part due to substantially smaller body of evidence on pediatric BPPV. No specific recommendations are made concerning surgical therapy for BPPV.

The guideline will focus on BPPV, recognizing that BPPV may arise in conjunction with other neurologic or otologic conditions, and that the treatment of the symptom components specifically related to BPPV may still be managed according to the guideline. This guideline will not discuss BPPV affecting the anterior semicircular canal, as this diagnosis is quite rare and its pathophysiology is poorly understood (Kim et al, 2014; Jackson et al, 2007) It will also not discuss benign paroxysmal vertigo of childhood, disabling positional vertigo due to vascular loop compression in the brainstem, or vertigo that arises from changes in head position *not* related to gravity (i.e. vertigo of cervical origin or vertigo of vascular origin). These conditions are physiologically distinct from BPPV.

In 2008, the American Academy of Otolaryngology-Head and Neck Surgery published a multidisciplinary clinical practice guideline: benign positional vertigo (Bhattacharyya et al, 2008). As eight years have elapsed since the publication of that guideline, a multidisciplinary guideline update group was convened to perform an assessment and planned update of that guideline utilizing the most current evidence base. Our goal was to revise the prior guideline with an a priori determined, transparent process, reconsidering a more current evidence base while also taking into account advances in knowledge with respect to BPPV.

The primary outcome considered in this guideline is the resolution of the symptoms associated with BPPV. Secondary outcomes considered include an increased rate of accurate diagnoses of BPPV, a more efficient return to regular activities and work, decreased use of inappropriate medications and unnecessary diagnostic tests, reduction in recurrence of BPPV and reduction in adverse events associated with undiagnosed or untreated BPPV. Other outcomes considered include minimizing costs in the diagnosis and treatment of BPPV, minimizing potentially unnecessary return physician visits and maximizing the health-related quality of life

of individuals afflicted with BPPV. The significant incidence of BPPV, its functional impact and the wide diversities of diagnostic and therapeutic interventions for BPPV (Table 2) make this an important condition for an up-to-date evidence-based practice guideline.

**Table 2. Interventions considered in BPPV guideline development.**

|           |   |
|-----------|---|
| Diagnosis | clinical history<br>review of the medication list<br>physical examination<br>Dix Hallpike (positional) testing<br>Supine roll test and Bow and lean test side-lying maneuver<br>post head shaking nystagmus<br>audiometry<br>magnetic resonance imaging<br>computed tomography<br>blood tests: complete blood count, serum chemistry, etc.<br>frenzel lenses and infrared goggle testing<br>electronystagmography<br>videonystagmography<br>vestibular evoked myogenic potentials<br>balance and gait testing<br>vestibular function testing<br>computerized posturography<br>orthostatic balance testing<br>vestibular caloric testing |
|-----------|---|



|            |  |
|------------|--|
| Treatment  | watchful waiting/observation<br>education/information/counseling<br>medical therapy (vestibular suppressant medications, benzodiazepines)<br>cervical immobilization with cervical collar<br>prolonged upright position<br>patient self-treatment with home-based maneuvers or rehabilitation<br>Brandt-Daroff exercises<br>Epley maneuver and modifications of the Epley maneuver<br>Semont maneuver<br>Gufoni maneuver<br>physical therapy/vestibular physical therapy<br>spinal manipulative therapy<br>mastoid vibration<br>posterior semicircular canal occlusion (excluded from guideline)<br>singular neurectomy (excluded from guideline)<br>vestibular neurectomy (excluded from guideline) |
| Prevention | head trauma or whiplash injury as potential causative factors<br>use of helmets to prevent head trauma and/or cervical collars<br>fall prevention  |

## HEALTHCARE BURDEN

Overall, the prevalence of BPPV has been reported to range from 10.7 to 140 per 100,000 population (Mizukoshi et al, 1984; Froehling et al, 1991, van der Zaag-Loonen et al. 2015) however studies of select patients have estimated a prevalence of 900 per 10,000 (Oghalai et al, 2000, Kollen et al, 2012, Kerrigan et al, 2013). Others have reported a lifetime prevalence of 2.4%, a one-year prevalence of 1.6% and a one-year incidence of 0.6%. (von Brevern et al, 2007) Women are more frequently affected than men with a female:male ratio of 2.2 to 1.5:1 (Neuhauser and Lempert, 2009). BPPV is also the most common vestibular disorder across the

lifespan, (Parnes et al, 2003; Nedzelski et al, 1986; Neuhauser, 2007) although the age of onset is most commonly between the fifth and seventh decades of life. (Baloh et al, 1987) Given the noteworthy prevalence of BPPV, its health-care and societal impacts are tremendous.

The costs to the health-care system and the indirect costs of BPPV are also significant. It is estimated that it costs approximately \$2000 to arrive at the diagnosis of BPPV and that greater than 65% of patients with this condition will undergo potentially unnecessary diagnostic testing or therapeutic interventions (Wang, et al, 2014). Therefore, healthcare costs associated with the diagnosis of BPPV alone approach \$2 billion per year. Furthermore despite the fact that the natural history of BPPV includes a spontaneous resolution rate ranging from 27 to 50%, this often takes a significant amount of time and almost 86% of patients with BPPV will suffer some interrupted daily activities and lost days at work due to BPPV.(von Brevern et al, 2007; Li et al, 2000) In addition, 68% of patients with BPPV will reduce their workload while 4% will change their job and 6% will quit their job as a result of the condition (Benecke et al 2014). Furthermore, BPPV is more common in older individuals with a correspondingly more pronounced health and quality-of-life impact. It has been estimated that 9% of elderly patients undergoing comprehensive geriatric assessment for non-balance related complaints have unrecognized BPPV. (Oghalai et al, 2000). More recent studies of symptomatic individuals have found BPPV to be present in 40% of geriatric patients seen for dizziness (Ekvall et al 2005; Katsarkas 2008) Others have found a cumulative lifetime incidence of BPPV of approximately 10% with a prevalence of 3.4% of those over age 60. (von Brevern et al, 2007).

Older patients with BPPV experience a greater incidence of falls, depression and impairments of their daily activities. (Oghalai et al, 2000) Furthermore, falls can cause secondary injury including fractures or brain injury and may lead to unplanned hospital and nursing home

admission. Persistent untreated or undiagnosed vertigo in the elderly leads to increased caregiver burden with resultant societal costs including decreased family productivity and increased risk of nursing home placement. Among an estimated 7.0 million elderly individuals reporting dizziness in the prior 12 months, 2.0 million (30.1%) reported vertigo and there were 230,000 office visits among the elderly with a diagnosis of BPPV. (Lin & Bhattacharyya, 2012; Lin & Bhattacharyya, 2011) With the increasing age of the United States population, the incidence and prevalence of BPPV may correspondingly increase over the next 20 years.

BPPV may be diagnosed and treated by multiple clinical disciplines. Despite its significant prevalence, quality of life and economic impacts, considerable practice variations exist in the management of BPPV across disciplines. (Lawson et al, 2005) These variations relate to both diagnostic strategies for BPPV, timeliness of referral and rates of utilization of various treatment options available for BPPV within and across the various medical specialties and disciplines involved in its management. For example, the utilization of medications for the treatment of BPPV vary substantially among primary care providers and across specialties (Fife et al, 2005) Delays in the diagnosis and treatment of BPPV have both cost and quality-of-life implications for both patients and their caregivers.

Fife and colleagues found that patients with BPPV suffer from delays in diagnosis and treatment on the order of months. (Fife et al, 2005) Other authors have found that only 10-20% of patients with BPPV seen by a physician will receive appropriate repositioning maneuvers (von Brevern 2004, von Brevern 2007). Furthermore, a large number of patients with BPPV will undergo unnecessary diagnostic testing and treatments prior to referral to a specialist. A recent study reported that 70% of patients with BPPV will undergo MRI scanning, 45% will have a CT scan and 41% will have an EKG while 53% will be treated with medications. (Grill et al, 2014)

Therefore, significant improvements in the diagnosis and treatment of patients with BPPV may lead to significant healthcare quality improvements as well as medical and societal cost savings. Such improvements may be achievable with the composition and implementation of a well-constructed clinical practice guideline for BPPV.

## **METHODS**

### General methods and literature search

In developing this update of the evidence-based clinical practice guideline, the methods outlined in the AAO-HNSF Guideline Development Manual, 3<sup>rd</sup> edition were followed explicitly. (Rosenfeld, et al, 2013)

An executive summary of the original BPPV guideline (Bhattacharyya 2008) was sent to a panel of expert reviewers from the fields of general otolaryngology, otology, neurotology, neurology, family practice, nursing, physical therapy, emergency medicine, radiology, audiology, and complimentary medicine who assessed the key action statements to decide if they should be kept in their current form, revised, or removed, and to identify new research that might affect the guideline recommendations. The reviewers concluded that the original guideline action statements remained valid but should be updated with minor modifications. Suggestions were also made for new key action statements.

An information specialist conducted two systematic literature searches using a validated filter strategy to identify clinical practice guidelines, systematic reviews, and randomized controlled trials (RCTs) published since the prior guideline (2008). Search terms used were "Benign Paroxysmal Positional Vertigo"[Mesh] OR "Benign Paroxysmal Positional Vertigo"[tab] OR

"Benign Positional Vertigo"[tiab] OR BPPV[tiab] OR (BPV[tiab] AND vertigo). In certain instances, targeted searches for lower level evidence were performed to address gaps from the systematic searches identified in writing the guideline. The original search was updated from January 2008 to September 2015 to include Medline, National Guidelines Clearinghouse, Canadian Medical Association (CMA) Database, NHS Evidence ENT and Audiology, National Institutes for Health and Care Excellence UK, Australian National Health and Medical Research Council, Guideline Internal Network, Cochrane Database of Systematic Reviews, Excerpta Medica database (EMBASE), Cumulative Index to Nursing and Allied Health (CINAHL), Web of Science, and the Allied and Complimentary Medicine Database (AMED).

1. The initial search for clinical practice guidelines identified two guidelines. Quality criteria for including guidelines were (a) an explicit scope and purpose, (b) multidisciplinary stakeholder involvement, (c) systematic literature review, (d) explicit system for ranking evidence, and (e) explicit system for linking evidence to recommendations. The final dataset retained two guidelines that met inclusion criteria.
2. The initial search for systematic reviews identified 44 systematic reviews or meta-analyses that were distributed to the panel members. Quality criteria for including reviews were (a) relevance to the guideline topic, (b) clear objective and methodology, (c) explicit search strategy, and (d) valid data extraction methods. The final data set retained was 20 systematic reviews or meta-analyses that met inclusion criteria.
3. The initial search for RCTs identified 38 RCTs that were distributed to panel members for review. Quality criteria for including RCTs were (a) relevance to the guideline topic, (b) publication in a peer-reviewed journal, and (c) clear methodology with randomized allocation to treatment groups. The total final data set retained 27 RCTs that met

inclusion criteria.

The AAO-HNSF assembled a guideline update group (GUG) representing the disciplines of otolaryngology – head and neck surgery, otology, neurotology, family medicine, audiology, emergency medicine, neurology, physical therapy, advanced practice nursing, and consumer advocacy. The GUG had several conference calls and one in-person meeting during which they defined the scope and objectives of updating the guideline, reviewed comments from the expert panel review for each key action statement, identified other quality improvement opportunities, and reviewed the literature search results.

The evidence profile for each statement in the earlier guideline was then converted into an expanded action statement profile for consistency with our current development standards. (Rosenfeld 2013) Information was added to the action statement profiles regarding the quality improvement opportunity to which the action statement pertained, the guideline panel's level of confidence in the published evidence, differences of opinion among panel members, intentional vagueness, and any exclusion to which the action statement does not apply. New key action statements were developed using an explicit and transparent a priori protocol for creating actionable statements based on supporting evidence and the associated balance of benefit and harm. Electronic decision support (BRIDGE-Wiz, Yale Center for Medical Informatics, CT) software was used to facilitate creating actionable recommendations and evidence profiles (Shiffman 2012).

The updated guideline then underwent Guideline Implementability Appraisal (GLIA) to appraise adherence to methodologic standards, to improve clarity of recommendations, and to predict potential obstacles to implementation (Shiffman, et al 2005). The GUG received

summary appraisals and modified an advanced draft of the guideline based on the appraisal. The final draft of the updated clinical practice guideline was revised based on comments received during multidisciplinary peer review, open public comment, and journal editorial peer review. A scheduled review process will occur at five years from publication, or sooner if new compelling evidence warrants earlier consideration.

#### Classification of evidence-based statements

##### *Classification of evidence-based statements*

Guidelines are intended to reduce inappropriate variations in clinical care, to produce optimal health outcomes for patients, and to minimize harm. The evidence-based approach to guideline development requires that the evidence supporting a policy be identified, appraised, and summarized and that an explicit link between evidence and statements be defined.

Evidence-based statements reflect both the *quality of evidence* and the *balance of benefit and harm* that is anticipated when the statement is followed. The definitions for evidence-based statements are listed in Tables 3 and 4.

**Table 3.** Strength of action terms in guideline statements and implied levels of obligation

| Strength | Definition | Implied obligation |
|----------|------------|--------------------|
|----------|------------|--------------------|

|                       |   |  |
|-----------------------|---|--|
| Strong Recommendation | A strong recommendation means the benefits of the recommended approach clearly exceed the harms (or, in the case of a strong negative recommendation, that the harms clearly exceed the benefits) and that the quality of the supporting evidence is high (Grade A or B)*. In some clearly identified circumstances, strong recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits strongly outweigh the harms. | Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present.           |
| Recommendation        | A recommendation means the benefits exceed the harms (or, in the case of a negative recommendation, that the harms exceed the benefits), but the quality of evidence is not as high (Grade B or C)*. In some clearly identified circumstances, recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits outweigh the harms.   | Clinicians should also generally follow a recommendation, but should remain alert to new information and sensitive to patient preferences. |



|        |   |   |
|--------|---|---|
| Option | An option means that either the quality of evidence is suspect (Grade D)* or that well-done studies (Grade A, B, or C)* show little clear advantage to one approach versus another. | Clinicians should be flexible in their decision making regarding appropriate practice, although they may set bounds on alternatives; patient preference should have a substantial influencing role. |
|--------|---|---|

\*See Table 4 for definitions of evidence grades

**Table 4.** Aggregate grades of evidence by question type\*

| Grade    | CEBM level | Treatment   | Harm  | Diagnosis   | Prognosis   |
|----------|------------|---|---|---|---|
| <b>A</b> | 1          | Systematic review <sup>‡</sup> of randomized trials   | Systematic review <sup>‡</sup> of randomized trials, nested case-control studies, or observational studies with dramatic effect <sup>‡</sup>                    | Systematic review <sup>‡</sup> of cross-sectional studies with consistently applied reference standard and blinding                 | Systematic review <sup>‡</sup> of inception cohort studies <sup>‡</sup>   |
| <b>B</b> | 2          | Randomized trials, or observational studies with dramatic effects or highly consistent evidence     | Randomized trials, or observational studies with dramatic effects or highly consistent evidence   | Cross-sectional studies with consistently applied reference standard and blinding   | Inception cohort studies <sup>‡</sup>   |
| <b>C</b> | 3-4        | Non-randomized or historically controlled studies, including case-control and observational studies | Non-randomized controlled cohort or follow-up study (post-marketing surveillance) with sufficient numbers to rule out a common harm; case-series, case-control, | Non-consecutive studies, case-control studies, or studies with poor, non-independent, or inconsistently applied reference standards | Cohort study, control arm of a randomized trial, case series, or case-control studies; poor quality prognostic cohort study |

|          |     |   |                                    |  |  |
|----------|-----|---|------------------------------------|--|--|
|          |     |   | or historically controlled studies |  |  |
| <b>D</b> | 5   | Case reports, mechanism-based reasoning, or reasoning from first principles   |                                    |  |  |
| <b>X</b> | n/a | Exceptional situations where validating studies cannot be performed and there is a clear preponderance of benefit over harm |                                    |  |  |

CEBM, Oxford Centre for Evidence-Based Medicine

\*Adapted from Howick and coworkers. (2011)

†A group of individuals identified for subsequent study at an early, uniform point in the course of the specified health condition, or before the condition develops

‡A systematic review may be downgraded to level B because of study limitations, heterogeneity, or imprecision

Guidelines are never intended to supersede professional judgment; rather, they may be viewed as a relative constraint on individual clinician discretion in a particular clinical circumstance. Less frequent variation in practice is expected for a strong recommendation than might be expected with a recommendation. Options offer the most opportunity for practice variability (Eddy, 1992). Clinicians should always act and decide in a way that they believe will best serve their individual patients' interests and needs, regardless of guideline recommendations. Guidelines represent the best judgment of a team of experienced clinicians and methodologists addressing the scientific evidence for a particular topic (AAP SCQIM, 2004).

Making recommendations about health practices involves value judgments on the desirability of various outcomes associated with management options. Values applied by the GUG sought to minimize harm and diminish unnecessary and inappropriate therapy. A major goal of the panel was to be transparent and explicit about how values were applied and to document the process.

## *Financial disclosure and conflicts of interest*

The cost of developing this guideline, including travel expenses of all panel members, was covered in full by the AAO-HNSF. Potential conflicts of interest for all panel members in the past 5 years were compiled and distributed before the first conference call and were updated at each subsequent call and in-person meeting. After review and discussion of these disclosures (Choudry, et al, 2002), the panel concluded that individuals with potential conflicts could remain on the panel if they: (1) reminded the panel of potential conflicts before any related discussion, (2) recused themselves from a related discussion if asked by the panel, and (3) agreed not to discuss any aspect of the guideline with industry before publication. Lastly, panelists were reminded that conflicts of interest extend beyond financial relationships, and may include personal experiences, how a participant earns a living, and the participant's previously established "stake" in an issue (Detsky, 2006).

## **Guideline Key Action Statements**

Each evidence-based statement is organized in a similar fashion: a key action statement is in bold, followed by the strength of the recommendation in italics. Each key action statement is followed by an 'action statement profile' that explicitly states the quality improvement opportunity, aggregate evidence quality, level of confidence in evidence (high, medium, low), benefit, harms, risks, costs and a benefits-harm assessment. Additionally, there are statements of any value judgments, the role of patient preferences, clarification of any intentional vagueness by the panel, exceptions to the statement, any differences of opinion, and a repeat statement of the strength of the recommendation. Several paragraphs subsequently discuss the evidence base supporting the statement. An overview of each evidence-based statement in this guideline can be

found in Table 5.

The role of patient preferences in making decisions deserves further clarification. The GUG classified the role of patient preference based upon consensus among the group as “none, small, moderate or large”. For some statements, where the evidence base demonstrates clear benefit, although the role of patient preference for a range of treatments may not be relevant (such as with intraoperative decision-making), clinicians should provide patients with clear and comprehensible information on the benefits in order to facilitate patient understanding and shared-decision making, which in turn leads to better patient adherence and outcomes. In cases where evidence is weak or benefits unclear, the practice of shared decision-making, again where the management decision is made by a collaborative effort between the clinician and an informed patient, is extremely useful. Factors related to patient preference include (but are not limited to) absolute benefits, adverse effects, cost of drugs or procedures, and frequency and duration of treatment, as well as certain less tangible factors such as religious and/or cultural beliefs or personal levels of desire for intervention.

Table 5. Summary of guideline key action statements

| Statement | Action | Strength |
|-----------|--------|----------|
|-----------|--------|----------|

|  |  |                          |
|--|--|--------------------------|
| 1a. Diagnosis of posterior canal BPPV            | Clinicians should diagnose posterior semicircular canal BPPV when vertigo associated with torsional, up-beating nystagmus is provoked by the Dix-Hallpike maneuver, performed by bringing the patient from an upright to supine position with the head turned 45 degrees to one side and neck extended 20 degrees with the affected ear down. The maneuver should be repeated with the opposite ear down if the initial maneuver is negative | Strong recommendation    |
| 1b. Diagnosis of lateral (horizontal) canal BPPV | If the patient has a history compatible with BPPV and the Dix-Hallpike test exhibits horizontal or no nystagmus, the clinician should perform, or refer to a clinician who can perform, a supine roll test to assess for lateral semicircular canal BPPV.  | Recommendation           |
| 2a. Differential diagnosis                       | Clinicians should differentiate, or refer to a clinician who can differentiate, BPPV from other causes of imbalance, dizziness and vertigo.  | Recommendation           |
| 2b. Modifying factors                            | Clinicians should assess patients with BPPV for factors that modify management including impaired mobility or balance, central nervous system disorders, a lack of home support, and/or increased risk for falling.  | Recommendation           |
| 3a. Radiographic testing                         | RADIOGRAPHIC testing: Clinicians should not obtain radiographic imaging in a patient who meets diagnostic criteria for BPPV in the absence of additional signs and/or symptoms inconsistent with BPPV that warrant imaging.  | Recommendation (against) |

|   |   |                                 |
|---|---|---------------------------------|
| 3b. Vestibular testing                          | Clinicians should not order vestibular testing in a patient who meets diagnostic criteria for BPPV in the absence of additional vestibular signs and/or symptoms inconsistent with BPPV that warrant testing. | Recommendation (against)        |
| 4a. Repositioning procedures as initial therapy | Clinicians should treat, or refer to a clinician who can treat, patients with posterior canal BPPV with a canalith repositioning procedure.   | Strong recommendation           |
| 4b. Post procedural restrictions                | Clinicians should not recommend post- procedural postural restrictions after canalith repositioning procedure for posterior canal BPPV.   | Strong recommendation (against) |
| 4c. Observation as initial therapy              | Clinicians may offer observation with follow up as initial management for patients with BPPV.   | Option                          |
| 5. Vestibular rehabilitation therapy            | The clinician may offer vestibular rehabilitation, either self-administered or with a clinician, in the treatment of BPPV.  | Option                          |
| 6. Medical therapy                              | Clinicians should not routinely treat BPPV with vestibular suppressant medications such as antihistamines and/or benzodiazepines.   | Recommendation (against)        |
| 7a. Outcome Assessment                          | Clinicians should reassess patients within 1 month after an initial period of observation or treatment to document resolution or persistence of symptoms.   | Recommendation                  |
| 7b. Evaluation of treatment failure             | Clinicians should evaluate or refer to a clinician who can evaluate, patients with persistent symptoms for unresolved BPPV and/or underlying peripheral vestibular or central nervous system disorders.       | Recommendation                  |

|              |  |                |
|--------------|--|----------------|
| 8. Education | Clinicians should educate patients regarding the impact of BPPV on their safety, the potential for disease recurrence and the importance of follow-up. | Recommendation |
|--------------|--|----------------|

**1a. DIAGNOSIS OF POSTERIOR SEMICIRCULAR CANAL BPPV: Clinicians should diagnose posterior semicircular canal BPPV when vertigo associated with torsional, up-beating nystagmus is provoked by the Dix-Hallpike maneuver, performed by bringing the patient from an upright to supine position with the head turned 45 degrees to one side and neck extended 20 degrees with the affected ear down. The maneuver should be repeated with the opposite ear down if the initial maneuver is negative. *Strong recommendation based on diagnostic studies with minor limitations and a preponderance of benefit over harm.***

#### *Action Statement Profile*

- Quality improvement opportunity: Promoting accurate and efficient diagnosis of BPPV (National Quality Strategy domains: promoting effective prevention/treatments, affordable quality care)
- Aggregate evidence quality: Grade B, based on diagnostic studies with minor limitations
- Level of confidence in the evidence: High
- Benefits: Improved diagnostic accuracy and efficiency
- Risks, harms, costs: Risk of provoking temporary symptoms of BPPV
- Benefits-harm assessment: Preponderance of benefit over harm
- Value judgments: Conclusion that paroxysmal positional nystagmus induced by the Dix-

Hallpike maneuver confirms the diagnosis of BPPV and is the gold standard test for diagnosis. The panel emphasized that a history of positional vertigo alone is not adequate to make the diagnosis of posterior canal BPPV

- Role of patient preferences: Small
- Intentional vagueness: None
- Exceptions: Patients with physical limitations including cervical stenosis, severe kyphoscoliosis, limited cervical range of motion, Down syndrome, severe rheumatoid arthritis, cervical radiculopathies, Paget's disease, ankylosing spondylitis, low back dysfunction, spinal cord injuries, known cerebrovascular disease and the morbidly obese
- Policy level: Strong recommendation
- Differences of opinion: None

#### *Supporting Text*

The purpose of this statement is to emphasize that clinicians should diagnose posterior semicircular canal BPPV when vertigo associated with torsional, up-beating nystagmus is provoked by the Dix-Hallpike maneuver (Figure 1), performed by bringing the patient from an upright to supine position with the head turned 45 degrees to one side and neck extended 20 degrees with the affected ear down. If the testing of the first side is negative, the Dix-Hallpike maneuver should be conducted with the other ear down before concluding a negative overall maneuver.

Posterior semicircular canal BPPV is diagnosed when (1) patients report a history of vertigo provoked by changes in head position relative to gravity and (2) when, on physical examination, characteristic nystagmus is provoked by the Dix-Hallpike maneuver (Table 6).



Although most cases of BPPV are due to freely mobile calcium carbonate material within the lumen of the affected semicircular canal (so-called canalolithiasis), a form of posterior canal BPPV due to calcium carbonate material actually attached to the cupula (cupulolithiasis) may occur which results in nystagmus that may persist for > 1 min. (von Brevern 2015).

**Table 6: Diagnostic criteria for posterior canal BPPV**

|                      |   |
|----------------------|---|
| History              | Patient reports repeated episodes of vertigo with changes in head position relative to gravity  |
| Physical Examination | <p>Each of the following criteria are fulfilled:</p> <ul style="list-style-type: none"><li>• Vertigo associated with torsional (rotatory), up-beating (towards the forehead) nystagmus is provoked by the Dix-Hallpike test</li><li>• There is a latency period between the completion of the Dix-Hallpike maneuver and the onset of vertigo and nystagmus</li><li>• The provoked vertigo and nystagmus increase and then resolve within 60 seconds from the onset of the nystagmus</li></ul> |

## HISTORY

Vertigo has been defined as an “illusory sensation of motion of either the self or the surroundings”. (Blakely & Goebel, 2001) The symptoms of vertigo resulting from posterior canal BPPV are typically described by the patient as a rotational or spinning sensation when the patient changes head position relative to gravity. The episodes are often provoked by every day activities and commonly occur when rolling over in bed or when the patient is tilting the head to look upward (e.g. to place an object on a shelf higher than the head) or bending forward (e.g. to tie his or her shoes). (von Brevern et al, 2007; Furman & Cass, 1999; Dix & Hallpike, 1952;

Whitney et al, 2005)

Patients with BPPV most commonly report discrete, episodic periods of vertigo lasting one minute or less and often report modifications or limitations of their general movements to avoid provoking the vertiginous episodes.(Ruckenstein & Shepard, 2007) Other investigators report that true "room spinning" vertigo is not always present as a reported symptom in posterior canal BPPV, with patients alternatively complaining of lightheadedness, dizziness, nausea, or the feeling of being "off balance".( Katsarkas, 1999; von Brevern et al, 2007; Furman & Cass, 1999; Herdman, 1997; Macias et al, 2000; Cohen, 2004; Haynes et al, 2002; Blatt et al, 2000;p Norre, 1995) Approximately 50% of patients also report subjective imbalance between the classic episodes of BPPV.(von Brevern et al, 2007) In contrast, a history of vertigo *without* associated lightheadedness may increase the a priori likelihood of a diagnosis of posterior canal BPPV.(Oghalai et al, 2000) In up to one third of cases with atypical histories of positional vertigo, Dix-Hallpike testing will still reveal positional nystagmus strongly suggesting the diagnosis of posterior canal BPPV.(Norre, 1995)

Other authors have loosened the historical criteria required for a BPPV diagnosis and have coined the term "subjective BPPV" without a positive Dix-Hallpike test. (Haynes et al, 2002; Nunez et al, 2000) However, in clinical practice there is a practical need to balance inclusiveness of diagnosis with accuracy of diagnosis. Given that the majority of treatment trials and systematic reviews of BPPV require both a history of episodic positional vertigo symptoms and a positive Dix-Hallpike test, history alone is insufficient to render an accurate diagnosis of BPPV.

418

## 419 PHYSICAL EXAMINATION

420 In addition to the historical criteria for the diagnosis of posterior canal BPPV, clinicians  
421 should confirm the diagnosis of posterior canal BPPV by performing the Dix-Hallpike maneuver  
422 (Figure 1).

423 The nystagmus produced by the Dix-Hallpike maneuver in posterior canal BPPV  
424 typically displays two important diagnostic characteristics. First, there is a latency period  
425 between the completion of the maneuver and the onset of subjective rotational vertigo and the  
426 objective nystagmus. The latency period for the nystagmus onset with this maneuver is largely  
427 unspecified in the literature, but the panel felt that a typical latency period would range from 5-  
428 20 seconds. In rare cases, the latency period may be as long as one minute (Baloh et al, 1987).  
429 Second, the provoked subjective vertigo and the nystagmus increase and then resolve within 60  
430 seconds from the nystagmus onset.

431 The fast component of the nystagmus provoked by the Dix-Hallpike maneuver  
432 demonstrates a characteristic mixed torsional and vertical movement (often described as  
433 upbeating-torsional) with the upper pole of the eye beating toward the dependent ear and the  
434 vertical component beating toward the forehead (when the eyes positioned looking straight  
435 forward in the mid-orbit when the provoking position is assumed) (**Figure 1**). (Furman & Cass,  
436 1999; Honrubia et al, 1999) Temporally, the rate of nystagmus typically begins gently, increases  
437 in intensity, and then declines in intensity as it resolves. This has been termed crescendo-  
438 decrescendo nystagmus. After the patient returns to the upright head position, the nystagmus is  
439 again commonly observed, and the direction of the nystagmus may be reversed.

440 Another classic feature associated with posterior canal BPPV is that the nystagmus

typically fatigues (a reduced nystagmus response) when the maneuver is repeated. (Dix & Hallpike, 1952; Honrubia et al, 1999) However, repeating the Dix-Hallpike maneuver to demonstrate fatigability is not recommended because it unnecessarily subjects patients to repeated vertigo symptoms, which is discomforting. Furthermore, repeating Dix-Hallpike maneuvers may interfere with the immediate bedside treatment of BPPV. (Furman & Cass, 1999) Therefore, the panel did not include nystagmus fatigability as a diagnostic criterion.

In addition to posterior canal BPPV, patients may rarely have anterior canal BPPV. Even though anterior canal BPPV is uncommon accounting for 1-3 % of cases (Heidenreich 2011), it is important to recognize the direction of the vertical component of the provoked torsional nystagmus to make the correct diagnosis. A down-beating vertical component in addition to the torsional nystagmus towards the dependent ear could imply anterior canal rather than posterior canal BPPV (Casani et al 2011, Lopez-Escamez et al 2006, Heidenreich et al 2011). This diagnosis should be considered with caution because down-beating positional nystagmus related to brainstem or cerebellar lesion can produce a similar pattern and should be ruled out. (Fife 2009)

## PERFORMING THE DIX-HALLPIKE DIAGNOSTIC MANEUVER

The Dix-Hallpike maneuver is performed by the clinician moving the patient through a set of specified head positions to elicit the expected characteristic nystagmus of posterior canal BPPV (**Figure 1**). (Furman & Cass, 1999; Dix & Hallpike, 1952) Before beginning the maneuver, the patient should be counseled regarding the upcoming movements and that they may experience a sudden onset of intense subjective vertigo, possibly with nausea, which should subside within 60 seconds. Since the patient is going to be placed in the supine position

relatively quickly with the head position slightly below the body, the patient should be oriented so that when placed supine, the head can "hang" with support off the posterior edge of the examination table by about 20 degrees. The examiner should ensure that he/she can support the patient's head and guide the patient through the maneuver safely and securely, without the examiner losing support or balance.

1. The maneuver begins with the patient in the upright seated position with the examiner standing at the patient's side. (Furman & Cass, 1999) If present, the patient's eyeglasses should be removed. We initially describe the maneuver to test the right ear as the source of the posterior canal BPPV.
2. The examiner rotates the patient's head 45° to the right to align the posterior semicircular canal with the mid sagittal plane of the body, and with manual support maintains the 45° head turn to the right during the next part of the maneuver. The patient is instructed to keep the eyes open. Fairly quickly, the examiner moves the patient from the seated to the supine right-ear down position and then extends the patient's neck slightly (approximately 20° below the horizontal plane) so that the chin is pointed slightly upward with the head hanging off the edge of the table (supported by the examiner). The examiner observes the patient's eyes for the latency, duration, and direction of the nystagmus. (Norre & Beckers, 1988; White et al, 2005) Again, the provoked nystagmus in posterior canal BPPV is classically described as a mixed torsional and vertical movement with the upper pole of the eye beating toward the dependent ear (in this example the right ear). The patient should also be queried as to the presence of subjective vertigo.

3. After the resolution of the subjective vertigo and the nystagmus, if present, the patient may be slowly returned to the upright position. During the return to the upright position, a reversal of the nystagmus may be observed and should be allowed to resolve.
4. If the initial result for the right side is negative, the Dix-Hallpike maneuver (steps 1-4) should then be repeated for the left side, with the left ear arriving at the dependent position. (Nunez et al, 2000) Again, the examiner should inquire about subjective vertigo and identify objective nystagmus, when present. This completes the Dix-Hallpike test.

The Dix-Hallpike maneuver is considered the gold standard test for the diagnosis of posterior canal BPPV. (Fife et al, 2008) It is the most common diagnostic criterion required for entry into clinical trials and for inclusion of such trials in meta-analyses. (Hilton & Pinder, 2004; Cohen & Kimball, 2005) The lack of an alternative external gold standard to the Dix Hallpike maneuver limits the availability of rigorous sensitivity and specificity data. Although it is considered the gold standard test for posterior canal BPPV diagnosis, its accuracy may vary between specialty and non-specialty clinicians. Lopez-Escamez et al, have reported a sensitivity of 82% and specificity of 71% for the Dix-Hallpike maneuvers in posterior canal BPPV, primarily among specialty clinicians.(Lopez-Escamez et al, 2000) In the primary care setting, Hanley and O'Dowd have reported a positive predictive value for a positive Dix-Hallpike test of 83% and a negative predictive value of 52% for the diagnosis of BPPV.(Hanley & O'Dowd, 2002) Therefore, a negative Dix-Hallpike maneuver does not necessarily rule out a diagnosis of posterior canal BPPV. Because of the lower negative predictive values, it has been suggested that

the Dix-Hallpike maneuver may need to be repeated at a separate visit in order to confirm the diagnosis and to avoid a false negative result. (Nunez et al, 2000; Viirre et al, 2005; Norre, 1994)



Factors that may affect the diagnostic accuracy of the Dix-Hallpike maneuver include the speed of head movements during the test, time of day, and the angle of the occipital plane during the maneuver. (Nunez et al, 2000) The Dix-Hallpike maneuver, may in certain circumstances be performed bilaterally in order to determine which ear(s) is(are) involved, particularly if the diagnosis is not clear with the first performance of the maneuver. (Nunez et al, 2000) In a small percentage of cases, the Dix-Hallpike maneuver may be bilaterally positive (i.e. the correspondingly appropriate nystagmus is elicited for each ear in the dependent position). For example, bilateral posterior canal BPPV is more likely to be encountered after head trauma. (Katsarkas, 1999)

While the Dix-Hallpike maneuver is the test of choice to confirm the diagnosis of posterior canal BPPV, it should be avoided in certain circumstances. Although there are no documented reports of vertebrobasilar insufficiency (VBI) provoked by performing the Dix-Hallpike maneuver, clinicians should be careful to consider the risk of stroke or vascular injury in patients with significant vascular disease.(Whitney & Morris, 2006) Care should also be exercised in patients with cervical stenosis, severe kyphoscoliosis, limited cervical range of motion, Down's syndrome, severe rheumatoid arthritis, cervical radiculopathies, Paget's disease, ankylosing spondylitis, low back dysfunction, spinal cord injuries, and morbid obesity.(Whitney et al, 2005; Whitney & Morris, 2006) Patients who are obese may be difficult for a single examiner to fully support the head through the maneuver and additional assistance may be required. For patients with the above concerns or other physical limitations, special tilting examination tables may allow the safe performance of the Dix-Hallpike maneuver. Such patients

may benefit from referral to more specialized clinicians and/or facilities with additional resources.

**Figure 1: Diagrammatic representation of performance of the Dix-Hallpike maneuver for the diagnosis of posterior canal BPPV (adapted from Fife et al, 2008)** In Panel A, the examiner stands at the patient's right side and rotates the patient's head 45° to the right to align the right posterior semicircular canal with the sagittal plane of the body. In Panel B, the examiner moves the patient, whose eyes are open, from the seated to the supine right-ear-down position and then extends the patient's neck 20° so that the chin is pointed slightly upward. The latency, duration, and direction of nystagmus, if present, and the latency and duration of vertigo, if present, should be noted. The arrows in the inset depict the direction of nystagmus in patients with typical benign paroxysmal positional vertigo. A presumed location in the labyrinth of the free floating debris thought to cause the disorder is also shown.





**1b. DIAGNOSIS OF LATERAL (HORIZONTAL) SEMICIRCULAR CANAL BPPV. If the patient has a history compatible with BPPV and the Dix-Hallpike test exhibits horizontal or no nystagmus, the clinician should perform, or refer to a clinician who can perform, a supine roll test to assess for lateral semicircular canal BPPV. *Recommendation based on diagnostic studies with limitations and a preponderance of benefit over harm.***

*Action Statement Profile*

- Quality improvement opportunity: Improve accurate and efficient diagnosis of lateral canal BPPV (National Quality Strategy domains: promoting effective prevention/treatment, affordable quality care)
- Aggregate evidence quality: Grade B based on several RCTs with supine roll test as the reference entry standard
- Level of confidence in evidence: High
- Benefit: Avoid missed diagnoses of lateral canal BPPV. Allows accurate diagnosis of lateral canal BPPV thereby avoiding unnecessary diagnostic tests and inappropriate treatment. Increased awareness of lateral canal BPPV
- Risks, harms, costs: Risk of provoking temporary symptoms of BPPV
- Benefits-harm assessment: Preponderance of benefit over harm
- Value judgments: None
- Intentional vagueness: None
- Role of patient preferences: Small
- Exceptions: Patients with physical limitations including cervical stenosis, severe kyphoscoliosis, limited cervical range of motion, Down's syndrome, severe rheumatoid arthritis, cervical radiculopathies, Paget's disease, ankylosing spondylitis, low back

dysfunction, spinal cord injuries, and the morbidly obese

- Policy level: Recommendation

- Differences of opinion: None

#### *Supporting Text*

The purpose of this statement is to clarify the diagnosis of lateral semicircular canal BPPV, also called horizontal semicircular canal BPPV, determine whether it is geotropic or apogeotropic type, and when possible to identify the affected side.

**Incidence.** Lateral semicircular canal BPPV is the second most common type of BPPV. (Imai et al, 2005; Steenerson et al 2005; Moon et al, 2006) Several studies have cited an incidence of approximately 5-22% in populations referred for evaluation and treatment of BPPV. (White et al, 2005; De La Meilleure 1996; Cakir et al, 2006; Hornibrook, 2004; Han et al, 2006; Caruso & Nuti, 2005; Casani 2011). The wide range of incidence of lateral semicircular canal BPPV reported in the literature is probably a function of how soon after the onset of vertigo the patient can be seen at each institution. Lateral semicircular canal BPPV tends to self-resolve more quickly than posterior semicircular canal BPPV (Imai 2005) so clinics seeing patients after more time has elapsed since symptom onset will likely see a lower percentage of the lateral semicircular canal form of BPPV cases and proportionally more posterior semicircular canal.

Lateral semicircular canal BPPV may occur following performance of the canalith repositioning procedure (e.g. Epley maneuver) for an initial diagnosis of posterior semicircular canal BPPV. This transition from posterior semicircular canal BPPV to lateral semicircular canal BPPV is thought to occur as freely mobile calcium carbonate material originating from otoconia of the utricle moves from the posterior semicircular canal to the lateral semicircular

canal (so called “canal conversion”). Since this type of transition is possible but uncommon, clinicians should be aware of lateral semicircular canal BPPV and its diagnosis. (White et al, 2005)

**Distinguishing features.** Lateral semicircular canal BPPV differs from the more common posterior semicircular canal BPPV in two important ways. First, the nystagmus elicited by the supine roll test in lateral semicircular canal BPPV is predominantly horizontal whereas the nystagmus from the Dix-Hallpike test in posterior semicircular canal BPPV is upbeating and torsional. Second, the vertigo and nystagmus are evoked by turning the head side to side while supine (supine head roll test, Figure 2) whereas vertigo and nystagmus are induced by the Dix Hallpike maneuver in the cases of posterior semicircular canal BPPV. Patients with a history compatible with BPPV (that is, repeated episodes of vertigo produced by changes in head position relative to gravity) who do not appear to have posterior semicircular canal BPPV by Dix Hallpike positioning, should be tested for lateral semicircular canal BPPV. The patient’s presenting symptomatic report of positional dizziness due to lateral semicircular canal BPPV is often indistinguishable from posterior semicircular canal BPPV. (Steenerson et al, 2005; Fife 2012)

**Supine head roll test (Pagnini-Lempert or Pagnini-McClure roll test).** The supine head roll test is the preferred maneuver to diagnose lateral semicircular canal BPPV. (Cakir et al, 2006; Fife 2012; Nuti et al, 1998, Casani 2011) The supine roll test is performed by initially positioning the patient supine with the head in neutral position followed by quickly rotating the head 90° to one side with the clinician observing the patient's eyes for nystagmus (**Figure 2**). After the nystagmus subsides (or if no nystagmus is elicited), the head is then returned to the straight face-up supine position. After any additional elicited nystagmus has subsided, the head

is then quickly turned 90° to the opposite side and the eyes are once again observed for nystagmus.

***Nystagmus characteristics of lateral canal BPPV.*** Two potential nystagmus findings may occur with this maneuver reflecting two types of lateral semicircular canal BPPV. Both types are so-called direction changing positional nystagmus. That is, the direction of the positional nystagmus changes with changes in the head position. (White et al, 2005; Nuti et al, 1998; Fife 2012; Tirelli & Russolo, 2004)

(A) GEOTROPIC TYPE: In most cases of lateral semicircular canal BPPV, when the patient is rolled to the pathological (affected) side there is a very intense horizontal nystagmus beating toward the undermost (affected) ear. The nystagmus beats toward the earth and is therefore geotropic nystagmus. When the patient is rolled to the healthy (non-affected) side, there is a less intense horizontal nystagmus again beating toward the undermost ear (again geotropic but the direction of the nystagmus has now changed). It seems probable that when lateral canal BPPV exhibits this form of nystagmus, the calcium carbonate debris is located in the long arm of the semicircular canal.

(B) APOGEOTROPIC TYPE: Less commonly, the roll test results in a horizontal nystagmus beating toward the uppermost ear (apogeotropic nystagmus). Upon rolling to the opposite side, the nystagmus will change direction, again beating toward the uppermost ear. It seems likely that when lateral semicircular canal BPPV exhibits the apogeotropic form of nystagmus, the


calcium carbonate debris is located adherent to (cupulolithiasis) or close to the ampulla of the semicircular canal. (Baloh 1993, Casani 2011)

**Identifying the affected side.** Effective treatments for lateral semicircular canal BPPV are somewhat predicated on knowing which side is affected, although it is recognized that determining the affected side can be complex and may require specialty referral after the initial diagnosis is made. Table 7 outlines some of the methods for determining which side is affected in lateral canal BPPV. The supine roll test is the most commonly utilized method for determining the affected ear in therapeutic trials of lateral semicircular canal BPPV.(Steenerson et al, 2005; Han et al, 2006, Lee 2007, Mandala 2013) Among the two types of lateral semicircular canal BPPV, the geotropic variant is the most common and the most amenable to treatment.(Steenerson et al, 2005; Nuti et al, 1998; Casani et al, 2011) Despite using some of the methods described in Table 7, clear lateralization remains unclear in about 20% of cases (Lee 2007, Fife 2012, Hwang 2015). In such situations, one may simply treat one side and then the other. Alternatively, other testing methods such as the Bow and lean procedure (Table 7) may be applied to add to the diagnosis certainty of side of involvement.

**Risk and benefit analysis.** Reports of harm or patient injury from the performance of the supine roll test were not identified in the literature review although many authors simply stated that patients who could not tolerate positional maneuvers were excluded. Care should also be exercised in patients with the same exclusionary criteria for the Dix Hallpike maneuver.(Whitney et al, 2005; Whitney & Morris, 2006) The benefit of performing the supine roll test is that it allows clinicians to confirm a diagnosis of lateral semicircular canal BPPV quickly and efficiently.(White et al, 2005; Fife et al, 2008) It also allows clinicians to more accurately and

comprehensively diagnose positional vertigo that is not due to the posterior canal whereas without supine roll testing, patients with lateral semicircular canal BPPV might be diagnostically missed if only traditional Dix-Hallpike testing were done. Further benefit may be realized if the supine roll test is done and the diagnosis recognized obviating unnecessary or unhelpful diagnostic testing.

**Figure 2**



**Figure 2:** Diagrammatic views of the supine roll test. (1) indicates the patient in the starting neutral position. The patient's head is turned rapidly to the right side (2) examining for characteristic nystagmus. Then the head is returned to the face-up position (1) allowing all nystagmus to subside and then turned rapidly to the left side (3) examining once again for nystagmus. (Adapted from <sup>19</sup>)

Table 7. Selected methods to determine the affected ear in lateral canal BPPV.

| Technique or Circumstance   | Conclusion regarding the affected ear   |
|---|---|
| <b>Supine roll testing</b> (Figure 2) reveals a direction changing nystagmus that is either geotropic (beating toward the ground) or apogeotropic (beating away from the ground) and is distinctly stronger on one side than the other (Nutti 2005, Lee 2007, Casani 2011, Fife 2012) | <u>Geotropic form</u> : the side with the <b>strongest nystagmus</b> is the affected ear;<br><u>Apogeotropic form</u> : the side <b>opposite</b> the strongest nystagmus is the affected ear.   |
| Posterior canal BPPV torsional upbeat nystagmus <b>converts to strongly horizontal nystagmus</b> (lateral canal BPPV) during positioning (Fife 2012)  | Same ear as was affected by the posterior semicircular canal BPPV   |
| Patient is moved from sitting to straight supine facing up results in transient horizontal nystagmus ( <b>lying-down nystagmus*</b> ) (Casani 2011, Nutti 2005, Lee 2007, Asprella-Libonati 2008, Koo 2006)   | <u>Geotropic</u> : Nystagmus beats <b>away</b> from the affected ear<br><u>Apogeotropic</u> : Nystagmus beats <b>toward</b> the affected ear  |
| With the patient in the straight supine position, the patient then sits up and the head bends down as a “Head Pitch Test” (head-bending nystagmus)<br>(Hwang 2015, Kim 2012, Asprella-Libonati 2008)  | <u>Geotropic</u> : Nystagmus usually beats <b>toward</b> the affected ear<br><u>Apogeotropic</u> : Nystagmus beats <b>away</b> from the affected ear<br>(opposite of lying-down nystagmus. )  |
| <b>Bow and lean test (BLT)*</b> in which the direction of nystagmus is noted when the patient bends the head forward facing down (bowing) and when facing upward (leaning). (Lee 2010, Choung 2006)   | <b>Geotropic</b> :<br><u>bowing position</u> (face down): nystagmus toward the affected ear<br><u>leaning position</u> (face up): nystagmus beats <b>away</b> from the affected ear.<br><b>Apogeotropic</b> : (reverse of geotropic type)<br><u>bowing (face down)</u> : nystagmus beats away from the affected ear<br><u>Leaning (face up) nystagmus</u> : beats <b>toward</b> the affected ear. |

\*The supine head roll test will still be needed to determine if there is a pattern of geotropic or apogeotropic direction changing nystagmus.



684

685 **2a. DIFFERENTIAL DIAGNOSIS: Clinicians should differentiate, or refer to a clinician**  
686 **who can differentiate, BPPV from other causes of imbalance, dizziness and vertigo.**

687 *Recommendation based on observational studies and a preponderance of benefit over harm.*

688 *Action Statement Profile*

- 689 • Quality improvement opportunity: Avoid incorrect diagnosis of BPPV (National Quality  
690 Strategy domain: promoting effective prevention/treatment)
- 691 • Aggregate evidence quality: Grade C, based on observational studies with limitations
- 692 • Level of confidence in evidence: Medium
- 693 • Benefits: Prevent false positive diagnosis of BPPV when another condition actually exists
- 694 • Risks, harms, costs: Healthcare costs of referral to another clinical.
- 695 • Benefits-harm assessment: Preponderance of benefit over harm
- 696 • Value judgments: None
- 697 • Intentional vagueness: None
- 698 • Role of patient preferences: Small
- 699 • Exceptions: None
- 700 • Policy level: Recommendation
- 701 • Differences of opinion: None

702

703 *Supporting Text*

704 The purpose of this statement is to improve diagnostic accuracy of BPPV by reducing  
705 misdiagnosis of other potential causes of dizziness.

Despite being the most common cause of peripheral vertigo, (Froehling et al, 2000) BPPV is still often under-diagnosed or misdiagnosed. (von Brevern et al, 2004) Other causes of vertigo which may be confused with BPPV can be divided into otologic, neurologic and other entities. Among patients presenting with dizziness, the frequency of various causes depends on the setting. In a German telephone survey of over 1000 patients with dizziness, BPPV accounted for 8% of cases. (von Brevern 2007) In an analysis of nearly 10,000 US emergency department patients with dizziness, nearly half of patients had a medical (non-vestibular and non-neurological) diagnosis. (Newman Toker 2008) Only a third of patients were given a vestibular-related diagnosis. In a British general practice setting, evaluation of patients presenting with vertigo, BPPV has been found to account for 42% of cases followed by vestibular neuritis (41%), Meniere's disease (10%), vascular causes (3%) and other causes (3%). (Hanley & O'Dowd, 2002) In subspecialty populations, BPPV accounts for 20-53% of patients referred to ENT specialty clinics for dizziness. (Luscher 2014).

The most common diagnoses that require distinction from BPPV are listed in Table 8. These conditions require distinction from BPPV as their natural history, treatment and potential for serious medical sequelae are significantly different from BPPV. Patients with BPPV may not specifically describe true vertigo and may complain of lightheadedness or non-specific dizziness and thus the clinician may need to initially consider a broader differential diagnosis. (Lawson 2005). BPPV has been described as occurring in conjunction with, or as a consequence of, other vestibular disorders as well, such as Meniere's disease and vestibular neuritis. (Karlberg et al, 2000) Therefore, clinicians must consider the possibility of more than one vestibular disorder being present in any patient who does not clearly have the specific symptoms of a single vestibular entity.

Recent studies emphasize that taking a history that focuses on timing and triggers of a patient's dizziness is more important than the specific descriptor that a patient uses (Newman Toker 2007, Kerber 2015, Bisforff 2015, Newman Toker 2015) Timing (acute versus episodic versus chronic) and triggers (discrete trigger versus spontaneous) of the dizziness and its evolution over time defines four distinct vestibular syndromes. (Newman Toker 2015) (Table 9): These include: an acute vestibular syndrome (AVS), triggered episodic vestibular syndrome (t-EVS), spontaneous episodic vestibular syndrome (s-EVS) and chronic vestibular syndrome (CVS). Each of these entities has its own differential diagnosis, with BPPV fitting the t-EVS criteria given its positional trigger and brief episodic occurrences of vertigo.

## OTOLOGIC DISORDERS

Whereas BPPV is characterized by acute, discrete episodes of brief positional vertigo without associated hearing loss, other otologic disorders causing vertigo may be differentiated by their clinical characteristics including temporal pattern and the presence or absence of hearing loss. (Kentala & Rauch, 2003) Meniere's disease is characterized by discrete episodic attacks, each attack exhibiting a characteristic clinical constellation of sustained vertigo with fluctuating hearing loss, aural fullness, and tinnitus in the affected ear. (Baloh et al, 1987; Sajjadi 2008) As opposed to BPPV, the duration of vertigo in an episode of Meniere's disease typically lasts longer (usually on the order of hours), is typically more disabling due to both severity and duration and is not triggered by any obligate head position changes. In addition, an associated contemporaneous decline in sensorineural hearing is required for the diagnosis of a Meniere's attack, whereas acute hearing loss should not occur with an episode of BPPV. (Thorpe et al, 2003)

Protracted nausea and vomiting are also more common during an attack of Meniere's disease. Meniere's disease would be categorized as an s-EVS.

Acute peripheral vestibular dysfunction syndromes (characterized as an AVS above) such as vestibular neuritis or labyrinthitis present with sudden, unanticipated, severe vertigo with a subjective sensation of rotational (room spinning) motion. If the auditory portion of the inner ear is affected, hearing loss and tinnitus may also occur and clinically this is consistent with labyrinthitis. (Baloh, 2003) These syndromes are commonly preceded by a viral prodrome. The time course of the vertigo is often the best differentiator between BPPV and vestibular neuritis or labyrinthitis. In vestibular neuritis or labyrinthitis, the vertigo is of gradual onset, developing over several hours, followed by a sustained level of vertigo lasting days to weeks. (Kentala & Rauch, 2003; Kentala, 1996; Kentala et al, 1999) The vertigo is present at rest (not requiring positional change for its onset) but it may be subjectively exacerbated by positional changes. These acute peripheral vestibular syndromes may also be accompanied by severe levels of nausea, vomiting, sweating, and pallor that are also typically sustained along with the vertigo.

Superior canal dehiscence syndrome (SCD) is clinically characterized by attacks of vertigo and oscillopsia (the sensation that viewed objects are moving or wavering back and forth) often brought on by loud sounds, Valsalva maneuvers or pressure changes of the external auditory canals. (Minor et al, 2001) SCD differs from BPPV in that vertigo is induced by pressure changes and not position changes. SCD syndrome may also present with an associated conductive hearing loss attributable to lower bone conducted thresholds for sound perception, when compared to air conducted thresholds and is diagnosed via computed tomography of the temporal bones, or alternatively, if available, vestibular evoked myogenic potential testing..(Rosowski et al, 2004; Texiheido 2008) Given that SCD would be categorized as a s-

EVS, similarly to BPPV, it should be differentiated from BPPV by its characteristic pressure related trigger (e.g. Valsalva). Similar to SCD, a perilymph fistula can produce episodes of vertigo and nystagmus triggered by pressure, thereby allowing differentiation from BPPV. PLF can occur after surgery involving the middle/mastoid or spontaneously and may be accompanied by a fluctuating hearing loss.

Post-traumatic vertigo can present with a variety of clinical manifestations including vertigo, disequilibrium, tinnitus, and headache. (Marzo et al, 2004, Hoffer 2015) These symptoms can be due to damage of the peripheral or central structures and are often complicated by overlay of depression or anxiety. Post-head trauma vestibular migraine has also been described. (Fife 2015). Although BPPV is most often idiopathic, in specific cases traumatic brain injury is associated with BPPV. (Davies et al, 1995)

## NEUROLOGIC DISORDERS

One of the key issues facing clinicians attempting to diagnose the etiology for vertigo is the differentiation between peripheral causes of vertigo (those causes arising from the ear or vestibular apparatus) and central nervous system causes of vertigo. Although at times this may be difficult, several clinical features may suggest a central cause of vertigo rather than BPPV.(Labuguen, 2006; Baloh,1998) Nystagmus findings that more strongly suggest a neurologic cause for vertigo rather than a peripheral cause such as BPPV include: down- beating nystagmus on the Dix-Hallpike maneuver (particularly without the torsional component), direction changing nystagmus occurring without changes in head position (i.e. periodic alternating nystagmus), gaze holding, direction switching nystagmus (e.g., beats to the right with right gaze, and to the left with left gaze) or baseline nystagmus manifesting without provocative

maneuvers (which also could be a manifestation of vestibular neuritis apart from a neurological cause). Failure to respond to conservative management, such as CRP or vestibular rehabilitation should raise concern that the underlying diagnosis may not be BPPV. (Dunniway & Welling, 1998). Among the central causes of vertigo that should be distinguished from BPPV are vestibular migraine, brainstem and cerebellar stroke or transient ischemic attacks (TIAs), and intracranial tumors or disorders, such as multiple sclerosis.

Vestibular migraine (or migraine associated vertigo) is very common with a lifetime prevalence of 3.2% (Lempert 2009) and may account for as many as 14% of cases of vertigo. (Kentala & Rauch, 2003). Diagnostic criteria include: 1)  $\geq 5$  episodes of vestibular symptoms lasting 5 minutes to 72 hours, 2) current or history of migraine according to International Headache Society Criteria, 3)  $\geq 1$  migraine symptoms during at least 50% of the dizzy episodes: migrainous headache, photophobia, phonophobia, visual or other aura, 4) other causes ruled out by appropriate investigations. (Seemungal 2015). It is distinguishable from BPPV by virtue of the diagnostic components enumerated above, which are not associated with classic BPPV. Furthermore, vestibular migraine would be characterized as a s-EVS.

Brainstem and cerebellar stroke are dangerous causes of vertigo. (Kerber 2013) In one series of 240 cerebellar strokes, 10% presented similar to a peripheral vestibular process. (Lee 2006) The onset tends to be more sudden than with neuritis. Physical examination will often disclose other neurological findings relating to the posterior circulation such as dysarthria, dysmetria, dysphagia, sensory or motor loss or findings of a Horner's syndrome. (Kerber 2013)

Another important cause of vertigo is posterior circulation TIA. (Blum 2015) A study of 1141 stroke patients, of which 24% were in the posterior circulation, showed that patients with vertebrobasilar strokes had an odds ratio of 15 to have had prior posterior circulation TIA in the

90 days preceding their stroke. (Paul 2015) Half of these attacks were isolated vertigo and 8% of the patients with vertebrobasilar stroke had a TIA of isolated vertigo. Because TIAs generally last < 1 hour, most patients are asymptomatic on presentation; however, if they were to have symptoms and signs on presentation, they would be the same as those associated with vertebrobasilar stroke.

Intracranial tumors and other brain stem lesions may rarely present with a history and symptomatology similar to those of BPPV. (Dunniway & Welling, 1998). One uncommon, but important, example is central paroxysmal positional vertigo, due to structural lesions (tumors, strokes and MS plaques) generally in the cerebellar vermis or region of the fourth ventricle, which can closely mimic BPPV. (Dunniway & Welling, 1998; Soto-Varela 2013). Multiple sclerosis (MS) patients are more often female, and will nearly always have other worrisome findings such as central nystagmus patterns, internuclear ophthalmoplegia and other abnormalities that localize to the central nervous system. (Pula 2013). Importantly, in patients with known MS, BPPV was found to be a more common cause of acute dizziness than a MS flare. (Frohman 2000 Neurology)

## OTHER DISORDERS

Several other non-otologic and non-neurologic disorders may present similarly to BPPV. Patients with panic or anxiety disorders may complain of symptoms of lightheadedness and dizziness. Although these symptoms are usually attributed to hyperventilation, other studies have shown high prevalence of vestibular dysfunction in these patients. (Jacob et al, 1996; Furman et al, 2006). Several medications, such as misonidazole, carbamazepine, phenytoin, sedatives, antihypertensive and cardiovascular medications, may produce side effects of

dizziness and/or vertigo and should be considered in the differential diagnosis.

Cervical vertigo has been described as vertigo arising in conjunction with degenerative cervical spine disease. (Bracher et al, 2000) Cervical vertigo may produce similar symptoms to BPPV due to proprioceptive abnormalities arising from cervical spine dysfunction. (Padoan et al, 1998) Symptoms of cervical vertigo may be triggered by rotation of the head relative to the body while in an upright posture (as opposed to vertigo triggered by changes in head position relative to gravity). Orthostatic (postural) hypotension also may produce episodic dizziness or vertigo. The symptoms, however, are provoked by moving from the supine or sitting to the upright position in distinction to the provocative positional changes of BPPV.

Although the differential diagnosis of BPPV is vast, most of these other disorders can be further distinguished from BPPV based on the responses to the Dix-Hallpike maneuver and the supine roll test. Clinicians should still remain alert for concurrent diagnoses accompanying BPPV, especially in patients with a mixed clinical presentation.

**Table 8: Basic differential diagnosis of BPPV**

| Otologic disorders                 | Neurologic disorders                 | Other entities  |
|------------------------------------|--------------------------------------|---|
| Meniere's disease                  | Vestibular migraine                  | Anxiety or panic disorder   |
| Vestibular neuritis                | Posterior circulation TIA and stroke | Cervicogenic vertigo  |
| Labyrinthitis                      | Demyelinating diseases               | Medication side-effects   |
| Superior canal dehiscence syndrome | Central nervous system lesions       | Postural hypotension  |
| Post-traumatic vertigo             | Vertebro-basilar insufficiency       | Various medical conditions (such as toxic, infectious and metabolic conditions) |
| Perilymphatic fistula              | Central positional vertigo           |   |
| Inner ear lesions                  |                                      |   |



**Table 9: Common causes of acute dizziness: differential diagnosis by timing and triggers category**

| Acute Vestibular syndrome  | Triggered Episodic Vestibular syndrome  | Spontaneous episodic vestibular syndrome  | Chronic vestibular syndrome   |
|--|---|---|---|
| Vestibular neuritis<br>Labyrinthitis<br>Posterior circulation stroke<br>Demyelinating diseases<br>Post-traumatic vertigo | BPPV<br>Postural hypotension<br>Perilymph fistula<br>Superior canal dehiscence syndrome<br>Vertebrobasilar insufficiency<br>Central paroxysmal positional vertigo | Vestibular migraine<br>Meniere's disease<br>Posterior circulation TIA<br>Medication side-effects<br>Anxiety or panic disorder | Anxiety or panic disorder<br>Medication side-effects<br>Post-traumatic vertigo<br>Posterior fossa mass lesions<br>Cervicogenic vertigo (variable) |

Acute vestibular syndrome = acute persistent continuous dizziness lasting days to weeks, and usually associated with nausea, vomiting and intolerance to head motion.

Triggered episodic vestibular syndrome = episodic dizziness that are triggered by specific and obligate actions, usually a change in head or body position. Episodes generally last less than 1 minute.

Spontaneous episodic vestibular syndrome = episodic dizziness that is NOT triggered and which can last minutes to hours.

Chronic vestibular syndrome = dizziness lasting weeks to months or longer

**2b. MODIFYING FACTORS: Clinicians should assess patients with BPPV for factors that modify management including impaired mobility or balance, central nervous system disorders, a lack of home support, and/or increased risk for falling. *Recommendation based on observational and cross-sectional studies and a preponderance of benefit over harm.***

*Action Statement Profile*

- Quality improvement opportunity: Decrease risks for complications from BPPV in at risk populations. (National Quality Strategy domains: safety, coordination of care)
- Aggregate evidence quality: Grade C, based on observational and cross-sectional studies.
- Level of confidence in evidence: Medium
- Benefits: Allow for management of patients with BPPV with an appropriately structured comprehensive treatment plan. Identify patients at risk for falls and prevent fall related injury.
- Risks, harms, costs: None.
- Benefits-harm assessment: Preponderance of benefit over harm.
- Value judgments: None.
- Intentional vagueness: Factors that modify management are intentionally vague as all factors cannot be listed and individual clinical judgment is required.
- Role of patient preferences: Small.
- Exceptions: None
- Policy level: Recommendation.
- Differences of opinion: None.

*Supporting Text*

895           The purpose of this statement is to consider factors that might modify treatment plans for  
896 the management of BPPV.

897           Although BPPV arises from dysfunction of the vestibular end organ, patients with BPPV  
898 often concurrently suffer from comorbidities, limitations and risks that may affect the diagnosis  
899 and treatment. Careful assessment of the patient with BPPV for factors that modify management  
900 is essential for improved treatment outcomes and ensuring patient safety. The majority of factors  
901 that may modify management of BPPV can be identified if the clinician questions patients for  
902 these factors and elicits a detailed history, (Rubenstein et al, 2001) including the potential social  
903 and economic impact this might have for the patient.

904           Given that BPPV occurs most commonly in the second half of the lifespan and its  
905 prevalence increases with age, patients suffering from BPPV often have medical comorbidities  
906 that may alter the management of BPPV.(Lawson et al, 2005) In cross-sectional surveys,  
907 patients with BPPV demonstrate higher rates of diabetes, anxiety, and history of head  
908 trauma.(Cohen et al, 2004) Other case-control studies have also found higher relative rates of  
909 migraine (34% in BPPV patients versus 10% in non-dizziness control group), history of stroke  
910 (10%, BPPV patients versus 1%, controls), diabetes (14% versus 5%), and hypertension (52%  
911 versus 22%).(von Brevern, 2007) Clinicians should assess patients with BPPV for these  
912 co-morbidities because their presence may modify management and influence treatment  
913 outcomes in BPPV.

914           One of the major concerns with BPPV and vertiginous conditions in general is the risk  
915 for falls and resultant injury. (Gazzola et al, 2006; Agrawal Y et al 2009; Mordin & Schilder  
916 2015) Data from the National Health and Nutrition Examination Survey (NHANES)  
917 demonstrated a 12-fold increase in the risk for falls among older individuals who were clinically

symptomatic (reporting dizziness). (Agrawal Y et al 2009) Among community dwelling adults over the age of 65, 1 in 3 fall each year. (Tinetti et al 1988) This creates a tremendous individual and societal burden related to the health care costs of the associated injuries that occur from falling. It is estimated that the costs from falls in the United States exceed \$20 billion annually. (Agrawal et al., 2013). In multiple studies concerning the etiology of falls, dizziness and vertigo were deemed the primary etiology 13% of the time, compared to existing balance and gait problems (17%), and person-environment interactions (31%).(Rubenstein, 2006) In a study by Oghalai, 9% of patients referred to a geriatric clinic for general geriatric evaluation had undiagnosed BPPV, and three fourths of those with BPPV had fallen within the 3 months prior to referral.(Oghalai et al, 2000) Thus, evaluation of patients with a diagnosis of BPPV should also include an assessment of risk for falls.(Lawson et al, 2005) In particular, elderly patients will be more statistically at risk for falls with BPPV. An initial falls risk screening might start with questions such as those suggested by the Centers for Disease Control and Prevention in 2015: 1) Have you had a fall in the past year? How many times? Were you injured? 2) Do you feel unsteady when standing or walking? 3) Do you worry about falling? A positive response to questions such as these might then prompt the clinician to conduct a more detailed falls risk assessment or refer to a clinician who can use tools such as the Get Up and Go test (Mathias et al. 1986), Tinetti Balance Assessment (Tinetti et al 1986), Berg Balance Scale (Berg et al, 1992) or others.

As noted above, comorbid conditions that occur commonly with BPPV such as a history of stroke or diabetes should also be identified when evaluating patients with BPPV. Patients with a history of stroke or a history of diabetes, particularly with peripheral neuropathy, may already have a pre-existing gait, balance or proprioceptive deficit. (Casellini & Vinik, 2007;

941 Richardson, 2002; Tilling et al, 2006) The additional symptoms of BPPV may increase their risk  
942 for fall and injury. Patients with visual disturbances often lack the ability to correct or  
943 compensate for a balance deficit with visual cues, and may also be at increased risk for falls.  
944 Possible associations between osteoporosis (osteopenia) and BPPV have also been reported. (Yu  
945 et al, 2014) Patients with both conditions may be at greater risk for fractures resulting from falls  
946 related to BPPV and therefore patients with combined osteoporosis and subsequent BPPV should  
947 be identified and monitored closely for fall and fracture risk. Examined from a different vantage  
948 point, patients with a history of recurrent falls, particularly among the elderly, should be assessed  
949 for underlying BPPV as one of the potential fall precipitating diagnoses. (Jonsson et al 2004)

950 BPPV may occur in the simultaneously with other central nervous system disorders.

951 Patients should be questioned as to the presence of pre-existing central nervous system disorders  
952 that may modify the management of BPPV. BPPV may occur relatively commonly after trauma  
953 or traumatic brain injury.(Hoffer et al. , 2004; Motin, et al, 2005) Posttraumatic BPPV is most  
954 likely to involve the posterior semicircular canal and studies indicate that post-traumatic BPPV is  
955 significantly more likely to require repeated CRP (up to 67% of cases) for resolution as  
956 compared to non-traumatic forms (14% of cases).(Gordon et al, 2004; Aron M et al 2015)

957 Because post-traumatic BPPV may be more refractory and/or bilateral thus requiring specialized  
958 treatment, a history of head trauma preceding a clinical diagnosis of BPPV should be  
959 elicited.(Motin et al, 2005; Ahn S-K et al 2011; Liu 2012) Although dizziness in the setting of  
960 multiple sclerosis may have a wide variety of etiologies, studies of acute vertigo occurring in  
961 multiple sclerosis report that a substantial number of patients may have BPPV with a positive  
962 Dix-Hallpike maneuver and successful response to a canalith repositioning procedure.(Frohman  
963 et al, 2003; Frohman et al, 2000) These studies support that care should be taken to not miss a

diagnosis of BPPV in patients with central nervous system disorders as they may be successfully diagnosed and treated with CRP for BPPV.

Finally, in a small percentage of cases, refractory or persisting BPPV may create difficulties from a psychological and/or social-functional perspective for affected individuals.(Gamiz & Lopez-Escamez, 2004; Lopez-Escamez et al, 2005) Outcomes studies have shown that patients with BPPV exhibit a lower quality of life scores compared to the normative population in multiple subscales of the Short Form-36 quality-of-life outcomes instrument.(Lopez-Escamez et al, 2005; Lopez-Escamez et al, 2003) Patients who have pre-existing comorbid conditions may require additional home supervision in the setting of BPPV.(Whitney et al, 2005) This may include counseling about the risk of falling at home or a home safety assessment

**3a. RADIOGRAPHIC TESTING: Clinicians should not obtain radiographic imaging in a patient who meets diagnostic criteria for BPPV in the absence of additional signs and/or symptoms inconsistent with BPPV that warrant imaging. *Recommendation against radiographic imaging based on diagnostic studies with limitations and a preponderance of benefit over harm.***

*Action Statement Profile*

- Quality improvement opportunity: Reduce unnecessary testing and costs, reduce unnecessary radiation and radiographic contrast exposure (National Quality Strategy domains: safety, affordable quality care)
- Aggregate evidence quality: Grade C, based on observational studies for radiographic imaging.

- Level of confidence in evidence: Medium
- Benefits: Facilitate timely treatment by avoiding unnecessary testing associated with low yield and potential false positive diagnoses. Avoid radiation exposure and adverse reactions to testing.
- Risks, harms, costs: None.
- Benefits-harm assessment: Preponderance of benefit over harm.
- Value judgments: The panel placed heavy value in the accuracy of the BPPV diagnosis at the outset in that a diagnosis made by appropriate history and Dix-Hallpike is adequate to proceed with management without further testing.
- Intentional vagueness: None.
- Role of patient preferences: None.
- Exceptions: Patients who have separate indications for radiographic or vestibular testing aside from confirming a diagnosis of BPPV.
- Policy level: Recommendation against.
- Differences of opinion: None

#### *Supporting Text*

The purpose of this statement recommending against radiographic imaging is to optimize patient care, promote effective diagnosis and therapy, and reduce variations in care. The committee chose to focus on radiographic imaging in BPPV (as opposed to other diagnostic measures that can be employed) as the cost of diagnostic imaging can be significant, its use common and there is a body of literature available examining its use in BPPV from which to draw conclusions. The diagnosis of BPPV is based on the clinical history and physical

examination. Routine radiographic imaging is unnecessary in patients who already meet clinical criteria for the diagnosis of BPPV (Table 6). Further radiographic may have a role in diagnosis if the clinical presentation is felt to be atypical, if Dix-Hallpike testing elicits equivocal or unusual nystagmus findings or if additional symptoms aside from those attributable to BPPV are present, suggesting an accompanying modifying central nervous system or otologic disorder.

Radiographic imaging, most commonly central nervous system imaging using magnetic resonance or computed tomographic techniques, is commonly obtained in the evaluation of a primary symptom complaint of vertigo. However, routine imaging is not useful in the diagnosis of BPPV because there are no radiological findings characteristic of or diagnostic for BPPV.(Turski et al, 1996; Turski et al, 2006) This is likely due to fact that the pathology presumed to occur in BPPV within the semicircular canals occurs at a microscopic level which is beyond the resolution of current neuroimaging techniques.(Parnes et al, 2003) On a broader scale, previous retrospective reviews of elderly patients with dizziness failed to detect any significant differences in cranial MRI findings when comparing dizzy versus non-dizzy patients.(Colledge et al, 1996; Day et al, 1990). In a retrospective cohort study of 2374 patients MRI testing was not contributory to the clinical diagnosis of BPPV and neuroimaging has been shown to be of little value (Grill et al 2014).

Radiographic imaging of the central nervous system should be reserved for patients who present with a clinical history compatible with BPPV but who also demonstrate additional neurological symptoms atypical for BPPV. Radiographic imaging may also be considered for patients with suspected BPPV but inconclusive positional testing or in patients with other neurologic signs on physical examination that are not typically associated with BPPV. Such symptoms include abnormal cranial nerve findings, visual disturbances, severe headache, among



others. It should be noted that intracranial lesions causing vertigo are rare. (Hanely et al, 2001) Potential lesions causing vertigo identifiable on central nervous system imaging include cerebro-vascular disease, demyelinating disease or an intracranial mass and these findings are most often located in the brainstem, cerebellum, thalamus or cortex.(Hanely et al, 2001) In small case series, positional vertigo and nystagmus have been associated with neuro-vascular compression of the VIIIth cranial nerve, vestibular schwannoma, Arnold Chiari malformation, and a variety of cerebellar disorders.(Brandt & Dieterich, 1994; Jacobson et al, 1995; Kumar et al, 2002)

In contrast to BPPV, such conditions are quite rare and typically present with additional neurologic symptoms in conjunction with the vertigo. Routine neuroimaging has not been recommended to discern these conditions from the more common causes of vertigo. (Gizzi et al, 1996) The costs of routine imaging in cases of BPPV are not justified given that it does not improve diagnostic accuracy in the vast majority of BPPV cases. Therefore, neuroimaging should not be routinely used in the diagnosis of BPPV.

**3b. VESTIBULAR TESTING: Clinicians should not order vestibular testing in a patient who meets diagnostic criteria for BPPV in the absence of additional vestibular signs and/or symptoms inconsistent with BPPV that warrant testing.** *Recommendation against vestibular testing based on diagnostic studies with limitations and a preponderance of benefit over harm.*

#### Action Statement Profile

- Quality improvement opportunity: Reduce unnecessary testing and costs (National Quality Strategy domains: safety, affordable quality care)
- Aggregate evidence quality: Grade C, based on diagnostic studies with limitations in referred patient populations and observational studies for vestibular testing.

- Level of confidence in evidence: Medium
- Benefits: Facilitate timely treatment by avoiding unnecessary testing associated with low yield and potential false positive diagnoses. Avoid patient discomfort from nausea and vomiting from vestibular testing. Reduced costs from unnecessary testing.
- Risks, harms, costs: None
- Benefits-harm assessment: Preponderance of benefit over harm
- Value judgments: None
- Intentional vagueness: None
- Role of patient preferences: None
- Exceptions: Patients who have separate indications for vestibular testing aside from confirming a diagnosis of BPPV
- Policy level: Recommendation against
- Differences of opinion: None

#### *Supporting Text*

The purpose of this statement is to emphasize that patients with a history and symptoms consistent with BPPV should not routinely undergo comprehensive vestibular testing unless there are other factors or concerns that would necessitate such testing.

Vestibular function testing involves a battery of specialized tests which primarily record nystagmus in response to labyrinthine stimulation and/or voluntary eye movements. The components of the vestibular function test battery identify abnormalities in ocular motility as

well as deficits in labyrinthine response to position change, caloric stimulation, rotational movement, and static positions (sitting and supine). Caloric testing is an established, widely accepted technique which is particularly useful in determining unilateral vestibular hypofunction. Rotational chair testing is considered the most sensitive and reliable technique for quantifying the magnitude of bilateral peripheral vestibular hypofunction (Fife et al, 2000). There are other tests which may also be considered. Postural stability testing allows for assessment of the impact of vestibular dysfunction on balance. Vestibular evoked myogenic potentials (VEMP) (ocular and cervical) provides information about the utricle and saccule, respectively. Video head impulse testing allows for assessment of the function of each semicircular canal. Some or all of these test components may be included in a vestibular test battery. These tests are useful in the evaluation of vestibular disorders that may not be evident from the history and clinical examination, and may provide information for quantification, prognostication and treatment planning (Gordon et al, 1996).

The diagnosis of BPPV is based on the clinical history and physical examination with a positive result on the Dix-Hallpike test. Fortunately, this can be accomplished by a trained clinician without specialized testing equipment and an appropriate canalith repositioning procedure (CRP) can be implemented immediately. In a retrospective chart review of 100 consecutive patients referred for vestibular assessment, Phillips et al, (2009) estimated a 9% reduction in referrals for this specialized testing could be realized if the initial provider obtained a thorough case history and completed a Dix-Hallpike test. Comprehensive vestibular testing is unnecessary in patients who already meet clinical criteria for the diagnosis of BPPV (Table 6). This does not imply that use of video-oculographic technology

with or without recording should not be used when available to help in identification and differentiation of types of BPPV.

Comprehensive vestibular testing may have a role in diagnosis if the clinical presentation is felt to be atypical, if Dix-Hallpike testing elicits equivocal or unusual nystagmus findings, if the diagnosis is unclear, or if additional symptoms aside from those attributable to BPPV are present, suggesting an accompanying modifying central nervous system or otologic disorder. It may also be beneficial when multiple concurrent peripheral vestibular disorders are suspected (Baloh et al, 1987; Kentala, 1996; Kentala et al, 2000).

In cases of BPPV where the nystagmus findings are suggestive but not clear, there may be benefit to using video-oculographic recordings of nystagmus associated with posterior canal BPPV, as the eye can be enlarged on a screen for detail, and may be replayed for further study or second opinion. In a small percentage of cases, patients with a history of positional vertigo but unclear nystagmus findings may undergo vestibular function testing. Among complex patients referred for subspecialty evaluation of BPPV, such atypical or unclear nystagmus findings may approach 13% in patients with diagnoses suspicious for BPPV (Bath et al, 2000).

BPPV is relatively frequently associated with additional vestibular pathology. Symptoms associated with an underlying, previously present, chronic vestibular dysfunction may persist following appropriate treatment for BPPV, even if the treatment is effective in resolving the specific complaint of positional vertigo. For example, in highly selected subsets of patients referred for subspecialty evaluation of BPPV, additional otopathology and/or vestibulopathy has been identified in 31% to 53% of BPPV patients (Baloh et al, 1987; Roberts et al, 2005;

Korres & Balatsouras, 2004). Abnormalities of the cervical VEMP have been reported in 25.8% to 34.8% of patients with BPPV (Hong et al, 2008; Longo et al, 2012). Lee et al. (2013) found that 50% of patients with recurrent BPPV had abnormalities on either cervical or ocular VEMP which was significantly more than the 15% of patients with non-recurrent BPPV. These VEMP abnormalities have been interpreted as suggestive of more complicated otolith dysfunction in some patients with BPPV and this negatively impacts quality of life for these patients (Hoseinabadi et al, 2015). These results have typically been measured for patients referred to specialty care centers such as audiology, neurology, or otolaryngology and may be higher than expected for patients seen by first-line, non-specialty clinicians. Vestibular disorders that have been associated with BPPV include Meniere's Disease, viral vestibular neuritis and labyrinthitis (Karlberg et al, 2000; Hughes & Proctor, 1997). Vestibular function testing may be obtained when these additional diagnoses are suspected based on signs or symptoms in addition to those of BPPV.

In patients with vestibular pathology in addition to BPPV, canalith repositioning procedures appear to be equally effective in resolving the positional nystagmus associated with BPPV, but complete symptom resolution is significantly less likely in this patient population. In one study, 86% of patients with BPPV without associated vestibular pathology reported complete resolution of symptoms after CRP versus only 37% reporting complete resolution when additional vestibular pathology was present (Pollak et al, 2002). Thus, patients with suspected associated vestibular pathology *in addition* to BPPV may be a subset who benefit from the additional information obtained from vestibular function testing. Similarly, 25% to 50% of patients with separate recurrences of BPPV are more likely to have associated vestibular pathology (Del Rio & Arriaga, 2004; Lee et al, 2013) and therefore

1144 patients with recurrent BPPV may be candidates for vestibular function testing which could  
1145 lead to additional targeted management

1146 In summary, patients with a clinical diagnosis of BPPV according to guideline criteria  
1147 should not routinely undergo vestibular function testing because the information provided from  
1148 such testing adds little to the diagnostic accuracy or subsequent management in many cases. The  
1149 Dix-Hallpike test and canalith repositioning procedures can be completed by most trained  
1150 clinicians in a variety of healthcare settings without specialized equipment. This increases access  
1151 to healthcare and decreases associated costs. Comprehensive vestibular function testing, or  
1152 components thereof, is warranted in patients (1) exhibiting atypical nystagmus, (2) suspected of  
1153 having additional vestibular pathology, (3) with a failed (or repeatedly failed) response to CRP  
1154 or (4) with frequent recurrences of BPPV.

1155 **4a. REPOSITIONING PROCEDURES AS INITIAL THERAPY: Clinicians should treat,**  
1156 **or refer to a clinician who can treat, patients with posterior canal BPPV with a canalith**  
1157 **repositioning procedure. *Strong recommendation based on systematic reviews of randomized***  
1158 ***controlled trials and a preponderance of benefit over harm.***

1159 *Action Statement Profile*

- 1160 • Quality improvement opportunity: To promote effective treatment of posterior canal  
1161 BPPV ((National Quality Strategy domain: promoting effective prevention/treatments)
- 1162 • Aggregate evidence quality: Grade A, based on systematic reviews of randomized  
1163 controlled trials.
- 1164 • Level of confidence in evidence: High for otolaryngology or subspecialty settings. Lower  
1165 in primary care settings where evidence is more limited.

- Benefits: Prompt resolution of symptoms with a relatively low number needed to treat ranging from 1 to 3 cases.
- Risks, harms, costs: Transient provocation of symptoms of BPPV by the procedure. Risk for falls due to imbalance after the procedure. No serious adverse events reported in RCTs.
- Benefits-harm assessment: Preponderance of benefit over harm.
- Value judgments: High value ascribed to prompt resolution of symptoms and the ease with which the CRP may be performed.
- Intentional vagueness: None
- Role of patient preferences: Moderate.
- Exceptions: Patients with physical limitations including cervical stenosis, Down's syndrome, severe rheumatoid arthritis, cervical radiculopathies, Paget's disease, morbid obesity, ankylosing spondylitis, low back dysfunction, retinal detachment, carotid stenosis and spinal cord injuries may not be candidates for this procedure or may need specialized examination tables for performance of the procedure.
- Policy level: Strong recommendation
- Differences of opinion: None.

#### *Supporting Text*

The purpose of this statement is to provide evidence for and promote the specific use of canalith repositioning procedures (CRP) as the initial treatment to resolve symptoms and disability secondary to posterior and lateral canal BPPV. There is high quality and compelling evidence that patients diagnosed with posterior and lateral semicircular canal BPPV should be offered expeditious treatment with CRP. These are specific and distinct from

1189 habituation/movement exercise such as the Cawthorne-Cooksey exercises or Brandt-Daroff  
1190 exercises. Treatment of BPPV with CRPs consistently eliminates the disabling vertigo and can  
1191 also improve quality of life, and reduce the risk of falling.

## 1192 POSTERIOR CANAL BPPV TREATMENTS

1193 There are two distinct basic types of CRP for posterior canal BPPV (1) the canalith  
1194 repositioning procedure (commonly referred to as the Epley maneuver) and (2) the liberatory  
1195 maneuver (commonly referred to as the Semont maneuver). Where previous therapeutic  
1196 exercises were based on habituation, these maneuvers work directly on either freeing/liberating  
1197 the adhered otoconia on the cupula (cupulolithiasis) and/or by moving free floating otoconia  
1198 (canalithiasis) out of the involved semicircular canal and back into the vestibule. There is  
1199 significant evidence for the efficacy of both procedures for BPPV in the posterior semicircular  
1200 canal and steadily advancing evidence for lateral semicircular canal.

1201

### 1202 *Treatment with canalith repositioning procedure (CRP) or “Epley maneuver”*

1203 CRP was first described by Epley in 1992. (Epley, 1992). Patients are moved  
1204 sequentially through a series of head position changes, designed to utilize gravity to move free-  
1205 floating particles through the alignment of the posterior semicircular canal back into the  
1206 vestibule, thereby relieving the pathologic stimulus which had been producing the vertigo in  
1207 BPPV. Figure 3 depicts the CRP for posterior semicircular canal BPPV. There are over 20  
1208 years of evidence to support CRP for this indication although many studies were non-  
1209 randomized case series (Lynn et al, 1995; Li, 1995; Lempert et al, 1997; Wolf et al, 1999;  
1210 Lopez-Escamez et al, 1999; Asawavichianginda, et al, 2000; Froehling et al, 2000; Sherman &  
1211 Massoud, 2001; Angeli et al, 2003; Yimtae et al, 2003; Change et al, 2004; White et al, 2005;



Woodworth et al, 2004; Teixeira & Machado, 2006). Most studies used symptom resolution as the primary outcome, but more recently conversion to a negative provocative procedure [Dix-Hallpike has been reported. A 2010 meta-analysis of the CRP (Prim-Espada et al 2010), found that patients treated with CRP had a 6 1/2 times greater chance of improvement in clinical symptoms relative to controls [OR of 6.52 (95%CI 4.17-10.20)] and similar likelihood of negative Dix-Hallpike maneuver [OR 5.19 (95% CI, 2.41-11.17)].

The 2014 updated Cochrane Collaborative Review (Hilton & Pinder, 2014), included 11 trials (745 patients) and reported that CRP is more effective compared to sham maneuvers or controls. Complete resolution of vertigo occurred significantly more often in the CRP treatment group when compared with sham or control [OR 4.42, (95% CI, 2.62 to 7.44)]. Conversion from a positive to a negative Dix-Hallpike was more likely in the CRP treatment group than the sham or controls [OR 9.62 (95% CI, 6.0 to 15.42)]. Importantly, a single CRP is over ten times more effective than a week of three times daily Brandt-Daroff (BD) Exercises [OR 12.38, 95% CI, 4.32 to 35.47)]. The randomized prospective clinical trial specifically cited in the Cochrane review (Amor-Dorado JC et al 2012) showed that by day 7 the Dix-Hallpike was negative in 80.5% of CRP versus 25% in the BD group. Differences between the groups remained statistically significant at one month. Bruintjes (Bruintjes TD, 2014), looked at CRP versus sham maneuver over long term (12 months). They found that both conversion too negative Dix-Hallpike [91% versus 46% (p=0.001) and perceived disability (p=0.003) as assessed by the Dizziness Handicap Inventory (DHI) significantly favored CRP.

The CRP is most commonly performed in the outpatient setting by a clinician after the diagnosis of posterior semicircular canal BPPV has been confirmed. (Fife et al, 2008) Patients should be informed that nausea, occasional vomiting and/or a sense of falling may arise during

the CRP.

(Uneri, 2005) Patients who previously manifested severe nausea and/or vomiting with the Dix-Hallpike maneuver may be offered antiemetic prophylaxis 30-60 minutes prior to CRP.

#### *Treatment with the liberatory maneuver (LM) or “Semont”*

The liberatory (Semont) maneuver, developed by Semont et al (Semont et al, 1988), (depicted in Figure 4) utilizes both inertial and gravity forces to move patients briskly down into a side lying position (involved side) and then through a rapid 180-degree arc to their uninvolved side. As with all CRP, the LM was designed to move the debris from the posterior semicircular canal back into the vestibule by principally breaking the canaliths free from adherence to the cupula (cupulolithiasis) and/or reposition free floating canaliths (canalithiasis). Early studies looking at the LM have demonstrated its effectiveness over sham treatments with initial success rates similar to CRP (Cohen & Kimball, 2005), and better than medication treatment (Salvinelli et al, 2003) or Brandt Daroff exercises (Soto Varel et al, 2001). Recent Cochrane Collaborative Review (Hilton & Pinder, 2014) showed no difference when comparing effectiveness of LM with CRP. Chen et al (Chen Y et al, 2012) demonstrated the short-term effectiveness of the LM in a double-blind randomized trial with conversion to negative Dix-Hallpike on the fourth day in 85% of patients treated LM versus 14% in control group ( $p=0.001$ ). Some authors advocate the LM over CRP in cases of resistant BPPV, however research is lacking to demonstrate a benefit of LM in this subgroup.

Table 10 summarizes recent RCTs evaluating CRP for posterior semicircular canal BPPV. Of note, treatment effects between CRP and control patients tended to diminish over time. *The*

majority of RCTs for CRP continue to take place in specialized or tertiary clinical settings, which may limit the generalizability of these results. For example, in the Munoz 2007 RCT, investigators were unable to demonstrate a significant benefit for the CRP based on symptomatic outcome in a primary care setting, although the conversion to a negative Dix-Hallpike at one week was more likely in the CRP group than those treated with sham maneuvers (Munoz et al, 2007). Since both the symptomatic response rates and conversion rates to a negative Dix-Hallpike maneuver are lower than those reported in specialty setting RCTs, further investigation into the effectiveness of the CRP in the primary care setting is warranted.

Considerable variability exists in terms of the number of times the CRP is applied for the initial treatment of BPPV, even across RCTs (Froehling et al, 2000; Lynn et al, 1995; Yimtae et al, 2003). Some investigators perform only one CRP cycle at the initial treatment whereas others repeat a fixed number of cycles or perform the CRP repeatedly until the vertiginous symptoms extinguish or the Dix-Hallpike converts to negative. (Lynn et al, 1995) Even further variability exists among published case series for CRP. (Ruckenstein, 2001; Sekine et al, 2006; Prokopakis et al, 2005). A rapid systematic review in 2014 (Reinink, 2014) concluded that multiple studies with high relevance and moderate risk of bias show a benefit of multiple treatments with the CRP in patients with BPPV who are not fully cleared. Specifically, in studies reviewed, 32%-90% of patients cleared in the first treatment session, 40-100% after second treatment session, 67%-98% after the third treatment session, 87%-100% after the fourth treatment session, and 100% in studies in which patients received 5 treatment sessions. Based on a review of the literature, it was not possible to determine the optimal number of treatments with the CRP however there is a demonstrated beneficial effect of multiple treatment sessions in patients with persistent nystagmus following the initial maneuver.

With respect to complications of treatment, CRP is associated with mild and generally self-limiting adverse effects in about 12% of those treated. (Fife et al, 2008) Some patients may experience an immediate falling sensation within 30 minutes after the maneuver and may benefit from counseling prior to the maneuver (Ear Nose Throat J. 2005 Feb;84(2):82, 84-5.). Serious complications from the CRP have not been identified in multiple randomized controlled trials. The most commonly encountered complications include nausea, vomiting, fainting and conversion to lateral canal BPPV during the course of treatment (so called “canal switch or conversion”). Canal conversion occurs in about 6-7% of those treated with CRP (Yimtae et al, 2003; Herdman & Tusa, 1996) underscoring the importance of recognizing the lateral canal variant of BPPV and need for more unique and different CRP. Another potential side effect after the CRP is postural instability that can last 24 hours with a tendency to fall backwards or forwards. Anecdotally, several investigators have suggested that the CRP should be applied cautiously in patients with cervical spine disease, certain vascular conditions, retinal detachment and other contraindications to its performance. (Sridhar & Panda, 2005)

#### LATERAL (HORIZONTAL) SEMI-CIRCULAR CANAL BPPV CRP TREATMENTS

Evidence is mounting for the effectiveness of unique repositioning procedures based on semi-circular canal involvement. Although such evidence exists, the complexities associated with determining the affected side and subtype (geotropic versus apogeotropic) of the lateral canal BPPV may limit the ease of applicability of such procedures since it is paramount to determine the sidedness prior to CRP treatment in lateral canal BPPV. Nonetheless, the panel felt that information on the use of these procedures would be valuable to include as the panel anticipated increased knowledge of this type of BPPV over the next guideline update cycle.

Given that any CRP for BPPV is a direct application of anatomy of the semi-circular canal with respect to gravity, lateral semicircular canal BPPV is usually unresponsive to canalith repositioning procedures used for posterior semicircular canal BPPV, but is being found responsive to other maneuvers intended to move the displaced otoconia in the unique plane of the lateral semicircular canal. Lateral semicircular canal BPPV exists in two forms, geotropic form or apogeotropic. The best researched and most clinically responsive form is the geotropic form. CRP effectiveness specific to the lateral semicircular canal were initially described in 1996 (Lempert & Tiel-Wilck, 1996; Herman & Tusa, 1996; Fife, 1998) with the first maneuver reported as 270-360 degree “Barbeque roll” in the plane of the lateral semicircular canal (White et al, 2005; Prokopakis et al, 2005). (Figure 5) A subsequent maneuver, termed the Gufoni maneuver, was developed by Gufoni in 1998 (original publication in English by Appiani and colleagues in 2001(Appiani GC et al 2001), which involves laying sideways onto the uninvolved side and then turning the head into the terminal nose down position. (Figure 6) As with the CRP for the posterior semicircular canal, either maneuver may be performed in the outpatient setting after a diagnosis of lateral semicircular canal BPPV has been made with the supine roll test (Figure 2).

Several cohort studies and case series have reported response rates from 50% to 100% using the barbecue roll maneuver to treat lateral semicircular canal BPPV (geotropic form) (White et al, 2005; Fife et al, 2008; Nuti et al, 1998; Tirelle & Russolo, 2004; Casani et al, 2002; Prokopakis et al, 2005; Fife, 1998; Lempert & Tiel-Wilck, 1996; Appiani et al, 1997; Asprella Libonati, 2005; Chiou et al, 2005). Lateral semicircular canal BPPV may spontaneously remit more quickly than other forms of BPPV. (Moon et al, 2006; Sekine et al, 2006). There have also been several recent randomized controlled studies on both forms of lateral semicircular canal

BPPV. (Casani, 2011; Kim JS et al, 2012; Kim JS et al, 2012b; Van den brock, 2014) Casani (Casani et al 2011) demonstrated the effectiveness of these two types of CRP's in treating the geotropic form of lateral semicircular canal BPPV, comparing the results of the barbeque maneuver plus forced prolonged positioning (resting in bed for at least 12 hours with the head turned toward the unaffected ear) versus the Gufoni maneuver in a randomized prospective clinical trial with 81% success versus 93%, respectively, as determined by absence of vertigo and nystagmus on the supine roll test at follow-up examination. A study by Kim in 2012 for geotropic lateral semicircular canal BPPV with 170 consecutive patients in 10 nationwide dizziness clinics in Korea (Kim JS et al 2012), reported that after a maximum of 2 maneuvers on the initial visit day, both the barbeque roll and Gufoni maneuver were better than sham maneuvers at both one hour and one month after treatment (69%, 61%, and only 35% respectively). In the Kim study for the apogeotropic lateral semicircular canal BPPV (Kim JS et al 2012b) statistically significant results were also noted for specific CRP (modified Gufoni or therapeutic headshaking) over sham maneuvers at 73%, 62%, and only 35% for both immediate and long-term outcomes. A recent systematic review of the Gufoni maneuver for the treatment of geotropic form of lateral semicircular canal BPPV (Van den brock et al, 2014), found the Gufoni maneuver was easy to perform and more effective than sham maneuver or vestibular suppressants.

Forced prolonged positioning, as mentioned in the previously discussed Casani study, is another treatment that has been found effective for lateral semicircular canal BPPV. This involves laying for an entire night on the uninvolved side (for the geotropic form) or the involved side (for the Apogeotropic form). It may be performed either alone or concurrently with other maneuvers (Casani, 2011). The effectiveness based on case series ranged from 75-90%. (Casani

et al, 2002; Appiani et al, 1997; Chiou et al, 2005; Vannucchi et al, 1997) Other lesser-known maneuvers such as the Vannucchi-Asprella liberatory maneuver (Asprella Libonati, 2005; Appiani et al, 2005,) have also been reported as effective in uncontrolled studies.

In summary, variations of the barbecue roll maneuver or Gufoni maneuver appear moderately effective for the geotropic form of lateral semicircular canal BPPV. Other methods are not supported by randomized controlled trials. For the apogeotropic form of lateral semicircular canal BPPV, there is only a single randomized control trial (Kim, 2012) providing insufficient evidence to recommend a preferred CRP.

#### SELF-ADMINISTERED CRP

CRP (Epley) and the liberatory maneuver have both been modified for self-administration by patients for the treatment of BPPV (Radtke et al, 1999; Radtke et al, 2004). Self-administered CRP appears to be more effective (64% improved) than self-treatment with Brandt Daroff exercises (23% improvement) (Radtke et al, 1999) Another trial reported that self-administered CRP (Epley) resulted in 95% resolution of positional nystagmus 1 week after treatment compared to 58% for patients self-administered liberatory maneuver (Semont) maneuver ( $p < 0.001$ ). (Radtke et al, 2004). No comparison studies have been published from which to make recommendations regarding self-treatment versus clinician-administered treatment of BPPV.

Table 10: RCTs evaluating the effectiveness of Epley vs. control/placebo; or Epley vs. Brandt-Daroff or Semont for posterior canal BPPV

| Reference | Time point of assessment | Improved in treatment group n/N | Improved in control group n/N | Endpoint | P value | Odds Ratio (95% CI) |
|-----------|--------------------------|---------------------------------|-------------------------------|----------|---------|---------------------|
|-----------|--------------------------|---------------------------------|-------------------------------|----------|---------|---------------------|

|                        |           |                      |                      |  |             |                            |
|------------------------|-----------|----------------------|----------------------|--|-------------|----------------------------|
| Amor<br>Dorado<br>2012 | 1 week    | 33/41 (80%)<br>Epley | 10/40<br>(25%)<br>BD | Negative<br>Dix-<br>Hallpike:<br>Epley vs<br>BD<br>exercises         | $P < 0.001$ | 12.38<br>[4.34,<br>35.47]  |
|                        | 1 month   | 92.00%**             | 42.50%<br>**         | Negative<br>Dix-<br>Hallpike:<br>Epley vs<br>BD<br>exercises         | $p < 0.001$ |                            |
| Bruintjes<br>2014      | 12 months | 20/22 (91%)          | 10/22<br>(45%)       | Negative<br>Dix-<br>Hallpike:<br>Epley vs<br>control or<br>placebo   | $p < 0.001$ | 12.00<br>[2.24,<br>64.28]  |
|                        | 1 month   | 21/22 (96%)          | 8/22<br>(36%)        | Negative<br>Dix-<br>Hallpike:<br>Epley vs<br>control or<br>placebo   | $p < 0.001$ |                            |
| Froehling<br>2000      | 1-2 weeks | 16/24 (67%)          | 5/26<br>(19%)        | Negative<br>Dix-<br>Hallpike:(<br>Epley vs<br>control or<br>placebo) | $P = 0.020$ | 3.20<br>[1.00,<br>10.20]   |
| Liang<br>2010          | 7 days    | 42/43 (98%)          | 34/44<br>(77%)       | cured*(E<br>pley vs<br>control or<br>placebo)                        | $p < 0.05$  | 12.35<br>[1.51,<br>101.36] |



|   |           |                      |                          |  |         |                             |
|---|-----------|----------------------|--------------------------|--|---------|-----------------------------|
| Lynn<br>1995                                  | 2 weeks   | 16/18 (89%)          | 4/15<br>(27%)            | Negative<br>Dix-<br>Hallpike:(<br>Epley vs<br>control or<br>placebo) | P<0.033 | 22.00<br>[3.41,<br>141.73]  |
| Mazoor<br>2011                                | 1 week    | 22/30 (73%)<br>Epley | 21/30<br>(70%)<br>Semont | Negative<br>Dix-<br>Hallpike:<br>(Epley vs<br>Semont)                | p=0.08  | 1.18<br>[.38,<br>3.63]      |
|   | 4 weeks   | 28/30 (93%)<br>Epley | 25/30<br>(83%)<br>Semont | Negative<br>Dix-<br>Hallpike:<br>(Epley vs<br>Semont)                | P=0.30  |                             |
| Munoz<br>2007<br>(Primary<br>care<br>setting) | Immediate | 13/38 (34%)          | 6/41<br>(14%)            | Negative<br>Dix-<br>Hallpike:(<br>Epley vs<br>control or<br>placebo) | p=0.04  | 3.03<br>[1.01,<br>9.07]     |
| von<br>Bevern<br>2006                         | 24 hours  | 28/35 (80%)          | 3/31<br>(10%)            | Negative<br>Dix-<br>Hallpike:(<br>Epley vs<br>control or<br>placebo) | P<0.001 | 37.33<br>[8.75,<br>159.22]  |
| Xie 2012<br>(Primary<br>care<br>setting)      | 7 days    | 54/58 (93%)          | 11/45<br>(24%)           | Cured*:(<br>Epley vs<br>control or<br>placebo)                       | p<0.05  | 41.73<br>[12.29,<br>141.65] |
| Yimtae<br>2003                                | 1 week    | 22/25 (88%)          | 13/20<br>(65%)           | Negative<br>Dix-<br>Hallpike:<br>(Epley vs<br>control or<br>placebo) | P=0.005 | 3.95<br>[0.87,<br>17.99]    |

|  |         |             |               |  |         |                     |
|--|---------|-------------|---------------|--|---------|---------------------|
|  | 4 weeks | 16/25 (64%) | 7/20<br>(35%) | Negative<br>Dix-<br>Hallpike:<br>(Epley vs<br>control or<br>placebo) | P=0.336 | 3.3 [1.0<br>- 11.3] |
|--|---------|-------------|---------------|--|---------|---------------------|

1371

1372 *RCT: Randomized Controlled Trials*

1373

1374 *BD: Brandt Daroff*

1375 *CI: Confidence*

1376 *OR: Odds ratio*

1377 *\*Cured: outcomes reported as a composite measure of symptom resolution and Hallpike test*

1378 *result)*


1379 *\*\* : Raw values not given in article*

1380 All RCTs completed in secondary or tertiary care otolaryngology settings except where

1381 designated

1382

1383



**Figure 3: Depiction of the canalith repositioning maneuver (Epley maneuver) for right ear posterior semicircular canal BPPV (refer to table 11 for description).**

**Table 11: Stepwise sequence for the performance of the canalith repositioning maneuver (see Figure 3)**


| Step | Action |
|------|--------|
|------|--------|

|   |   |
|---|---|
| 1 | The patient is placed in the upright position with the head turned 45° toward the affected ear (the ear that was positive on the Dix-Hallpike testing).   |
| 2 | The patient is rapidly laid back to the supine head-hanging 20 ° position, which is then maintained for 20-30 seconds.  |
| 3 | Next, the head is turned 90° toward the other (unaffected) side and held for about 20 seconds.  |
| 4 | Following this, the head is turned a further 90° (usually necessitating the patient's body to also move from the supine position to the lateral decubitus position) such that the patient's head is nearly in the facedown position. This is also held for 20-30 seconds. |
| 5 | The patient is then brought into the upright sitting position, completing the maneuver.   |

1394

1395

1396



**Figure 4. Semont Liberatorary Maneuver for treatment of right posterior semicircular canal BPPV (see Table 12 for description).**

**Table 12: Stepwise description of the performance of the Semont liberatory maneuver (right ear affected)**

| Step | Description  |
|------|--|
| 1    | Start with the patient sitting on a table or flat surface with head turned away from the affected side.  |
| 2    | Quickly put the patient into the side-lying position, toward the affected side with the head turned up. Nystagmus will occur shortly after arriving at the side-lying position. Keep the patient in this position until at least 20 seconds after all nystagmus has ceased (some recommend up to 1-2 minutes). |

|   |  |
|---|--|
| 3 | Quickly move the patient back up and through the sitting position so that he or she is in the opposite side-lying position with head facing down (head did not turn during the position change). Keep the patient in this position for about 30 seconds (some recommend 2-10 minutes). |
| 4 | At a normal or slow rate, bring the patient back up to the sitting position.   |


1404

1405

1406

CONFIDENTIAL DRAFT

**Lempert Roll Maneuver**



1408

1409

1410

1411

1412

1413

Figure 5. The Lempert 360-degree roll maneuver (sometimes referred to as the barbecue roll maneuver) for the treatment of right lateral SSC BPPV-geotropic type.

**Table 13: Stepwise description of the performance of the Lempert 360° roll maneuver (barbecue roll maneuver) for the treatment of right lateral canal BPPV-geotropic type**


| Step | Description*   |
|------|--|
| 1    | Starting from the supine position OR                 |
| 2    | Some recommend rolling to start on the involved side |

|       |  |
|-------|--|
| 3     | Roll his/her head (or full body) to the unaffected side.   |
| 4     | Keep rolling in the same direction until his/her head is completely nose down or prone. Some recommend ending the maneuver here and returning to sit (270-degree roll) as anatomically the debris is repositioned. |
| 5,6,7 | As originally published, however, complete the final roll (full 360) and return to sitting.  |

\*Each position pictured is held for 15-30 seconds or until nystagmus stops.



Gufoni: Geotropic **1**



1418

1419 **Figure 6. Gufoni maneuver for treatment of right-sided lateral semicircular canal BPPV-**  
1420 **geotropic type (see Table 14 for description).**

1421


1422 **Table 14: Gufoni maneuver for treatment of right-sided lateral semicircular canal BPPV-**  
1423 **geotropic type.**

| Step | Description   |
|------|---|
| 1    | The patient is taken from the sitting position to the straight side lying position on the unaffected side for about 30 seconds. |
| 2    | Then patient's head is quickly turned toward the ground 45-60 degrees and held in position for 1-2 minutes.                     |
| 3    | The patient then sits up again with the head held toward the left shoulder until fully upright and then may be straightened.    |

1424

1425

# Gufoni: Ageotropic



1426

1427 **Figure 7. Gufoni maneuver for treatment of right-sided lateral semicircular canal BPPV-**

1428 **Apogeotropic type (See Table 15 for description).**

1429

1430 **Table 15: Gufoni maneuver for treatment of right-sided lateral semicircular canal BPPV-**

1431 **Apogeotropic type.**

| Step | Description |
|------|-------------|
|------|-------------|

|   |   |
|---|---|
| 1 | The patient is taken from the sitting position to the straight side lying position on the affected side (right side in this instance) for about 30 seconds  |
| 2 | From this point there are <u>2 variations of this maneuver</u> that have been utilized, based on the possibility that debris can be on either on the on the utricular <b>OR</b> the canal side of the cupula (or just lodged in the anterior arm of the lateral semicircular canal).  |
| 3 | <p><b>(Pictured here)</b> The patient's head is then quickly turned toward the ground 45-60 degrees and held in position for 1-2 minutes which would free the debris from the utricular side of the cupula. The patient then sits up again with the head held toward the left shoulder until fully upright and then may be straightened.</p> <p><b>(Not pictured):</b> In variation 2, move the patient's head NOSE UP 45-60 degrees and held in that position for 1-2 minutes that would free the debris from the canal side of the cupula (or from being lodged in the anterior arm of the lateral semicircular canal).</p> |

**4b. POST-PROCEDURAL RESTRICTIONS: Clinicians should not recommend post- procedural postural restrictions after canalith repositioning procedure for posterior canal BPPV. *Strong recommendation against restrictions based on randomized controlled trials with minor limitations and a preponderance of benefit over harm.***

1439

1440 *Action Statement Profile*

- 1441 • Quality improvement opportunity: Avoidance of unnecessary interventions, engaging
- 1442 patients, decreasing use of ineffective treatments (National Quality Strategy domain:
- 1443 coordination of care)
- 1444 • Aggregate evidence quality: Grade A
- 1445 • Level of confidence in evidence: High
- 1446 • Benefits: Faster return to normal lifestyle, reduced anxiety, less sleep or work
- 1447 interruption, reduced musculoskeletal discomfort, reduced cost (e.g., of cervical collars)
- 1448 • Risk, harm, cost: Potential risk for increased failure risk in a small subset of patients
- 1449 • Benefit-harm assessment: Preponderance of benefit
- 1450 • Value judgments: None
- 1451 • Intentional vagueness: The generic term restrictions is used but that can include sleeping
- 1452 upright, laying on the involved side, use of a cervical collar, or any type of restriction
- 1453 • Role of patient preferences: Small
- 1454 • Exclusions: None
- 1455 • Policy level: Strong Recommendation Against
- 1456 • Differences of opinion: Several panel members had only medium confidence in the
- 1457 evidence

1458 *Supporting Text*

1459 The purpose of this statement is to emphasize that clinicians should not routinely apply  
1460 postural restrictions to patients following CRP for posterior semicircular canal BPPV.

1461 As canalith repositioning maneuvers grew in acceptance as a favored treatment choice for

BPPV, clinicians often advised patients regarding various post-maneuver restrictions. The rationale has been that mobile otoconial debris returned to the vestibule during treatment may move back into the semicircular canal if patients do not carefully avoid certain movements and positions. The actual restrictions vary among clinicians and even among reports describing research in this area. Common restrictions include avoidance of the following: sleeping without elevation of the head, sleeping with the treated ear in a dependent position, vertical head movement, etc. Soft cervical collars have been used to help remind patients to avoid certain head movements. Again, there is lack of clarity on exactly which positions and head movements should be avoided or for how long these limitations should be recommended. Some authors have reported that complications including neck stiffness are observed when patients are given these types of restrictions (De Stefano et al, 2011).

Comparison of studies, in particular the treatment arms for RCTs, reveals similar response rates whether or not post-treatment postural or activity restrictions are observed (i.e., Massoud & Ireland, 1996; Roberts et al, 2005; De Stefano et al, 2011; Balikci & Ozbay, 2014). There are at least nine investigations which indicate no effect. There are two investigations that report statistically significant benefit of using post-maneuver restrictions (Cohen & Kimball, 2004; Cakir et al, 2006).

Devaiah and Andreoli (2010) conducted a meta-analysis using data from six investigations with 523 patients meeting all inclusion criteria. Using this analysis, they found no effect when outcome of the patients from the two groups were compared. The authors state their findings contradict recommendations that post-maneuver head restrictions are necessary to maintain the effectiveness of BPPV maneuvers. This finding contrasts with a more recent systematic review by Hunt et al, 2012 which identified nine studies for further analysis of effects

of postural restrictions on BPPV treatment efficacy. They included data from 528 patients from the nine trials. Their results indicated benefit of using postural restrictions which provided a statistically significant improvement in outcome when the pooled data were considered. Still, the authors note a small effect size and state the statistically significant effect only highlights a small improvement in treatment efficacy. Since this report was published, there have been two additional investigations which report no significant effect of post-maneuver restrictions on BPPV treatment outcome (Toupet et al, 2012; Balikci & Ozbay, 2014).

Overall, there is insufficient evidence to recommend post-maneuver restrictions for most patients with posterior semicircular canal BPPV who are treated with a CRP. The clinician must bear in mind that these published investigations specifically excluded patients with BPPV and concomitant vertiginous disorders such as Meniere's disease, migraine, vestibular neuritis, etc. Patients with bilateral and/or multicanal involvement were also excluded. There is a small subset of patients with BPPV who will present with frequently recurring BPPV. That group was also not investigated in these reports. It is possible some of these groups may benefit from post-maneuver restrictions and this may be considered by the clinician in select cases.

**4c. OBSERVATION AS INITIAL THERAPY: Clinicians may offer observation with follow up as initial management for patients with BPPV.** *Option based on data from cohort and observational studies with heterogeneity and a relative balance of benefits and harms.*

#### *Action Statement Profile*

- Quality improvement opportunity: Decreased costs due to less intervention and incorporating patient preferences. (National Quality Strategy domains: engaging patients, affordable quality care)

- 1507 • Aggregate evidence quality: Grade B, based on control groups from RCTs and  
1508 observational studies with heterogeneity in follow-up and outcomes measures.
- 1509 • Level of confidence in evidence: High
- 1510 • Benefits: Symptom resolution in 15-85% at one month without intervention.
- 1511 • Risks, harms, costs: Prolonged symptoms compared to other interventions that may  
1512 expose patients to increased risks for falls or lost days of work. Indirect costs of delayed  
1513 resolution compared to other measures.
- 1514 • Benefits-harm assessment: Relative balance of benefits and harms.
- 1515 • Value judgments: The panel felt strongly in favor of treatment with CRP rather than  
1516 observation, particularly with respect to the value of an expedited time to symptom  
1517 resolution. The panel felt that observation for older patients, patients with preexisting  
1518 balance disorders or in individuals at high risks for falls may not be suitable for  
1519 observation.
- 1520 • Intentional vagueness: Definition of follow up is not explicitly specified.
- 1521 • Role of patient preferences: Large.
- 1522 • Exceptions: None.
- 1523 • Policy level: Option
- 1524 • Differences of opinion. Some panel members thought that this option was not the optimal  
1525 choice for management given the data for other interventions.

1526

1527 *Supporting Text*

1528 The purpose of this statement is to provide evidence and rationale for the use of  
1529 “observation” as a treatment option for patients with known BPPV, including the use of waiting



times prior to canalith repositioning procedure (CRP) for acute episodes or recurrences of BPPV, especially when contra-indications to treatments or a history of adverse consequences from prior treatments for BPPV are present or as per stated preferences by the patient. Delaying referrals for specialty evaluations and/or vestibular rehabilitation are also included within the category of “observation”, until such time that they are mutually agreeable with all involved.

“Observation” may be defined as a “watchful waiting”, or not immediately utilizing specific therapeutic interventions for a given disease or medical condition. Observation is typically considered when the course of the disease or condition is self-limited, and/or when it is likely to be benign, perhaps with limited sequelae as a result of no active intervention. In BPPV, observation implies that therapeutic interventions, such as vestibular rehabilitation and/or CRP, will also be withheld, thereby anticipating a natural and spontaneous improvement of the symptoms and severity of BPPV. With a course of observation, patients may still be instructed to avoid activities that may increase the risk of injury (e.g., falls), until symptoms either resolve, or until the patients are re-assessed clinically for symptom resolution.

In order to consider observation as an option in the management of BPPV, the natural history of BPPV needs to be understood. BPPV is a common, often self-limiting condition, but it can be either acute as a single episode, chronic and/or persisting. Although BPPV can manifest along all ages of the lifespan, it is relatively rare in children with steady and dramatic increase after age 40. Prevalence in patients over the age of 60 is 7x greater than ages 18-39. (von Brevern et al 2007). The cumulative lifetime incidence of BPPV was almost 10% by age 80 in one population-based survey from Germany, although the diagnoses were made by historic criteria alone, with no confirmation by the Dix-Hallpike maneuver. (Von Brevern, et al., 2007) The natural history of BPPV is usually one of eventual resolution of symptoms in most patients.

1553 In several studies, the spontaneous rate of symptomatic resolution of BPPV ranges from 27-38%  
1554 (Hilton 2014). Similarly, review of a recent commentary in a Cochrane Report states, the  
1555 "...successful resolution of BPPV with no treatment except observation in 35% - 50% of patients  
1556 indicates the rate of spontaneous recovery as part of the natural history of this condition."  
1557 (Burton, 2012)

1558 Adverse effects associated with CRP may influence decisions to avoid or delay treatment  
1559 for BPPV, in favor of observation. However, adverse effects from CRP are infrequently  
1560 reported. There are usually no serious adverse effects of treatment reported, although the rates of  
1561 nausea during the repositioning maneuver varied from 16.7% to 32%. (Hilton & Pinder, 2014) In  
1562 addition, some patients were unable to tolerate CRP because of cervical spine problems, while  
1563 others complained of headache or pain in the neck after treatments. Patients with any of the  
1564 relative contraindications cited elsewhere in this report, including cervical spondylosis, known  
1565 cervical disk disease, and/or unstable cardiac conditions, may be candidates for observation  
1566 rather than active treatment.

1567 There was no consensus present among the guideline panel members regarding the  
1568 optimal duration of observation for patients with symptomatic BPPV. However, the panel  
1569 strongly favored initial treatment with CRP, particularly in subsets of patients who are either at  
1570 higher risk for falls or are reporting more disabling symptoms given the high success rates  
1571 detailed in section 4a. For example, there is evidence in the elderly, the most common age group  
1572 to experience BPPV, that BPPV has not only a significant impact on health-related quality of life  
1573 that improves with CRP (Gamiz, 2004), but that unrecognized (or untreated) BPPV has  
1574 significant associated morbidity (impaired ADL/IADL capacity and fall prevalence at 78%  
1575 versus 35%,  $p=0.026$  with odds ratio of 6.2 (95% CI 1.2-31). (Oghalai, et al 2000) Additionally,

1576 BPPV can be a triggering event for more chronic disabling dizziness in patients who are more  
1577 distraught/anxious (Heinrichs et al, 2007) for which timely treatment is indicated. Widespread  
1578 adoption of CRP for treatment of BPPV has yet to be seen, despite CRP's documented efficacy.  
1579 Some authors are already citing the poor utilization of CRP as indicators of sub-optimal  
1580 treatment quality patterns in primary care. (Kerber, 2015) However, if cases of BPPV are not as  
1581 severe among those patients seen in primary care settings, compared to those patients visiting  
1582 subspecialty clinics or emergency departments (spectrum bias or selection bias), then observation  
1583 may become a more suitable treatment option within primary care settings. Waiting for  
1584 recurrence or persistence of what would be expected to be self-limited BPPV symptoms may be  
1585 one possible option to make the routine use of CRP and vestibular rehabilitation services a more  
1586 rational and cost-effective policy. More research is needed to resolve the influence of a potential  
1587 spectrum bias and the possible impact upon clinical trials, especially in those that include  
1588 observation as a viable option.

1589       The natural history of lateral canal BPPV is less well-defined than that of posterior canal  
1590 BPPV. Some authors have commented that lateral canal BPPV may be prone to more rapid  
1591 spontaneous resolution than posterior canal BPPV. (Moon et. al., 2006; Sekine et. al., 2006) One  
1592 study of untreated patients with posterior canal BPPV determined a mean interval from onset of  
1593 symptoms to spontaneous resolution to be about twice that of those patients with lateral canal  
1594 BPPV (39 days; n=69 vs. 16 days; n=34), and the mean time between the onset of vertigo in  
1595 lateral canal BPPV to spontaneous symptom resolution was about 16 days. (Imai, et. al., 2005)  
1596 Although repositioning maneuvers have shown success in lateral canal BPPV, the available high  
1597 quality comparative data regarding treatment versus observation, such as RCTs, are limited in  
1598 this subtype of BPPV (Sekine K. et al, 2006) Thus, observation as a management strategy for

patients with lateral canal BPPV remains as a rational option. More research is needed for the interventional management of lateral canal BPPV.

In summary, observation is an option for the management of posterior canal semicircular canal BPPV and lateral semicircular canal BPPV in some patients. Observation offers the potential benefits of avoiding provocation of new symptoms and any discomfort associated with the repositioning maneuvers themselves, or with vestibular rehabilitation. There may also be cost savings from decreased rates of referral for vestibular rehabilitation or CRP. Patients who elect observation should be informed about the possibility of longer duration of symptoms when compared to patients receiving active treatment maneuvers. There is also a potential for higher recurrence rates of another episode of BPPV with the observation option. Patient education materials may be offered to those electing the observation approach to BPPV. (Furman, et al, 2013)

**5. VESTIBULAR REHABILITATION: The clinician may offer vestibular rehabilitation in the treatment of BPPV.** *Option based on controlled observational studies and a balance of benefit and harm.*

*Action Statement Profile*

- Quality improvement opportunity: Offer additional therapy for patients with additional impairments, who fail initial CRP attempts, who are not candidates for CRP and/or who refuse CRP. Promoting effective therapy and increased patient safety (National Quality Strategy domains: safety, promoting effective prevention/treatment)
- Aggregate evidence quality: Grade “B”, based on subset analysis of a SR and limited

- 1621 RCTs.
- 1622 • Level of confidence in evidence: Medium
- 1623 • Benefits: Offer additional therapy for patients with additional impairments; prevention of
- 1624 falls, improved return of natural balance function.
- 1625 • Risks, harms, costs: No serious adverse events noted in published trials. Transient
- 1626 provocation of BPPV symptoms during rehabilitation exercises. Potential for delayed
- 1627 symptom resolution as compared to CRP as a sole intervention. Need for repeated visits
- 1628 if done with clinician supervision. Cost of therapy.
- 1629 • Benefits-harm assessment: Relative balance of benefits and harm.
- 1630 • Value judgments: The panel felt that vestibular rehabilitation, as defined in this guideline,
- 1631 may be better as an adjunctive therapy rather than a primary treatment modality. Subsets
- 1632 of patients with preexisting balance deficit, CNS disorders or risk for falls may derive
- 1633 more benefit from VR than the patient with isolated BPPV.
- 1634 • Intentional vagueness: Non-specification of type of VR nor timing (initial vs adjunctive)
- 1635 of therapy
- 1636 • Role of patient preferences: Large.
- 1637 • Exceptions: Patients with physical limitations such as cervical stenosis, Down syndrome,
- 1638 severe rheumatoid arthritis, cervical radiculopathies, Paget's disease, morbid obesity,
- 1639 ankylosing spondylitis, low back dysfunction, and spinal cord injuries.
- 1640 • Policy level: Option.
- 1641 • Differences of opinion: None

1642

1643 *Supporting Text*

The purpose of this statement is to define Vestibular Rehabilitation (VR), clarify various components of VR, including the distinction between movement/habituation-based VR versus isolated CRP, and to provide evidence for the most effective application of VR in patients with BPPV.

Vestibular rehabilitation (VR) has been defined as physical maneuvers or exercise regimens to treat dizziness and balance disorders. VR has long been recognized as an effective method for managing peripheral vestibular deficits (Cawthorne, 1944; Cooksey, 1946; Dix, 1979; Whitney & Sparto, 2011; Hillier & McDonnell 2011; McDonnell & Hillier 2015) by promoting habituation, adaptation, central compensation mechanisms and more recently *mechanical repositioning*. Thus, VR is not a single specific protocol but it refers to a broad designation of therapies that include CRP itself, as well as habituation exercises, exercises for gaze stabilization, balance retraining and facilitation of sensory and motor integration, gait retraining, fall prevention, relaxation training, conditioning exercises, functional and occupational skills retraining, and patient and family education.(Herdman et al, 2000; Telian & Shepard, 1996; Whitney & Rossi, 2000, Hall et al. 2016 (in press), McDonnell et al 2015) For the purpose of this key action statement, VR is being more narrowly defined as any additional therapy beyond isolated CRP for patients who either fail initial CRP attempts, are not candidates for CRP, have additional impairments, and/or who refuse CRP.

Two movement/habituation-based VR treatment protocols with respect to BPPV deserve specific mention, as they are well defined in the literature and often adopted in clinical practice. These are the Cawthorne-Cooksey exercises and the Brandt-Daroff exercise. The Cawthorne and Cooksey (Cawthorne, 1944) exercises consist of a series of eye, head and body movements in a hierarchy of increasing difficulty intended to provoke vestibular symptoms. Cawthorne-

1667 Cooksey type exercises begin with simple head movement exercises performed in the sitting or  
1668 supine position and progress to complex activities including walking on slopes and steps with  
1669 eyes open and closed and sports activities requiring eye-hand coordination. These exercises  
1670 theoretically fatigue the vestibular response and force the central nervous system to compensate  
1671 by habituation to the stimulus (Han et al, 2011). The Brandt and Daroff exercise was developed  
1672 specifically for BPPV and involves a sequence of rapid lateral head/trunk tilts repeated serially to  
1673 promote loosening and ultimately dispersion of debris toward the vestibule. (Brandt & Daroff,  
1674 1980; Brandt et al, 1994) In this exercise, the patient starts in a sitting position moving quickly to  
1675 the right side lying position with head rotated 45 degrees facing upward. This position is  
1676 maintained until the vertigo stops. The patient then moves rapidly to a left side lying position  
1677 with head rotated 45 degrees facing upward.

1678 Several studies have compared movement/habituation-based VR to CRP in the treatment  
1679 of posterior canal BPPV. In a RCT of 124 patients randomized to CRP (Epley or modified LM),  
1680 Brandt-Daroff exercises, vestibular habituation exercises, or sham, both habituation routines  
1681 were more effective than sham. (Cohen & Kimball, 2005; Hillier & Hollohan, 2007) However  
1682 CRP was found more effective than both habituation routines. (Cohen & Kimball, 2005; Hillier  
1683 & Hollohan, 2007) Soto Varela comparatively analyzed a total of 106 BPPV patients randomly  
1684 assigned to receive Brandt-Daroff habituation exercises, or one of two CRP (LM or the Epley  
1685 maneuver) (Soto Varela et al, 2001). At the one-week follow-up, patients treated with CRP (LM  
1686 and Epley maneuvers) experienced resolution rates of 71-74% compared to only 24% with the  
1687 Brandt & Daroff exercise. More recently, Toledo found in 2000 that CRP (LM specifically) was  
1688 superior to Cawthorne-Cooksey exercises at both 15 days and at 3 months (Toledo, 2000). In the  
1689 2015 Cochrane review of VR for unilateral peripheral vestibular dysfunction, McDonnell &

Hillier, reported not only a significant effect of VR over control or no intervention (OR of 2.67 @ 95% CI ,1.85-3.86) but that CRP was found to be superior to movement/habituation-based VR (e.g. Cawthorne-Cooksey, Brandt-Daroff) with OR of .19 (95% CI .07-.49, odds ratio for improvement with VR versus CRP). Concluding statements from the Cochrane review support intuitive thought that the primary intervention for patients with BPPV should be maneuvers (CRP) that directly treat the condition, e.g. mechanical repositioning but that other aspects of movement/habituation-based VR may further aide and support long term functional recovery. (McDonnel & Hillier, 2015, Amor-Dorado et al 2012)

Although there is evidence that movement/habituation VR should not be considered as a substitute for CRP in the initial treatment of BPPV, there is a role for VR as adjuvant therapy in the management of selected patients with BPPV. BPPV can result in significant residual complaints of more generalized dizziness (abnormal motion sensitivities not associated with provocation of nystagmus) and definable abnormal postural control with heightened fall risk even after CRP has successfully resolved paroxysmal positional nystagmus (Di Girolamo S et al 1998; Giacomini P et al 2002). There is a statistically significant increased risk for persistent postural abnormalities in the elderly in general (Blatt PJ et al 2000) where multifactorial comorbid impairments may be present. A randomized control trial found that individuals with BPPV who were treated with CRP and additional VR exercises (balance/habituation) had significantly improved measures of overall gait stability compared to those that had received isolated CRP (Epley) for their BPPV (Chang et al. 2008). Additionally, this study documented that increased balance performance was achieved in patients only when additional movement/habituation-based VR was administered. BPPV has also been noted to trigger the development of more chronic disabling dizziness which was originally described as Phobic



1713 Postural Vertigo (Brandt T 1996) and more recently Chronic Subjective Dizziness (CSD) or  
1714 Persistent Perceptual Postural Dizziness (PPPD) for which VR appears to offer critical additional  
1715 improvement. (Staab, 2012) If balance and motion tolerance doesn't improve in a timely manner  
1716 in patients treated successfully with CRP, then further clinical assessment and VR is often not  
1717 only indicated but necessary to complete healing and optimal resolution of disability.

1718 Historically, VR is offered as either a home exercise-based standardized progression or  
1719 more specialized and individually tailored exercise, termed customized VR. Where home  
1720 exercise-based VR programs (e.g. Cawthorne-Cooksey exercises) are most often provided as a  
1721 handout to a patient during initial consult with no anticipated follow-up and limited education  
1722 and instruction, customized VR is usually prescribed by a therapist who individually tailors the  
1723 exercises based on patient specific impairments/tolerance with the anticipation of follow-up to  
1724 progress the routine. Evidence for the benefits of customized VR over home exercise-based VR  
1725 have been shown in early studies (Horak FB et al 1992; Shepard & Telian 1995). Although  
1726 larger randomized controlled studies are needed, customized VR has the potential to improve  
1727 outcomes of BPPV. When delivered by a VR specialist, customized VR can provide secondary  
1728 assessment that can gather further diagnostic information and can provide individualized  
1729 modifications to the CRP (e.g. more ideal positioning with use of a trendelenburg table in  
1730 patients with limited ROM). in cases of resistive forms of BPPV or complicating co-morbidities  
1731 customized VR can offer an exercise prescription that is more comprehensive e.g. combinations  
1732 of liberatory, habituation, more specific balance and gait retraining techniques. Examples of  
1733 comorbidities that can often require customization include cervical stenosis, Down syndrome,  
1734 severe rheumatoid arthritis, cervical radiculopathies, Paget's disease, morbid obesity, ankylosing  
1735 spondylitis, low back dysfunction, and spinal cord injuries. Additionally, patients with BPPV

but with other co-morbid otologic or neurologic disorders may benefit from customized VR since they may have other vestibular, mechanical or neurological deficits that require more comprehensive and customized rehabilitation.

In summary, given the substantial evidence that movement/habituation-based VR is significantly less effective than CRP as an initial treatment for BPPV, VR should be considered an option in the treatment of BPPV rather than a recommended first-line treatment modality for BPPV. VR is, however indicated for patients with BPPV who have persistent disability following CRP, refuse CRP, or who are not candidates for CRP. VR is particularly indicated in patients with additional impairments where further therapy is needed to resolved more non-specific dizziness and those patients with heightened fall risk (e.g. elderly).

**6. MEDICAL THERAPY: Clinicians should not routinely treat BPPV with vestibular suppressant medications such as antihistamines and/or benzodiazepines. *Recommendation against routine medication based on observational studies and a preponderance of benefit over harm.***

#### *Action Statement Profile*

- Quality improvement opportunity: Decreased use of unnecessary medications with potentially harmful side effects. Reduced costs. National Quality Strategy domains: safety, promoting effective prevention/treatment, affordable quality care)
- Aggregate evidence quality: Grade C based on observational and cross-sectional studies.
- Level of confidence in evidence: Medium
- Benefits: Avoidance of adverse effects from or medication interactions with these

medications. Prevention of decreased diagnostic sensitivity from vestibular suppression during performance of the Dix-Hallpike maneuvers.

- Risks, harms, costs: None.
- Benefits-harm assessment: Preponderance of benefit over harm.
- Value judgments: To avoid harm from ineffective treatments. The panel felt that data regarding harms and side effects from non-BPPV populations with vertigo would be applicable to the BPPV patient population.
- Intentional vagueness: The panel recognized that there most likely is a very small subgroup of patients with severe symptoms who may need vestibular suppression until more definitive treatment can be offered (e.g. CRP) or immediately before and/or after treatment with CRP.
- Role of patient preferences: Small.
- Exceptions: Severely symptomatic patients refusing other treatment options and patients requiring prophylaxis for CRP.
- Policy level: Recommendation against.
- Differences of opinion: None

*Supporting Text*

The purpose of this statement is to dissuade the routine use of medication in the treatment of BPPV.

The symptoms of vertigo, due to many different underlying etiologies, may commonly be treated with medications. Clinicians may prescribe pharmacologic management to either (1) reduce the spinning sensations of vertigo specifically and/or (2) to reduce the accompanying

1781 motion sickness symptoms. These motion sickness symptoms include a constellation of  
1782 autonomic or vegetative symptoms such as nausea, vomiting, and diarrhea, which can  
1783 accompany the vertigo. Such pharmacologic therapies for vertigo may be broadly termed  
1784 vestibular suppressant medications. (Hain & Uddin, 2003; Hain & Yacovino, 2005)

1785         Several categories of vestibular suppressant medications may be used to treat a variety of  
1786 vestibular disorders in general. Among these, the most often considered are the benzodiazepine  
1787 and antihistamine drug classes. Benzodiazepines, such as diazepam and clonazepam, have  
1788 anxiolytic, sedative, muscle relaxant, and anticonvulsant properties derived from potentiating the  
1789 inhibitory effect of the gamma-amino butyric acid (GABA) system. In prolonged dizziness,  
1790 these medications can reduce the subjective sensation of spinning, but also can interfere with  
1791 central compensation in peripheral vestibular conditions. Antihistamines, on the other hand,  
1792 appear to have a suppressive effect on the central emetic center to relieve the nausea and  
1793 vomiting associated with motion sickness. Common examples of antihistamines used to treat  
1794 symptoms of vertigo and/or associated motion sickness include meclizine and diphenhydramine.  
1795 Other medications that are often used for motion sickness include promethazine, which is a  
1796 phenothiazine with antihistamine properties, and ondansetron, which is a serotonin-5HT<sub>3</sub>  
1797 antagonist. Lastly, anticholinergic medications such as scopolamine block acetylcholine, a  
1798 widespread central nervous system transmitter, and help with motion sickness by reducing neural  
1799 mismatching. (Hain & Uddin, 2003; Hain & Yacovino, 2005)

1800         Conversely, vestibular suppressant medications have the potential for significant harm.  
1801 All of these medications may produce drowsiness, cognitive deficits, and interference with  
1802 driving or operating machinery.(Ancelin et al, 2006; Hebert et al, 2007; Barbone et al, 1998;  
1803 Engeland et al, 2007; Jauregui et al, 2006) Medications used for vestibular suppression,

especially psychotropic medications such as benzodiazepines, are a significant independent risk factor for falls.(Hartikainen et al, 2007) The risk of falls increases in patients taking multiple medications and with the use of medications such as antidepressants.(Lawson et al, 2005; Hienle, et al, 2005) The potential for polypharmacy when adding vestibular suppressants further exposes the elderly to additional risk.(Landi et al, 2007) Educational programs to modify a practitioner's use of such medications can result in a reduction of falls.(Pit et al, 2007)

There are other potential harmful side effects of vestibular suppressants. Benzodiazepines and antihistamines interfere with central compensation for a vestibular injury. (Hanley et al, 2001; Baloh, 1998a; Baloh, 1998b) The use of vestibular suppressants may obscure the findings on the Dix-Hallpike maneuvers. In addition, there is evidence of additional potential harm from the antihistamine class of medications on cognitive functioning (Ancelin et al, 2006) and on GI motility, urinary retention, vision and dry mouth in the elderly. (Rudolph et al, 2008)

There is no evidence in the literature to suggest that any of these vestibular suppressant medications are effective as a definitive, primary treatment for BPPV, or effective as a substitute for repositioning maneuvers.(Frohman et al, 2003; Hain & Uddin, 2003; Carlow, 1986; Cesarani et al, 2004; Fujino et al, 1994) Some studies show a resolution of BPPV over time with medications, but these studies, however, follow patients for the period of time during which spontaneous resolution would typically occur.(Sacco et al, 2014, Woodworth et al, 2004; Salvinelli et al, 2004; Itaya et al, 1997; McClure & Willet, 1980) In one double blind controlled trial comparing diazepam, lorazepam and placebo, all groups showed a gradual decline in symptoms with no additional relief in the drug treatment arms.(McClure & Willett, 1980) A small study compared particle repositioning maneuvers to a medication alone treatment arm and found that particle repositioning maneuvers had substantially higher treatment responses (78.6%-

1827 93.3% improvement) compared to medication alone (30.8% improvement) at two weeks follow-  
1828 up.(Itaya et al, 1997) The data reinforced previous data which also indicated superiority of  
1829 vestibular training for BPPV over medication use alone.(Fujino et al, 1994) Similar findings  
1830 were noted when comparing canal repositioning maneuvers to betahistine where patients  
1831 randomized to canal repositioning maneuvers had faster physical and mental recovery than their  
1832 pharmacologic counterparts. (Maslovara et al 2012). A more recent study showed that patients  
1833 who underwent the Epley maneuver alone recovered faster than those who underwent the Epley  
1834 maneuver and concurrently received a labyrinthine sedative. (Sundararajan et al, 2011) Also, the  
1835 addition of an antihistamine to canal repositioning maneuvers demonstrated no change in the  
1836 dizziness handicap inventory score. (Kim et al 2014).

1837         However, more recent studies have shown that there may be some pharmacological  
1838 benefit in select patients. In one randomized study, the addition of a benzodiazepine to canal  
1839 repositioning maneuvers significantly decreased the functional and emotional scores of the  
1840 dizziness handicap inventory but did not affect the physical score compared to patients who were  
1841 treated with canal repositioning maneuvers alone suggesting a role in treating psychological  
1842 anxiety secondary to BPPV. (Jung et al 2011). In one trial, betahistine has been shown to be  
1843 effective in reducing symptoms in patients older than 50, with hypertension, with symptom onset  
1844 < 1month, with brief attacks under 1 minute when used concurrently with canal repositioning  
1845 maneuvers. (Guner 2012) A general lack of isolated benefit from vestibular suppressants and  
1846 inferiority to particle repositioning maneuvers indicate that clinicians should not routinely  
1847 substitute pharmacologic treatment of symptoms associated with BPPV in lieu of other more  
1848 effective treatment modalities. However, when used judiciously in conjunction with canal  
1849 repositioning maneuvers, pharmacologic therapy may have a role.

In summary, vestibular suppressant medications are not routinely recommended for treatment of BPPV, other than for the short term management of autonomic symptoms such as nausea or vomiting in a severely symptomatic patient. Examples of potential short term uses include patients who are severely symptomatic yet refuse therapy or patients who become severely symptomatic after a CRP. Antiemetics may also be considered for prophylaxis for patients who have previously manifested severe nausea and/or vomiting with the Dix-Hallpike maneuvers and in whom a CRP is planned. If prescribed for these very specific indications, clinicians should also provide counseling that the rates of cognitive dysfunction, falls, drug interactions, and machinery and driving accidents increase with use of vestibular suppressants.

**7a. OUTCOME ASSESSMENT: Clinicians should reassess patients within 1 month after an initial period of observation or treatment to document resolution or persistence of symptoms.** *Recommendation based on observational outcomes studies and expert opinion and a preponderance of benefit over harm.*

*Action Statement Profile*

- Quality improvement opportunity: Obtain outcomes data for treatment of BPPV; ability to assess treatment effectiveness. (National Quality Strategy domains: safety, engaging patients, coordination of care, promoting effective prevention/treatment)
- Aggregate evidence quality: Grade C studies with known significant failure rates for an observation option and lower failure rates for CRP.
- Level of confidence in evidence: Medium
- Benefits: Increased accuracy of BPPV diagnosis. Identify patients initially treated

with observation who have persistent symptoms and may benefit from CRP or vestibular rehabilitation to hasten symptom resolution.

- Risks, harms, costs: Cost of reassessment.
- Benefits-harm assessment: Preponderance of benefit over harm.
- Value judgments: Panel valued ensuring the accuracy of diagnosis that may be enhanced by follow-up and capturing patients who could benefit from treatment or re-treatment to improve symptom resolution. Panel valued the potential importance of outcomes measures in the overall healthcare data environment.
- Intentional vagueness: The term reassess could represent various types of follow-up including phone calls from office staff or other methods to document outcome.
- Role of patient preferences: Small
- Exceptions: None.
- Policy level: Recommendation.
- Differences of opinion: Some panel members felt there is value in return visits to establish symptom resolution or to document objective improvement. Most other panel members felt that phone contact versus open-ended follow-up if symptoms persist or recur is sufficient.

#### *Supporting Text*

The purpose of this statement is to emphasize that clinicians should reassess patients within 1 month after an initial period of observation or treatment to document resolution or persistent symptoms.

#### *Importance of Patient Reassessment*



Patients with BPPV, regardless of the initial treatment option, will have variable responses to therapy (Cohen and Kimball 2005). The response to therapy may depend on several factors including the accuracy of diagnosis, the duration of symptoms prior to the diagnosis, and patient compliance with the prescribed therapy (Hilton & Pinder 2004, Rupa 2004). It is important to reassess patients because those who continue to have vestibular symptoms remain at risk for falls, have decreased quality-of-life, and other consequences of unresolved BPPV. Furthermore, patients with continued vestibular symptoms should be reassessed for an accurate diagnosis and evaluated for further treatment needs.

The most effective treatment for BPPV is CRP. Recent studies have shown that the vast majority of patients are adequately treated with 1-2 CRP (79.4-92.7%) (Amor-Dorado et al. 2012; Balikci 2014; Bruintjes et al. 2014; Badawy et al. 2015). However, 12.8-15.3% of patients will require a second CRP, and 5.1% will be classified as treatment failures after 2 CRPs. (Amor-Dorado et al. 2012; Balikci 2014; Bruintjes et al. 2014; Badawy, et al. 2015).

If initial therapy fails, the patient should be reassessed for BPPV diagnosis accuracy. Symptoms of central nervous system disorders may mimic BPPV, and these conditions would not respond to BPPV treatments. In cohort studies, the rates of false positive diagnosis for BPPV subsequently found to be central nervous system lesions *after failed treatment* with CRP ranges from 1.1-3% (Dal, Ozl  oğlu et al. 2000, Rupa 2004). Thus, persistence of symptoms after initial management requires clinicians to reassess and reevaluate patients for other etiologies of vertigo. Conversely, resolution of BPPV symptoms after BPPV-targeted initial therapy, such as CRP, would corroborate and provide further evidence as to an accurate diagnosis.

*Definition of Treatment Failure*

In order to define a BPPV treatment failure, a failed outcome criterion as well as an appropriate time interval for reassessment needs to be defined. In clinical trials, successful BPPV treatment outcomes are traditionally defined as subjective symptom resolution and/or conversion to a negative Dix-Hallpike test (Hilton and Pinder 2004, Woodworth et al. 2004, Teixeira and Machado 2006).

Although conversion to a negative Dix-Hallpike test may have the advantage of being a more objective reassessment compared with subjective symptom resolution, it also carries the disadvantage of requiring a repeat clinical visit, which is associated with direct and indirect costs. The alternative of a symptom-based reassessment allows practitioners to use clinical judgment regarding the most appropriate follow-up modality for individual patients, including telephone communication, electronic communication, or office-based re-examination. Symptom-based assessment of treatment resolution should be detailed enough to distinguish those patients whose symptoms have decreased or minimized because of positional avoidance (who may not be treatment successes) from those with true symptom resolution (Woodworth, et al. 2004). If the patient was initially diagnosed and treated in an acute care setting (e.g. an emergency room or urgent care clinic), their primary care provider or specialist would be a suitable provider to reassess the patient.

#### *Definition of Time Interval*

There is no widely accepted time interval to assess patients for treatment failure. Therapeutic BPPV trials report follow-up assessments for treatment outcomes at 40 hours, 2 weeks, 1 month, and up to 6 months. However, the most common follow-up interval is within or at 1 month (Hilton and Pinder 2004, Woodworth, Gillespie et al. 2004, Teixeira and Machado

2006). Spontaneous symptom resolution at 1 month ranges from 20-80% (Lynn, Pool et al. 1995, Froehling, Bowen et al. 2000, Yimtae, Srirompotong et al. 2003, Sekine, Imai et al. 2006, von Brevern, Seelig et al. 2006, Munoz, Micklea et al. 2007). At the 1-month reassessment, patients should be evaluated for further interventional treatment for unresolved BPPV as well as reassessed for accurate diagnosis (Lynn, Pool et al. 1995, Froehling, Bowen et al. 2000, Yimtae, Srirompotong et al. 2003, Sekine, Imai et al. 2006, von Brevern, Seelig et al. 2006, Munoz, Micklea et al. 2007).

Of note, the panel was somewhat divided regarding the need for a method of assessment for treatment failure. The panel recognized that BPPV is often in and of itself a self-limiting condition and that CRP is a very effective maneuver for its treatment. Given that the vast majority of patients ultimately come to symptom resolution the panel recognized that a requirement for reassessment would be tracking this vast majority of patients who do well. In contradistinction, however, the panel also felt that there was a need for documentation of symptom resolution to ensure an added layer of safety with respect to the accuracy of diagnosis of BPPV and to reduce the quality-of-life impact of unresolved BPPV, even though numerically this may be a small fraction of initial patients suffering from BPPV. This may be of greater importance as the management of BPPV may move to the primary care or ED setting rather than subspecialty settings. The panel also felt that assessment would allow for collection of longitudinal comparative effectiveness data in a real-world setting which may be of future value from a research and healthcare quality perspective.

**7b. EVALUATION OF TREATMENT FAILURE: Clinicians should evaluate, or refer to a clinician who can evaluate, patients with persistent symptoms for unresolved BPPV and/or underlying peripheral vestibular or central nervous system disorders.**

1964 Recommendation based on observational studies of diagnostic outcomes in patients with BPPV  
1965 and a preponderance of benefit over harm.

1966 *Action Statement Profile*

- 1967 • Quality improvement opportunity: Capture missed or erroneous diagnoses; offer re-  
1968 treatment to those patients with early recurrence of BPPV or failed initial CRP (National  
1969 Quality Strategy domain: safety, promoting effective prevention/treatment)
- 1970 • Aggregate evidence quality: Grade A for treatment of observation failure and Grade B for  
1971 CRP failure based on RCT and SR examining treatment responses and failure rates.
- 1972 • Level of confidence in evidence: Medium
- 1973 • Benefits: Expedite effective treatment of patients with persistent BPPV and associated  
1974 co-morbidities. Decrease the potential for missed serious medical conditions that require  
1975 a different treatment algorithm.
- 1976 • Risks, harms, costs: Costs of re-evaluation and the additional testing incurred.
- 1977 • Benefits-harm assessment: Preponderance of benefit over harm.
- 1978 • Value judgments: Valued comprehensive treatment of not only BPPV but associated  
1979 conditions that affect balance and function. The panel also valued expeditiously treating  
1980 cases of persistent BPPV following observation or vestibular rehabilitation with a CRP as  
1981 more definitive therapy.
- 1982 • Intentional vagueness: Characterization of persistent symptoms was intentionally vague  
1983 to allow clinicians to determine the quality a degree of symptoms that should warrant  
1984 further evaluation or re-treatment.
- 1985 • Role of patient preferences: Small.
- 1986 • Exceptions: None

- 1987       • Policy level: Recommendation
- 1988       • Differences of opinion: None

1989

1990

1991   *Supporting Text*

1992           The purpose of this statement recommending evaluation of patients with persistent

1993 symptoms after initial treatment of BPPV is to expeditiously identify treatment failures, promote

1994 the timely diagnosis and management of underlying peripheral or central nervous system

1995 disorders and, by doing so, reduce the risk of secondary complications related to unresolved or

1996 unidentified disease.

1997           Patients with persistent symptoms of vertigo, dizziness, or unsteadiness after initial

1998 therapy for BPPV are classified as treatment failures. Treatment failures require re-evaluation

1999 for the following reasons: 1) persistent BPPV may be present and responsive to additional

2000 maneuvers; 2) co-existing vestibular conditions may be present that can be identified and treated;

2001 and 3) serious central nervous system disorders may simulate BPPV and need to be identified.

2002 (Furman & Casss, 1999; Rupa, 2004; Furman & Cass, 1995)

2003

## 2004   PERSISTENT BPPV

2005           Patients with BPPV who initially are treated with observation may fail to resolve

2006 spontaneously. Also, based on failure rates of vestibular rehabilitation or a single-session CRP

2007 ranging from 8-50%, a significant number of patients initially managed with vestibular

2008 rehabilitation or CRP will have persistent BPPV after initial therapy, also indicating a treatment

2009 failure.(Furman & Cass, 1999; Hilton & Pinder, 2004; Cohen & Kimball, 2005; Teixeira &

2010 Machado, 2006; von Brevern et al, 2006; Amor-Dorado et al, 2012; Helminski et al., 2010;  
2011 Bruintjes et al, 2014; Hillier & McDonnell, 2011; Hilton & Pinder, 2014; McDonnell & Hillier,  
2012 2015; Prim-Espada, 2010; van Duijn et al, 2014) As such, re-evaluation of a treatment failure is  
2013 advisable and should include obtaining a history of vertigo and determining if the vertigo is  
2014 provoked by positional change relative to gravity (i.e. lying down in bed, rolling over, bending  
2015 down or tilting their head back), which then suggests persistent BPPV. As with the original  
2016 diagnostic criteria, the Dix-Hallpike test should be repeated to confirm the diagnosis of BPPV.  
2017 If the Dix-Hallpike maneuver is still positive, repeat canalith repositioning maneuvers can then  
2018 be performed as a preferred treatment. The rate of successful treatment of BPPV reaches 90-  
2019 98% when additional repositioning maneuvers are subsequently performed. (Brocchetti et al,  
2020 2003; Beynon et al, 2000; Reinink et al, 2014) Therefore, the CRPs are the treatment of choice  
2021 for initial BPPV treatment failures deemed to be due to persistent BPPV. For treatment failures  
2022 refractory to multiple CRP, surgical plugging of the involved posterior semicircular canal or  
2023 singular neurectomy have a greater than 96% success rate; however, the quality of data  
2024 supporting these interventions precludes the ability to make definitive recommendations for their  
2025 utilization (Fife et al, 2008).

2026 A similar approach may be adopted for the re-evaluation of persistent symptoms of  
2027 vertigo after an initial diagnosis of lateral canal BPPV. The supine roll test should be repeated  
2028 and if characteristic nystagmus is elicited, a CRP appropriate for lateral canal BPPV may be  
2029 repeated as well. There are limited data regarding the management of treatment failures after  
2030 CRP for lateral canal BPPV since this condition seems to respond more consistently to CRP and  
2031 it also has a higher spontaneous resolution rate. (Tirelli & Russolo, 2004; Sekine et al, 2006;  
2032 Fife, 1998; Asprella Libonati, 2005; van den Broek, 2014) Some studies indicate cure rates of

86-100% with up to four CRP treatments in lateral canal BPPV. (Casani et al, 2002; Chiou et al, 2005) Further sub-analysis suggests that the apogeotropic variant of lateral canal BPPV may be more refractory to therapy. (White et al, 2005; Casani et al, 2002; van den Broek, 2014)

A small percentage of patients initially diagnosed and treated for lateral canal BPPV may experience a “canal conversion”. In these cases, initially lateral canal BPPV may transform into posterior canal BPPV in up to 6% of cases.(Nutietal, 1998; Tirelli & Russulo, 2004) Similarly, a small fraction of patients (also approximating 6%) initially presenting with posterior canal BPPV may after treatment transition to lateral canal BPPV.(Yimtae et al, 2003; Herdman & Tusa, 1996) A small subset of patients who do not respond to treatment for posterior canal and/or lateral canal BPPV may suffer from anterior canal BPPV, and may need to be evaluated accordingly.(Jackson et al, 2007) In addition, although rare, two semicircular canals may be simultaneously involved. The second canal’s involvement may become evident at the time of reassessment if one of the involved canals was appropriately treated. (Rupa, 2004) Finally, it is possible that initial treatment was not properly directed to the involved canal thus increasing the chance of persistent symptoms. Thus, reassessment of persistent positional vertigo in BPPV should include examination for involvement of other semicircular canals other than that which was originally diagnosed.

#### CO-EXISTING VESTIBULAR SYSTEM DYSFUNCTION

A BPPV treatment failure may be subsequently found to be a case manifesting vertiginous symptoms that are: provoked by head and body movements in general (i.e. not primarily provoked by positional changes relative to gravity), unprovoked (i.e. spontaneous) episodes of vertigo occurring while not moving, or in fact, a constant unsteadiness. These

specific findings should be identified by clinicians as such findings suggest the presence of vestibular system dysfunction associated with, or in addition to, the initially treated BPPV.

In a study by Monobe, treatment failure of the CRP was most commonly seen in patients with BPPV secondary to head trauma or vestibular neuritis.(Monobe et al, 2001) Since vestibular neuritis and head trauma are both frequently associated with vestibular dysfunction, the cause of persistent symptoms following treatment of BPPV is likely related to widespread dysfunction within the vestibular system in this setting.(Bergenius et al, 1999) Because BPPV is more common in patients with Meniere's disease and migraine, vestibular system dysfunction associated with these disorders can lead to prolonged symptoms of BPPV, greater chance for recurrence BPPV and increased risk for falls, particularly in older persons.(Gordon et al, 2004; Roberts et al, 2005; Hughes & Proctor, 1997; Dornhoffer & Colvin, 2000; Uneri, 2004; Kayan & Hood, 1984) In addition, BPPV not associated with other otologic or neurological disease can still be associated with an underlying impaired vestibular function and affected individuals are more likely to have incomplete resolution of symptoms even if their Dix-Hallpike testing normalizes with CRP.(Pollak et al, 2002) Finally, transient vestibular dysfunction can also occur following repositioning maneuvers. Evidence suggests that balance function continues to be affected between 1-3 months post repositioning maneuvers and that some patients may need additional balance therapy (i.e., counseling, vestibular rehabilitation) in order to prevent falls and decrease their fear of falling after the vertigo from BPPV has resolved.(Blatt et al, 2000; Chang et al, 2006; Giacomini et al, 2002; Black & Nashner, 1984) Thus, re-evaluation of BPPV treatment failures should include a search for these associated conditions.

When co-existing vestibular system dysfunction is suspected, additional testing should be considered. This may include audiometric testing to screen for Meniere's disease and 8th nerve



pathology such as acoustic neuroma, vestibular function testing to detect central and peripheral vestibular dysfunction, and CNS imaging to detect CNS pathology. Such subsequent testing will need to be tailored to the clinical presentation and clinicians should exercise their clinical judgment. Vestibular rehabilitation has been shown to be an effective treatment for vestibular symptoms due to the potentially persistent vestibular dysfunction associated with BPPV and may reduce fall risk. (Angeli et al, 2003)

#### CNS DISORDERS MASQUERADING AS BPPV

While vertigo of central origin is frequently associated with neurological symptoms such as gait, speech, and autonomic dysfunction, it is important to recognize that, rarely, central nervous system disorders can masquerade as BPPV. (Bertholon et al, 2002) Many of these have been previously discussed in the section on differential diagnosis but the relative likelihood of their diagnosis increases in the face of initial treatment failure. In one study, a CNS disorder explaining BPPV treatment failure was found in 3% of patients. (Dal et al, 2000)

Whenever the signs and symptoms of BPPV are atypical or refractory to treatment, additional history and physical examination should be obtained to address the possibility of undiagnosed CNS disease.(Smouha & Roussos, 1995) Patients with symptoms consistent with those of BPPV who do not show improvement or resolution after undergoing the CRP, especially after 2 or 3 attempted maneuvers, or those who describe associated auditory or neurologic symptoms should be evaluated with a thorough neurological examination, additional CNS testing and/or magnetic resonance imaging of the brain and posterior fossa to identify possible intracranial pathologic conditions.(Dunniway & Welling, 1998; Buttner et al, 1999)

**8. EDUCATION: Clinicians should educate patients regarding the impact of BPPV on their safety, the potential for disease recurrence and the importance of follow-up.**

*Recommendation based on observational studies of diagnostic outcomes and recurrence in patients with BPPV and a preponderance of benefit over harm.*

*Action Statement Profile*

- Quality improvement opportunity: Education allows patients to understand the implications of BPPV on quality of life and patient safety, especially falls. (National Quality Strategy domains: safety, engaging patients, promoting effective prevention/treatment)
- Aggregate evidence quality: Grade C based on observational and cross-sectional studies of recurrence and fall risk.
- Level of confidence in evidence: Medium
- Benefits: Increased awareness of fall risk potentially decreasing injuries related to falls. Increased patient awareness of BPPV recurrence which allows prompt intervention.
- Risks, harms, costs: None.
- Benefits-harm assessment: Preponderance of benefit over harm
- Value judgments: None.
- Intentional vagueness: None.
- Role of patient preferences: None.
- Exceptions: None.
- Policy level: Recommendation.
- Differences of opinion: None.

2125 *Supporting Text*

2126       The purpose of this statement is to discuss the importance of patient education with  
2127 respect to the impact of BPPV on the daily lives of patients with this diagnosis and to emphasize  
2128 the importance of education as part of the plan of care for clinicians managing these patients.  
2129 BPPV has multiple treatment options, is not always cured with the first treatment and can  
2130 re-occur, so it becomes a safety issue especially with respect to an increased risk of falling. The  
2131 socio-economic impact of the patient's inability to meet family and work responsibilities can be  
2132 an added burden. Patient education should include a discussion of factors that might predispose  
2133 to BPPV, diagnosis and treatment options, and risk for reoccurrence. This information can be  
2134 reassuring to patients and help with their understanding of appropriate diagnostic testing and  
2135 management. Written handouts can provide this information (Table 16). Patients can also be  
2136 directed to numerous support groups through social media or searching [www.vestibular.org](http://www.vestibular.org).

2137       One of the most important goals of education is an understanding of what BPPV is. The  
2138 acute onset of vertiginous symptoms can mimic those of a stroke or other neurological problems  
2139 and are very frightening for patients and their families. A thorough neurological exam and a  
2140 simple Dix Hallpike test can reliably identify BPPV, making medications and expensive  
2141 radiologic testing unnecessary. Explaining this to patients will help to put them at ease regarding  
2142 their diagnosis.

2143       Although BPPV generally responds well to treatment, there is a significant rate of BPPV  
2144 recurrence after initial resolution or clinical cure. Most trials of BPPV maintain limited follow  
2145 up, rarely beyond 3 months. In the few trials of BPPV with longer term follow-up, the rate of  
2146 recurrent BPPV (that is, BPPV symptoms manifesting again after a symptom free period) is  
2147 reported to be 5-13.5% at 6-months follow up.(Macias et al, 2000; Sridhar & Panda, 2005) At

one year after treatment, the rate of recurrence has been reported at a slightly higher rate of 10-18% (Prokopakis et al, 2005; Sakaida et al, 2003) The recurrence rate continues to increase over time and may be as high as 36% (Hilton et al, 2014) Patients with BPPV after trauma are likely to demonstrate an even higher recurrence rate of their BPPV.(Gordon et al, 2004)

Thus, clinicians should be aware of the recurrence risk of BPPV and should counsel patients accordingly. Counseling will likely have several benefits. These include earlier recognition by patients of recurrent BPPV, allowing earlier return for CRP or vestibular rehabilitation. Also, counseling regarding recurrence will offset the potential anxiety patients may feel when BPPV recurs and allow them to make corresponding adjustments in their daily routine to minimize the impact of BPPV symptomatology.

As with any balance or vestibular disorder, patients with BPPV should be counseled that BPPV places them at greater risk for falls. (Brandt & Dieterich, 1993) This may be particularly applicable for patients with pre-existing balance disorders or vestibular deficits and a separate onset of BPPV. The propensity for falling may actually be a significant motivating factor for patients to be referred for evaluation and management of BPPV. (Lawson et al, 2005) The risk of falls and fear of falls are significant considerations in the management of the elderly who suffer from chronic dizziness. (Gazzola et al, 2006) In study of 120 elderly patients with chronic vestibular disorders, 36.7% carried the diagnosis of BPPV. Fifty-three percent of subjects had fallen at least once in the past year, and 29.2% had recurrent falls. (Gazzola et al, 2006) Other authors have confirmed a relatively high rate of BPPV and associated falling tendencies in the elderly. (Oghalai et al, 2000; Imbaud Genieys, 2007)

Practically speaking, clinicians should counsel patients and their families regarding the risk of falls associated with BPPV. This is particularly important in the elderly and frail who

may be more susceptible to serious injury as a result of falling. Such counseling could include assessment of home safety, activity restrictions and the need for home supervision until BPPV is resolved. (Rubenstein, 2006) Patients may be particularly vulnerable in the time interval between initial diagnosis of BPPV and definitive treatment when they are referred to another clinician for CRP or vestibular rehabilitation. Counseling should therefore occur at the time of initial diagnosis. The direct costs of such counseling are anticipated to be minimal and will enhance patient and public safety and avoid potential post-traumatic sequelae.

Finally, patients should be counseled regarding the importance of follow-up after the diagnosis of BPPV. Patients initially treated with observation should be counseled that if BPPV fails to resolve spontaneously, effective therapies such as the CRP may then be undertaken, particularly if an observation option is initially elected. Also, patients should be educated about atypical symptoms (subjective hearing loss, gait disturbance, non-positional vertigo, nausea, vomiting, etc.) whose occurrence or persistence after resolution of the primary symptoms of BPPV warrant further clinical evaluation. (Rupa, 2004) As noted, such symptoms, particularly when un-masked by the resolution of BPPV may indicate an underlying or concurrent vestibular or central nervous system disorder

Table 16. Patient Information: Frequently Asked Questions

| Question      | Answer   |
|---------------|--|
| What is BPPV? | Benign Paroxysmal Position Vertigo (BPPV) is the most common inner ear problem and cause of vertigo or false sense of spinning.<br><br>BPPV is both a specific diagnosis and a specific description of the disorder. It is "benign" because it is not life-threatening despite, at times, the alarming intensity & severity of symptoms. It is |

|  |   |
|--|---|
|  | <p>"paroxysmal" because it comes on suddenly and then eases in brief distinct spells. It is "positional" because it is <u>triggered</u> by certain head positions or movements. And finally, it is "vertigo" because of the sense of spinning motion often associated with the distinct attacks.</p>  |
| What causes BPPV?                                    | <p>BPPV is caused by displaced crystals or otoconia that have become unglued from their normal settled location in the center pouch of the inner ear and are now free floating and/or stuck on delicate sensors in the wrong or canal part of the inner ear. Where the crystals are a normal part of our inner ear and help us with balance and motion perception when they are in the "pouch", they can create intense false messages of spinning when they are moving in the canals. BPPV symptoms therefore are literally caused by these <i>crystals dropping</i> or the <i>sensors hanging</i> in these very sensitive canals. The most intense part of the BPPV symptoms are directly related to how long it takes the crystal/sensor to settle after a person moves or changes head/body position. In other words, as the crystals move/settle, your brain is being given powerful (false) messages that you are violently spinning when all you have done is perhaps laid down or rolled over in bed.</p> |
| What are common symptoms and how can BPPV affect me? | <p>Although everyone will experience BPPV uniquely, the most common symptoms are distinct <u>triggered</u> spells of vertigo or spinning sensations that are most often accompanied by nausea (occasionally vomiting) and/or a severe sense of disorientation in space or instability. These symptoms will last most intensely for seconds to</p>   |

|                        |   |
|------------------------|---|
|                        | <p>minutes however can leave some people feeling a persistent sense of vaguer dizziness and instability. In some people, especially seniors, BPPV can present more as an isolated sense of instability brought on by position change e.g. sitting up, looking up, bending over and reaching. BPPV does not cause constant severe dizziness that is unaffected by position or movement. BPPV can NOT affect your hearing or produce fainting. The natural course/history of BPPV is to lessen in severity over time and so people will often report that the severity of their very first BPPV spinning episode will be the worse their symptoms will ever be.</p> |
| How common is BPPV?    | BPPV is very common. It is more common in older people. Many of us will experience it at some time in their life.   |
| What caused my BPPV?   | The vast majority of cases of BPPV occur for no reason however it can occasionally be associated with trauma, migraine, other inner ear problems, diabetes, osteoporosis, and prolonged time lying in bed (e.g. preferred sleep side, surgical procedures, illness)   |
| How is BPPV diagnosed? | Normal medical imaging (e.g. scans, X-rays) or medical laboratory testing cannot show or confirm BPPV however simple bedside testing can help to confirm the diagnosis. The bedside testing requires an examiner to move a person's head into a specific position that makes the crystal move (e.g. hanging head slightly off the edge of the bed or rolling the person's head while lying in bed) which provokes a distinct characteristic eye movement that the examiner will be able to  |

|  |   |
|--|---|
|  | <p>see and characterize to confirm the diagnosis. The most common tests are called either the Dix-Hallpike test or supine roll test.</p>  |
| <p>Can BPPV be treated?</p>                        | <p>Yes. The good news is, that although medications are not indicated other than for relief of immediate distress, e.g. nausea, the vast majority of cases can be corrected with a bedside mechanical repositioning maneuvers that take only a minute or two to complete and have high success rates (around 80%) with only 1-3 treatments. These bedside mechanical repositioning maneuvers are designed to literally guide the crystals back to their original location in the inner ear. These maneuvers are often performed at the same time the bedside diagnostic testing is being performed however you can also be referred to a professional (e.g. medical provider, audiologist or therapist) who can perform these maneuvers. Being referred to a professional is particularly indicated if you have any of the following: severe disabling symptoms, you are a senior with history of past falls or fear of falling, and/or you have difficulty maneuvering (e.g. joint stiffness especially in your neck and back and/or weakness). You can also be taught and learn how to perform these maneuvers by yourself with supervision which is called "self-repositioning".</p> |
| <p>Is there any downside to BPPV repositioning</p> | <p>During the actual BPPV treatment there can be some momentary distress from vertigo, nausea and feelings of disorientation characteristic of your usual BPPV episodes. Following the treatment,</p>   |



|   |  |
|---|--|
| treatments?                                   | <p>some people report their symptoms start too clear almost immediately, however frequently people will report some degree of persistent motion sickness-type symptoms and mild instability that can take a few hours to resolve to more rarely a few days to gradually clear.</p>   |
| Can BPPV go away on its own?                  | <p>There is evidence that left untreated, BPPV can go away within weeks. However, remember that while the crystal is out of place, in addition to feeling sick and sensitive to motion, your unsteadiness can make you at increased risk for falling so you need to take precautions to not fall. If you are a senior or have another underlying balance disorder, there is particularly increased risk for injury and more pronounced disability and because of this, seniors are encouraged to seek more timely and professional help to resolve symptoms.</p> |
| How do I know my BPPV is effectively treated? | <p>The strong positionally-provoked spinning vertigo that has been distinctly provoked with position changes should be dramatically if not completely resolved, with a steady resolution of even more vague complaints and mild instability over the next few days to couple of weeks.</p>   |
| How long will it take before I feel better?   | <p>Even after successful repositioning/treatment of BPPV some people can feel some mild residual sensitivities to movement and generalized unsteadiness that can take a few days to a few weeks to gradually resolve. It is important to follow up with your medical provider or therapist if your symptoms of dizziness/instability do not resolve in a timely manner (days to couple weeks). If you are a senior with a</p>  |

|  |  |
|--|--|
|  | <p>history of falls or fear of falling, there is evidence that some of the instability that was initially caused by the BPPV may need further exercises or balance therapy to completely resolve your complaints and fall risk.</p>  |
| <p>Is there anything I should or shouldn't do to help my BPPV?</p> | <p>Yes. You need to take precautions that you don't fall as your balance will be "off" and you will feel increased sensitivity to movement until the BPPV has been successfully treated and healed. After your BPPV has been stabilized with a repositioning maneuver and your symptoms are steadily resolving, it is important to resume normal activities that you can safely tolerate as the gradual exposure to motion and movement will help to speed final residual healing.</p>                           |
| <p>Can BPPV come back and/or can I prevent it?</p>                 | <p>Unfortunately, BPPV is a condition that can re-occur periodically however individual risk for recurrence can vary dramatically from relatively low risk (rare experiences in lifetime) to a higher vulnerability or risk which is often caused by some secondary factor (e.g. traumatic causes, other inner ear or medical conditions, aging). Medical research has not found any way to prevent recurrences of BPPV however if it does come back or recur it is as treatable with as high success rates.</p> |

|  |   |
|--|---|
| <p>What happens if I'm still experiencing persistent symptoms following my initial treatments?</p> | <p>There are a number of reasons your initial treatment could have failed.</p> <ol style="list-style-type: none"> <li>1. It is not uncommon to need more than one repositioning session to get the crystals back in their proper place, so further trials may be the only thing you need.</li> <li>2. There are a number of different forms or types of BPPV which can require more specialized or customized treatment. The most common self-treatment is designed for only the most common form of BPPV. There are however a number of other treatment techniques available dependent on the different types and forms of BPPV.</li> <li>3. BPPV can occasionally be in more than one canal and/or side at the same time and this would require multiple treatments to resolve.</li> <li>4. If your initial attempts at repositioning have failed, particularly if you have only tried is self-repositioning, having a professional who specializes in BPPV complete the maneuver may allow for more effective repositioning. It can be difficult to achieve the most accurate positioning, where a professional may be able to achieve more optimal positioning and/or use adaptive equipment.</li> <li>5. There can be some significant left-over or residual dizziness even after the BPPV crystals have been properly repositioned. This dizziness may require more time (few days to couple of weeks) or may need and/or be appropriate for a different exercise/movement routine. It is VERY important that if you are having persistent symptoms, you follow-up with your healthcare provider who may be able to refer you for further testing to confirm your diagnosis and/or</li> </ol> |
|--|---|

|            |   |
|------------|---|
|            | offer further treatment options.  |
| Resources: | Vestibular Disorders Association (VEDA): <a href="mailto:INFO@vestibular.org">INFO@vestibular.org</a><br>5018 NE 15th Ave., Portland OR 97211, (800) 837-8428 |

#### IMPLEMENTATION CONSIDERATIONS:

The complete guideline is published as a supplement to *Otolaryngology-Head and Neck Surgery* which will facilitate reference and distribution. An executive summary will be published highlighting key recommendations from the guideline to facilitate information dissemination. Portions of the guideline will be presented at various clinical meetings including planned presentation in as a mini seminar at the annual meeting of the American Academy of Otolaryngology-Head and Neck Surgery. Existing brochures and publications by the AAO-HNSF will be updated to reflect the guideline recommendations. A visual depiction of the anticipated diagnostic and therapeutic treatment algorithm that arises from the current guideline's recommendations is presented in Figure 8. This treatment algorithm emphasizes the diagnosis and evidence-based treatment of BPPV with canalith repositioning procedures. Members of the panel will be representing the guideline at their specialty societies for possible

2202 presentation and endorsement.

2203           Because the guideline presents recommendations for an office-based diagnosis of BPPV  
2204 based on positional maneuvers, an anticipated barrier to implementation is clinician unfamiliarity  
2205 with the Dix-Hallpike maneuver and with the supine roll test. In addition to the descriptive and  
2206 diagrammatic representations of the diagnostic tests, Web-based video links will be provided to  
2207 the reader illustrating performance of these maneuvers as well as video representations of the  
2208 expected diagnostic nystagmus findings, especially in the case of lateral canal BPPV. This may  
2209 also be assisted by a laminated teaching card describing the maneuvers. It will be important to  
2210 incorporate guideline recommendations into the development of point of care decision support  
2211 tools to encourage point of service adherence to the guidelines and to facilitate rapid clinical  
2212 decision-making in a busy office environment.

2213           Another barrier to implementation of this guideline is potential clinician or patient  
2214 preference for the ordering of diagnostic tests to evaluate vertigo. Because the differential  
2215 diagnosis of vertigo may be vast and at times complex, clinicians may feel obligated to order  
2216 diagnostic testing such as central nervous system imaging or vestibular testing to rule out other  
2217 causes of vertigo even when diagnostic criteria for BPPV are met. In addition, patients may  
2218 expect imaging or additional testing based on the perception that such testing is required or a  
2219 safer course of action in the routine management of vertigo. The guideline's current strong  
2220 recommendation for CRP with its anticipated high, almost immediate symptom resolution rate is  
2221 anticipated to decrease such expectations and tendencies. Informational pamphlets for patients  
2222 regarding their diagnosis and expectations regarding the natural history of BPPV may ease this  
2223 difficulty. Specialty clinicians may exhibit a tendency for ordering additional diagnostic testing  
2224 due to a variety of factors. Clinician and patient education regarding outcomes expectations and

2225 counseling on proper follow-up may offset these issues.


2226         With respect to treatment with CRP, several barriers may still need to be overcome.

2227 First, many clinicians are likely to be unfamiliar with the CRP or other treatment maneuvers. In  
2228 a busy clinical setting, diagnosing physicians may be unable or unwilling to take additional time  
2229 to treat BPPV at the same office visit as diagnosis. In such cases, increasing familiarity with  
2230 CRP or additional training of clinicians such as audiologists, physical therapists and other  
2231 providers may facilitate patients' access to CRP. Training courses on performance of the CRP  
2232 offered at clinical education meetings will also help overcome this barrier.

2233         Finally, patients may seek what are perceived to be simpler solutions such as medication  
2234 therapy for BPPV. Given that medication therapy has not been shown effective in the treatment  
2235 of BPPV, clinicians will need to educate patients that these medications offer more harm than  
2236 benefit. Additional education of patients will be required in the form of handouts or brochures  
2237 that inform patients of the risks associated with symptomatic BPPV including risks for falls,  
2238 recurrence of BPPV and treatment options. Algorithms for fall assessment and home safety  
2239 assessment will allow clinicians to stratify patients as to these risks. (Rubenstein et al, 2001)

2240

2241 **Figure 8: Algorithm showing the relationship of guideline key action statements**



2243

## 2244 **RESEARCH NEEDS**

2245       As determined by the panel's review of the literature, assessment of current clinical  
2246 practices and evidence gaps, research needs were determined as follows:

- 2247       1. Conduct diagnostic and cost-effectiveness studies to identify which subsets of patients,  
2248       based on specific history or physical examination findings, should be submitted for  
2249       additional vestibular testing and/or radiographic imaging in the setting of presumed  
2250       BPPV.
- 2251       2. Diagnostic and cost-effectiveness studies evaluating the utility and costs of audiometry in  
2252       the diagnostic evaluation of BPPV are needed.
- 2253       3. Determine whether education and application of clinical diagnostic criteria for BPPV will  
2254       change physician behavior in terms of anticipated decreases in ordering of diagnostic  
2255       tests.
- 2256       4. Determine the optimal number of CRPs and the time interval between performance of  
2257       CRP's for patients with posterior canal BPPV.
- 2258       5. Cost-effectiveness studies for the potential advantages of earlier intervention based on  
2259       earlier diagnosis and earlier symptom resolution with expedient CRP's for BPPV are  
2260       needed. Both direct healthcare and global economic costs require assessment.
- 2261       6. Extended cohort studies with longer follow-up to determine if measures such as self-  
2262       performance of CRP or longitudinal vestibular rehabilitation decrease recurrence rates for  
2263       BPPV or complications from BPPV such as falls.
- 2264       7. Determine whether vestibular therapy after the CRP offers additional benefits over CRP  
2265       alone in select patient populations.
- 2266       8. Studies on the functional impact of BPPV as they relate to home safety, work safety and



- 2267 absences and driving risks.
- 2268 9. Epidemiological studies on the rates of falls with BPPV as an underlying cause/diagnosis.
- 2269 10. Assess the impact of BPPV on quality of life for those affected using general QOL and/or
- 2270 dizziness specific QOL metrics.
- 2271 11. Develop and validate a disease specific quality of life measure for BPPV to assess
- 2272 treatment outcomes.
- 2273 12. Perform studies to evaluate the effect of structured versus “as needed” follow up
- 2274 regimens on the outcomes of patients with BPPV.
- 2275 13. Clarify and standardize the terms used to describe repositioning maneuvers for BPPV of
- 2276 the lateral canal to enable meaningful comparison of their efficacy.
- 2277 14. Perform studies to evaluate the effectiveness of mastoid vibration in the treatment of
- 2278 BPPV.
- 2279 15. Epidemiological studies to characterize the relative risk of factors associated with the
- 2280 development of BPPV such as osteoporosis, dental procedures and other devices that
- 2281 deliver cranial vibrations (massage devices, motorized toothbrushes, etc.).
- 2282 16. Identify patient and treatment related risk factors for the development of recalcitrant
- 2283 BPPV.
- 2284 17. Perform studies to evaluate the sensitivity, specificity and predictive values of the
- 2285 available exam maneuvers to determine the presence and laterality of BPPV affecting the
- 2286 anterior semicircular canal.
- 2287 18. Perform studies to characterize the accuracy of diagnostic maneuvers for posterior and
- 2288 lateral canal BPPV and to evaluate the treatment outcomes for patients with BPPV seen
- 2289 in non-specialty settings.

2290

2291 **DISCLAIMER**

2292 The clinical practice guideline is provided for information and educational purposes only. It is  
2293 not intended as a sole source of guidance in managing BPPV. Rather, it is designed to assist  
2294 clinicians by providing an evidence-based framework for decision-making strategies. The  
2295 guideline is not intended to replace clinical judgment or establish a protocol for all individuals  
2296 with this condition and may not provide the only appropriate approach to diagnosing and  
2297 managing this program of care. As medical knowledge expands and technology advances,  
2298 clinical indicators and guidelines are promoted as conditional and provisional proposals of what  
2299 is recommended under specific conditions but are not absolute. Guidelines are not mandates;  
2300 these do not and should not purport to be a legal standard of care. The responsible provider, in  
2301 light of all circumstances presented by the individual patient, must determine the appropriate  
2302 treatment. Adherence to these guidelines will not ensure successful patient outcomes in every  
2303 situation. The AAO-HNS, Inc. emphasizes that these clinical guidelines should not be deemed to  
2304 include all proper treatment decisions or methods of care, or to exclude other treatment decisions  
2305 or methods of care reasonably directed to obtaining the same results.

2306

2307

2308 **ACKNOWLEDGEMENT**

2309 We gratefully acknowledge the support of Jean C. Blackwell, MLS for her assistance with the  
2310 literature searches. In addition, we acknowledge the work of the original guideline development  
2311 group that included: Neil Bhattacharyya, MD; Reginald F. Baugh, MD; Laura Orvidas, MD;  
2312 David Barrs, MD; Leo J. Bronston, DC, MAppSc; Stephen Cass MD, MPH; Ara A. Chalian,  
2313 MD; Alan L. Desmond, AuD; Jerry M Earll, MD; Terry D. Fife, MD; Drew C. Fuller, MD,

2314 MPH; James O. Judge, MD; Nancy R. Mann, MD; Richard M. Rosenfeld, MD, MPH; Linda T.  
2315 Schuring, MSN, RN; Robert W. P. Steiner, MD, PhD; Susan L. Whitney, PhD; Jenissa Haidari,  
2316 MPH

2317

## 2318 **DISCLOSURES**

2319 **Competing interests:** Neil Bhattacharyya, Consultant for rhinology-based companies for sinus  
2320 instruments; Michael D. Seidman, Founder, Body Language Vitamins Co.; Royalties from ViSalus  
2321 Sciences for products developed; Research funding from NIH, Auris Medical, Microtransponder Inc.;  
2322 Richard W. Waguespack, Consulting fee from McKesson/InterQUAL, Patient Advocacy Committee,  
2323 Member AMA CPT Advisor, Editorial Board for Laryngoscope Journal; Maureen D. Corrigan, salaried  
2324 employee of American Academy of Otolaryngology—Head and Neck Surgery Foundation.

2325 **Sponsorship:** American Academy of Otolaryngology—Head and Neck Surgery Foundation

2326 **Funding source:** American Academy of Otolaryngology—Head and Neck Surgery Foundation

2327

## 2328 **REFERENCES**

2329

2330 AAP SCQIM (American Academy of Pediatrics Steering Committee on Quality Improvement  
2331 and Management). Policy Statement. Classifying recommendations for clinical practice  
2332 guidelines. Pediatrics 2004;114:874-7.

2333 Agrawal Y, Carey JP, Ella Santina CC, Schubert MC, Minor LB. Disorders of balance and  
2334 vestibular function in US adults: data from the National Health and Nutrition Examination  
2335 Survey. 2001-2004. (Erratum appears in Arch Intern Med. 2009; 169: 1419) Arch Intern Med  
2336 169: 938-44.

2337 Agrawal, Y. , Ward,B.K. and Minor L.B. ( 2013) Vestibular dysfunction: Prevalence , impact,

2338 and need for targeted treatment, *Journal of Vestibular Research: Equilibrium and Orientation*,  
 2339 23(3), 113-117. <http://doi.org/10.3233/VES-130498>

2340 Ahn S-K, jeon S-Y, Kim J-P, Park JJ, Hur DG, Kim D-W, Woo, S-H, Kwon O-J, Kim J-Y.  
 2341 Clinical Characteristics and treatment of BPPV after TBI. *J Trauma*. 2011; 70:442-446.

2342 Amor-Dorado JC, Barreira-Fernandez MP, Aran-Gonzalez I, Casariego-Vales E, Llorca J,  
 2343 Gonzalez-Gay MA. Particle Repositioning Maneuver Versus Brandt-Daroff Exercise for  
 2344 Treatment of Unilateral Idiopathic BPPV of the Posterior Semicircular Canal: A Randomized  
 2345 Prospective Clinical Trial with short- and long-term Outcome. *Otology & Neurotology* 2012;  
 2346 33:1401-1407.

2347 Anagnostou E, Kouzi I, Spengos K. Diagnosis and Treatment of Anterior-Canal BPPV. *Journal*  
 2348 *of Clinical Neurology* 2015; 11(3):262-267.

2349 Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly  
 2350 people and use of anticholinergic drugs: longitudinal cohort study. *BMJ* 2006;332:455-9.

2351 Angeli SI, Hawley R, Gomez O. Systematic approach to benign paroxysmal positional vertigo in  
 2352 the elderly. *Otolaryngol Head Neck Surg* 2003;128:719-25.

2353 Appiani GC, Catania G, Gagliardi M, et al. Repositioning maneuver for the treatment of the  
 2354 apogeotropic variant of horizontal canal benign paroxysmal positional vertigo. *Otol Neurotol*  
 2355 2005;26:257-60.

2356 Appiani GC, Catania G, Gagliardi M. A liberatory maneuver for the treatment of horizontal  
 2357 canal paroxysmal positional vertigo. *Otol Neurotol*. 2001; 22 (1):66

2358 Appiani GC, Gagliardi G, Magliulo G. Physical treatment of horizontal canal benign positional  
 2359 vertigo. *Eur Arch Otorhinolaryngol* 1997;254:326-28.

2360 Aron M, Lea J, Nakku D, Westerberg BD. Symptom Resolution Rates of Posttraumatic versus

2361 Nontraumatic BPPV: A Systematic Review. 2015; 153(5) 721-730.

2362 Asawavichianginda S, Isipradit P, Snidvongs K, et al. Canalith repositioning for benign  
2363 paroxysmal positional vertigo: a randomized, controlled trial. Ear Nose Throat J 2000;79:732-4,  
2364 36-7.

2365 Asprella Libonati G. Diagnostic and treatment strategy of lateral semicircular canal  
2366 canalolithiasis. Acta Otorhinolaryngol Ital 2005;25:277-83.

2367 Asprella-Libonati G. Pseudo-spontaneous nystagmus: a new sign to diagnose the affected side in  
2368 lateral semicircular canal benign paroxysmal positional vertigo. Acta Otorhinolaryngol ital  
2369 2008;28(2):73-78.

2370 Asprella-Libonati G. Pseudo-Spontaneous nystagmus: a new sign to diagnose the affected side in  
2371 lateral semicircular canal benign paroxysmal positional vertigo. Acta Otorhinolaryngol  
2372 Ital. 2008;28:73–78.

2373 Badawy, W. M., E. K. Gad El-Mawla, A. E. Chedid and A. H. Mustafa (2015). "Effect of a  
2374 hybrid maneuver in treating posterior canal benign paroxysmal positional vertigo." J Am Acad  
2375 Audiol 26(2): 138-144.

2376 Balikci HH, Ozbay I. Effects of postural restriction after modified Epley maneuver on recurrence  
2377 of benign paroxysmal positional vertigo. Auris Nasus Larynx 2014; 41(5):428-31.

2378 Baloh RW, Honrubia V, Jacobson K. Benign positional vertigo: clinical and oculographic  
2379 features in 240 cases. Neurology 1987;37:371-8.

2380 Baloh RW, Jacobson K, Honrubia V. Horizontal semicircular canal variant of benign positional  
2381 vertigo. Neurology 1993;43:2542-9.

2382 Baloh RW. Clinical practice. Vestibular neuritis. N Engl J Med 2003;348:1027-32.

2383 Baloh RW. Dizziness: neurological emergencies. Neurol Clin 1998;16:305-21.

2384 Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with  
 2385 benzodiazepine use. *Lancet* 1998;352:1331-6.

2386 Bath AP, Walsh RM, Ranalli P, et al. Experience from a multidisciplinary "dizzy" clinic. *Am J*  
 2387 *Otol* 2000;21:92-7.

2388 Benecke H, Agus S, Kuessner D, Goodall G, Strupp M. The burden and impact of vertigo:  
 2389 findings from the REVERT patient registry. *Front Neurol* 2013; 4:136.

2390 Berg K, Wood-Dauphinee S, Williams JJ, Maki, B (1992). Measuring balance in the elderly:  
 2391 validation of an instrument. *Can. J. Pub. Health* July/August supplement 2:S7-11

2392 Bergenius J, Perols O. Vestibular neuritis: a follow-up study. *Acta Otolaryngol* 1999;119:895-9.

2393 Bertholon P, Bronstein AM, Davies RA, et al. Positional down beating nystagmus in 50 patients:  
 2394 cerebellar disorders and possible anterior semicircular canalolithiasis. *J Neurol Neurosurg*  
 2395 *Psychiatry* 2002;72:366-72.

2396 Beynon GJ, Baguley DM, da Cruz MJ. Recurrence of symptoms following treatment of posterior  
 2397 semicircular canal benign positional paroxysmal vertigo with a particle repositioning manoeuvre.  
 2398 *J Otolaryngol* 2000;29:2-6.

2399 Bhattacharyya N, Baugh RF, Orvidas L, et al. Clinical practice guideline: benign paroxysmal  
 2400 positional vertigo. *Otol Head Neck Surg* 2008; 129: S47-S81.

2401 Black FO, Nashner LM. Postural disturbance in patients with benign paroxysmal positional  
 2402 nystagmus. *Ann Otol Rhinol Laryngol* 1984;93:595-9.

2403 Blakley BW, Goebel J. The meaning of the word "vertigo". *Otolaryngol Head Neck Surg*  
 2404 2001;125:147-50.

2405 Blatt PJ, Georgakakis GA, Herdman SJ, et al Effect of canalith repositioning maneuver on  
 2406 resolving postural instability in patients with BPPV. *Am J Otol.* 2000;21:356.

2407 Blatt PJ, Georgakakis GA, Herdman SJ, et al. The effect of the canalith repositioning maneuver  
 2408 on resolving postural instability in patients with benign paroxysmal positional vertigo. *Am J Otol*  
 2409 2000;21:356-63.

2410 Bracher ES, Almeida CI, Almeida RR, et al. A combined approach for the treatment of cervical  
 2411 vertigo. *J Manipulative Physiol Ther* 2000;23:96-100.

2412 Brandt T, Daroff RB. Physical therapy for benign paroxysmal positional vertigo. *Arch*  
 2413 *Otolaryngol* 1980;106:484-5.

2414 Brandt T, Dieterich M. Vestibular falls. *J Vestib Res* 1993;3:3-14.

2415 Brandt T, Dieterich M. VIIIth nerve vascular compression syndrome: vestibular paroxysmia.  
 2416 *Baillieres Clin Neurol* 1994;3:565-75.

2417 Brandt T, Phobic Postural Vertigo. *Neurology* 1996; 46 (6): 1515-1519.

2418 Brandt T, Steddin S, Daroff RB. Therapy for benign paroxysmal positioning vertigo, revisited.  
 2419 *Neurology* 1994;44:796-800.

2420 Brocchetti F, Garaventa G, Ameli F, et al. Effect of repetition of Semont's manoeuvre on benign  
 2421 paroxysmal positional vertigo of posterior semicircular canal. *Acta Otorhinolaryngol Ital*  
 2422 2003;23:428-35.

2423 Bruintjes TD, Companjen J, van der Zaag-Loonen HJ, van Benthem, PPG. A randomized sham-  
 2424 controlled trial to assess the long-term effect of the Epley manoeuvre for the treatment of  
 2425 posterior canal benign paroxysmal positional vertigo. *Clinical Otolaryngology* 2014; 39: 39-44.

2426 Burton MJ, Eby TL, and R.M. Rosenfeld, *Extracts from The Cochrane Library Modifications of*  
 2427 *the Epley (Canalith Repositioning) Maneuver for Posterior Canal Benign Paroxysmal Positional*  
 2428 *Vertigo*. *Otolaryngology--Head and Neck Surgery*, 2012: p. 0194599812457134.

2429 Burton, MJ, Eby, TL, Rosenfeld, RM. Extracts from the Cochrane Library: modifications of the

2430 epley (canalith repositioning) maneuver for posterior canal benign paroxysmal positional  
2431 vertigo. 2012; 147(3):407-411.

2432 Buttner U, Helmchen C, Brandt T. Diagnostic criteria for central versus peripheral positioning  
2433 nystagmus and vertigo: a review. *Acta Otolaryngol* 1999;119:1-5.

2434 Cakir BO, Ercan I, Cakir ZA, et al. What is the true incidence of horizontal semicircular canal  
2435 benign paroxysmal positional vertigo? *Otolaryngol Head Neck Surg* 2006;134:451-4.

2436 Carlow TJ. Medical treatment of nystagmus and ocular motor disorders. *Int Ophthalmol Clin*  
2437 1986;26:251-64.

2438 Caruso G, Nuti D. Epidemiological data from 2270 PPV patients. *Audiological Med* 2005;3:7-  
2439 11.

2440 Casani AP, Nacci A, Dallan I, et al. Horizontal semicircular canal benign paroxysmal positional  
2441 vertigo: effectiveness of two different methods of treatment. *Audiol Neurotol*. 2011;16(3):175-  
2442 84.

2443 Casani AP, Vannucci G, Fattori B, et al. The treatment of horizontal canal positional vertigo: our  
2444 experience in 66 cases. *Laryngoscope* 2002;112:172-8.

2445 Casellini CM, Vinik AI. Clinical manifestations and current treatment options for diabetic  
2446 neuropathies. *Endocr Pract* 2007;13:550-66.

2447 Cawthorne T. The physiologic basis for head exercises. *J Chart Soc Physiother* 1944:106-07.

2448 Cesarani A, Alpini D, Monti B, et al. The treatment of acute vertigo. *Neurol Sci* 2004;25 Suppl  
2449 1:S26-30.

2450 Chang AK, Schoeman G, Hill M. A randomized clinical trial to assess the efficacy of the Epley  
2451 maneuver in the treatment of acute benign positional vertigo. *Acad Emerg Med* 2004;11:918-24.

2452 Chang WC, Hsu LC, Yang YR, et al. Balance ability in patients with benign paroxysmal



2453 positional vertigo. *Otolaryngol Head Neck Surg* 2006;135:534-40.

2454 Chang WC, Yang YR, Hsu LC, Chern CM, Wang RY. Balance improvement in patients with  
 2455 benign paroxysmal positional vertigo. *Clin Rehabil.* 2008 Apr;22(4):338-47.

2456 Chen Y, Zhaung J, Zhang L, Li Y, Jin Z, Zhao Z, Zhao Y, Zhou H. Short-Term Efficacy of  
 2457 Semont Maneuver for BPPV: A Double-Blind Randomized Trial. *Otology & Neurotology* 2012;  
 2458 33:1127-1130.

2459 Chiou WY, Lee HL, Tsai SC, et al. A single therapy for all subtypes of horizontal canal  
 2460 positional vertigo. *Laryngoscope* 2005;115:1432-5.

2461 Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice  
 2462 guidelines and the pharmaceutical industry. *JAMA* 2002;287:612-7.

2463 Choung YH, Shin YR, Kahng H, Park K, Choi SJ. 'Bow and lean test' to determine the affected  
 2464 ear of horizontal canal benign paroxysmal positional vertigo. *Laryngoscope.* 2006  
 2465 Oct;116(10):1776-81.

2466 Cohen HS, Kimball KT, Stewart MG. Benign paroxysmal positional vertigo and comorbid  
 2467 conditions. *ORL J Otorhinolaryngol Relat Spec* 2004;66:11-5.

2468 Cohen HS, Kimball KT. Effectiveness of treatments for benign paroxysmal positional vertigo of  
 2469 the posterior canal. *Otol Neurotol* 2005;26:1034-40.

2470 Cohen HS, Kimball KT. Treatment variations on the Epley maneuver for benign paroxysmal  
 2471 positional vertigo. *Am J Otolaryngol* 2004;25(1):33-7.

2472 Colledge NR, Barr-Hamilton RM, Lewis SJ, et al. Evaluation of investigations to diagnose the  
 2473 cause of dizziness in elderly people: a community based controlled study. *BMJ* 1996;313:788-  
 2474 92.

2475 Cooksey, FS. Rehabilitation in vestibular injuries, *Proc R Soc Med* 39 (1946)

2476 Dal T, Ozluoglu LN, Ergin NT. The canalith repositioning maneuver in patients with benign  
 2477 positional vertigo. *Eur Arch Otorhinolaryngol* 2000;257:133-6.

2478 Dal, T., L. N. Ozl  ođlu and N. T. Ergin (2000). "The canalith repositioning maneuver in patients  
 2479 with benign positional vertigo." *Eur Arch Otorhinolaryngol* 257(3): 133-136.

2480 Davies RA, Luxon LM. Dizziness following head injury: a neuro-otological study. *J Neurol*  
 2481 1995;242:222-30.

2482 Day JJ, Freer CE, Dixon AK, et al. Magnetic resonance imaging of the brain and brain-stem in  
 2483 elderly patients with dizziness. *Age Ageing* 1990;19:144-50.

2484 De La Meilleure G, Dehaene I, Depondt M, Damman W, Crevits L, Vanhooren G: Benign  
 2485 paroxysmal positional vertigo of the horizontal canal. *J Neurol Neurosurg Psychiatry*  
 2486 1996;60:68–71.

2487 De Stefano A, Dispenza F, Citraro L, et al. Are postural restrictions necessary for management  
 2488 of posterior canal benign paroxysmal positional vertigo?. *Ann Otol Rhinol Laryngol*  
 2489 2011;120(7):460–4.

2490 Del Rio M, Arriaga MA. Benign positional vertigo: prognostic factors. *Otolaryngol Head Neck*  
 2491 *Surg* 2004;130:426-9.

2492 Detsky AS. Sources of bias for authors of clinical practice guidelines. *CMAJ* 2006;175:1033, 35.

2493 Devaiah AK, Andreoli S. Postmaneuver restrictions in benign paroxysmal positional vertigo: An  
 2494 individual patient data meta-analysis. *Otolaryngol Head Neck Surg* 2010;142:155-9.

2495 Di Girolamo S, Paludetti G, Briglia G, et al. Postural control in BPPV before and after recovery.  
 2496 *Acta Otolaryngol (Stockh)* 1998; 118: 289.

2497 Dix MR, Hallpike CS. The pathology, symptomatology and diagnosis of certain common  
 2498 disorders of the vestibular system. *Ann Otol Rhinol Laryngol* 1952;61:987-1016.

2499 Dix,MR. The rationale and technique of head exercises in the treatment of vertigo. *Acta*  
 2500 *Otorhinolaryngol Bel* 1979; 33:370-84.

2501 Dornhoffer JL, Colvin GB. Benign paroxysmal positional vertigo and canalith repositioning:  
 2502 clinical correlations. *Am J Otol* 2000;21:230-3.

2503 Dunniway HM, Welling DB. Intracranial tumors mimicking benign paroxysmal positional  
 2504 vertigo. *Otolaryngol Head Neck Surg* 1998;118:429-36.

2505 Eddy DM. A manual for assessing health practices and designing practice policies: the explicit  
 2506 approach. In. Philadelphia: American College of Physicians; 1992.

2507 Ekvall Hansson E, Mansson NO, Hakansson A. Benign paroxysmal positional vertigo among  
 2508 elderly patients in primary health care. *Gerontology* 20015; 51(6):386-9.

2509 Engeland A, Skurtveit S, Morland J. Risk of road traffic accidents associated with the  
 2510 prescription of drugs: a registry-based cohort study. *Ann Epidemiol* 2007;17:597-602.

2511 Epley JM. The canalith repositioning procedure: for treatment of benign paroxysmal positional  
 2512 vertigo. *Otolaryngol Head Neck Surg* 1992;107:399-404.

2513 Fife D, FitzGerald JE. Do patients with benign paroxysmal positional vertigo receive prompt  
 2514 treatment? Analysis of waiting times and human and financial costs associated with current  
 2515 practice. *Int J Audiol* 2005;44:50-7.

2516 Fife TD, Iverson DJ, Lempert T, et al. Practice Parameter: Therapies for benign paroxysmal  
 2517 positional vertigo (an evidence-based review): Report of the Quality Standards Subcommittee of  
 2518 the American Academy of Neurology. *Neurology* 2008;70:2067-74.

2519 Fife TD, Iverson DJ, Lempert T, et al. Practice parameter: therapies for benign paroxysmal  
 2520 positional vertigo (an evidence-based review): report of the Quality Standards Subcommittee of  
 2521 the American Academy of Neurology. *Neurology*. 2008 May 27;70(22):2067-74.

2522 Fife TD, Tusa RJ, Furman JM, et al. Assessment: vestibular testing techniques in adults and  
2523 children: report of the Therapeutics and Technology Assessment Subcommittee of the American  
2524 Academy of Neurology. *Neurology* 2000;55:1431-41.

2525 Fife TD. Benign Paroxysmal positional vertigo. *Semin Neurol* 2009;29:500-508

2526 Fife TD. Recognition and management of horizontal canal benign positional vertigo. *Am J Otol*  
2527 1998;19:345-51.

2528 Fife TD. Positional dizziness. *Continuum (Minneap Minn)*. 2012 Oct;18(5 Neuro-otology):1060-  
2529 85.

2530 Froehling DA, Bowen JM, Mohr DN, et al. The canalith repositioning procedure for the  
2531 treatment of benign paroxysmal positional vertigo: a randomized controlled trial. *Mayo Clin*  
2532 *Proc* 2000;75:695-700.

2533 Froehling DA, Silverstein MD, Mohr DN, et al. Benign positional vertigo: incidence and  
2534 prognosis in a population-based study in Olmsted County, Minnesota. *Mayo Clin Proc*  
2535 1991;66:596-601.

2536 Frohman EM, Kramer PD, Dewey RB, et al. Benign paroxysmal positioning vertigo in multiple  
2537 sclerosis: diagnosis, pathophysiology and therapeutic techniques. *Mult Scler* 2003;9:250-5.

2538 Frohman EM, Zhang H, Dewey RB, et al. Vertigo in MS: utility of positional and particle  
2539 repositioning maneuvers. *Neurology* 2000;55:1566-9.

2540 Fujino A, Tokumasu K, Yosio S, et al. Vestibular training for benign paroxysmal positional  
2541 vertigo. Its efficacy in comparison with antivertigo drugs. *Arch Otolaryngol Head Neck Surg*  
2542 1994;120:497-504.

2543 Furman JM, Cass SP. A practical work-up for vertigo. *Contemp Intern Med* 1995;7:24-7, 31-2,  
2544 35-8.

2545 Furman JM, Cass SP. Benign paroxysmal positional vertigo. N Engl J Med 1999;341:1590-6.

2546 Furman JM, Raz Y, Whitney SL. Geriatric vestibulopathy assessment and management. Current  
2547 opinion in Otolaryngology & Head Neck Surgery 2010, 18: 386-391.

2548 Furman JM, Redfern MS, Jacob RG. Vestibulo-ocular function in anxiety disorders. J Vestib Res  
2549 2006;16:209-15.

2550 Furman JM, *UPTD Date" Wolters Kluwer.*, 2013, accessed at

2551 Gamiz MJ, Lopez-Escamez JA. Health-related quality of life in patients over sixty years old with  
2552 benign paroxysmal positional vertigo. Gerontology 2004;50:82-6.

2553 Gazzola JM, Gananca FF, Aratani MC, et al. Circumstances and consequences of falls in elderly  
2554 people with vestibular disorder. Rev Bras Otorrinolaringol (Engl Ed) 2006;72:388-92.

2555 Giacomini PG, Alessandrini M, Magrini A. Long-term postural abnormalities in benign  
2556 paroxysmal positional vertigo. ORL J Otorhinolaryngol Relat Spec 2002;64:237-41.

2557 Gizzi M, Riley E, Molinari S. The diagnostic value of imaging the patient with dizziness. A  
2558 Bayesian approach. Arch Neurol 1996;53:1299-304.

2559 Gordon CR, Levite R, Joffe V, et al. Is posttraumatic benign paroxysmal positional vertigo  
2560 different from the idiopathic form? Arch Neurol 2004;61:1590-3.

2561 Gordon CR, Shupak A, Spitzer O, et al. Nonspecific vertigo with normal otoneurological  
2562 examination. The role of vestibular laboratory tests. J Laryngol Otol 1996;110:1133-7.

2563 Grill E, Strupp M, Muller M, Klaus J. Health Services Utilization of Patients with Vertigo in  
2564 Primary Care: a Retrospective Cohort Study. J Neurol (2014) 261:1492-1498.

2565 Guneri EA, Kustutan O. The effects of betahistine in addition to epley maneuver in posterior  
2566 canal benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg. 2012 Jan;146(1):104-  
2567 8. doi: 10.1177/0194599811419093. Epub 2011 Aug 18.

2568 Hain TC, Uddin M. Pharmacological treatment of vertigo. *CNS Drugs* 2003;17:85-100.

2569 Hain TC, Yacovino D. Pharmacologic treatment of persons with dizziness. *Neurol Clin*

2570 2005;23:831-53, vii.

2571 Hall CD, Herdman SJ, Whitney SL, Cass SP, Clendaniel RA, Fife TD, Furman JM, Getchius

2572 TSD, Goebel JA, Shepard NT, Woodhouse SN. Vestibular Rehabilitation for Peripheral

2573 Vestibular Hypofunction: An Evidence-based Clinical Practice Guideline. *Journal of Neurologic*

2574 *Physical Therapy* 2016;40(1):xx-xx (in press). Currently available at:

2575 [https://vestibular.org/sites/default/files/APTA\\_CPG\\_Vestibular.pdf](https://vestibular.org/sites/default/files/APTA_CPG_Vestibular.pdf)

2576 Han BI, Oh HJ, Kim JS: Nystagmus while recumbent in horizontal canal benign paroxysmal

2577 positional vertigo. *Neurology* 2006;66:706– 710

2578 Han BI, Song HS, Kim JS. Vestibular Rehabilitation Therapy: Review of Indications,

2579 Mechanisms, and Key Exercises. *J Clin Neurol.* 2011 Dec;7(4):184–196.

2580 Hanley K, O' Dowd T. Symptoms of vertigo in general practice: a prospective study of

2581 diagnosis. *Br J Gen Pract* 2002;52:809-12.

2582 Hanley K, O'Dowd T, Considine N. A systematic review of vertigo in primary care. *Br J Gen*

2583 *Pract* 2001;51:666-71.

2584 Hartikainen S, Lonnroos E, Louhivuori K. Medication as a risk factor for falls: critical

2585 systematic review. *J Gerontol A Biol Sci Med Sci* 2007;62:1172-81.

2586 Haynes DS, Resser JR, Labadie RF, et al. Treatment of benign positional vertigo using the

2587 semont maneuver: efficacy in patients presenting without nystagmus. *Laryngoscope*

2588 2002;112:796-801.

2589 Hebert C, Delaney JA, Hemmelgarn B, et al. Benzodiazepines and elderly drivers: a comparison

2590 of pharmacoepidemiological study designs. *Pharmacoepidemiol Drug Saf* 2007;16:845-9.

2591 Heidenreich KD, Kerber KA. Carender WJ, et al. Persistent positional nystagmus: a case of  
 2592 superior semicircular canal benign paroxysmal positional vertigo? *Laryngoscope* 2011;121:1818-  
 2593 1820  
 2594 Heinrichs, M., & Gaab, J. (2007). Neuroendocrine mechanisms of stress and social interaction:  
 2595 implications for mental disorders. *Current Opinion in Psychiatry*, 20(2), 158-162.  
 2596 Helminski JO, Zee DS, Janssen I, Hain TC. Effectiveness of particle repositioning maneuvers in  
 2597 the treatment of benign paroxysmal positional vertigo: a systematic review. *Phys Ther*. 2010;  
 2598 9D(5):663-78.  
 2599 Herdman SJ, Blatt PJ, Schubert MC. Vestibular rehabilitation of patients with vestibular  
 2600 hypofunction or with benign paroxysmal positional vertigo. *Curr Opin Neurol* 2000;13:39-43.  
 2601 Herdman SJ, Tusa RJ. Complications of the canalith repositioning procedure. *Arch Otolaryngol*  
 2602 *Head Neck Surg* 1996;122:281-6.  
 2603 Herdman SJ. Advances in the treatment of vestibular disorders. *Phys Ther* 1997;77:602-18.  
 2604 Hien le TT, Cumming RG, Cameron ID, et al. Atypical antipsychotic medications and risk of  
 2605 falls in residents of aged care facilities. *J Am Geriatr Soc* 2005;53:1290-5.  
 2606 Hillier SL, Hollohan V. Vestibular rehabilitation for unilateral peripheral vestibular dysfunction.  
 2607 *Cochrane Database Syst Rev* 2007:CD005397.  
 2608 Hilton M, Pinder D. The Epley (canalith repositioning) manoeuvre for benign paroxysmal  
 2609 positional vertigo. *Cochrane Database Syst Rev* 2004:CD003162  
 2610 Hoffer ME, Gottshall KR, Moore R, Balough BJ, Wester D. Characterizing and treating  
 2611 dizziness after mild head trauma. *Otol Neurotol*. 2004 Mar. 25(2):135-8.  
 2612 Hong SM, Yeo, SG, Kim SW, Cha CI. The results of vestibular evoked myogenic potentials  
 2613 (VEMP), with consideration of age-related changes, in vestibular neuritis, benign paroxysmal

2614 positional vertigo, and Meniere's disease. *Acta Oto-Laryngologica* 2008;128:861-865.

2615 Honrubia V, Baloh RW, Harris MR, et al. Paroxysmal positional vertigo syndrome. *Am J Otol*

2616 1999;20:465-70.

2617 Horak FB, Jones-Rycewicz C, Black FO, Shumway-Cook A. effects of Vestibular Rehabilitation

2618 on dizziness and imbalance. *Otolaryngol Head Neck Surg* 1992; 106:2: 175-80.

2619 Hornibrook J. Horizontal canal benign positional vertigo. *Ann Otol Rhinol Laryngol*

2620 2004;113:721-5.

2621 Hoseinabadi R, Pourbakht A, Yazdani, N. The effects of abnormality of cVEMP and oVEMP on

2622 rehabilitation outcomes in patients with idiopathic benign paroxysmal positional vertigo. *Eur*

2623 *Arch Otorhinolaryngol* 2015;Apr 1.

2624 <http://www.uptodate.com/contents/dizziness-and-vertigo-beyond-the-basics?view=print>.

2625 Hughes CA, Proctor L. Benign paroxysmal positional vertigo. *Laryngoscope* 1997;107:607-13.

2626 Hunt WT, Zimmermann EF, Hilton MP. Modifications of the Epley (canalith repositioning)

2627 manoeuvre for posterior canal benign paroxysmal positional vertigo (BPPV). *Cochrane Database*

2628 *Sys Rev* 2012:CD008675.

2629 Hwang M, Kim SH, Kang KW, et al. Canalith repositioning in apogeotropic horizontal canal

2630 benign paroxysmal positional vertigo: Do we need faster maneuvering? *J Neurol Sci*

2631 2015;358(Issue 1-2):183-187.

2632 Ibekwe TS, Rogers C. Clinical Evaluation of posterior canal BPPV. *Nigerian Medical Journal*

2633 2012; 53 (2): 94-101.

2634 Imai T, Ito M, Takeda N, et al. Natural course of the remission of vertigo in patients with benign

2635 paroxysmal positional vertigo. *Neurology* 2005;64:920-1.

2636 Imai T, Ito M, Takeda N, Uno A, Matsunaga T, Sekine K, Kubo T: Natural course of the



2637 remission of vertigo in patients with benign paroxysmal positional vertigo. *Neurology*  
2638 2005;64:920–921.

2639 Imbaud Genieys S. Vertigo, dizziness and falls in the elderly. *Annales d Oto-Laryngologie et de*  
2640 *Chirurgie Cervico-Faciale* 2007;124:189-96.

2641 Itaya T, Yamamoto E, Kitano H, et al. Comparison of effectiveness of maneuvers and  
2642 medication in the treatment of benign paroxysmal positional vertigo. *ORL J Otorhinolaryngol*  
2643 *Relat Spec* 1997;59:155-8.

2644 Jackson LE, Morgan B, Fletcher JC, Jr., et al. Anterior canal benign paroxysmal positional  
2645 vertigo: an underappreciated entity. *Otol Neurotol* 2007;28:218-22.

2646 Jacob RG, Furman JM, Durrant JD, et al. Panic, agoraphobia, and vestibular dysfunction. *Am J*  
2647 *Psychiatry* 1996;153:503-12.

2648 Jacobson G, Butcher JA, Newman CW, et al. When paroxysmal positional vertigo isn't benign.  
2649 *Jnl Am Acad Audiol* 1995;6:346-9.

2650 Jauregui I, Mullol J, Bartra J, et al. H1 antihistamines: psychomotor performance and driving. *J*  
2651 *Investig Allergol Clin Immunol* 2006;16 Suppl 1:37-44.

2652 Jönsson R, Sixt E, Landahl S, et al. Prevalence of dizziness and vertigo in an urban elderly  
2653 population. *J Vestib Res* 2004;14:47-52.

2654 Jung HJ, Koo JW, Kim CS, Kim JS, Song JJ. Anxiolytics reduce residual dizziness after  
2655 successful canalith repositioning maneuvers in benign paroxysmal positional vertigo. *Acta*  
2656 *Otolaryngol.* 2012 Mar;132(3):277-84. doi: 10.3109/00016489.2011.637179. Epub 2011 Dec 27.

2657 Karlberg M, Hall K, Quickert N, et al. What inner ear diseases cause benign paroxysmal  
2658 positional vertigo? *Acta Otolaryngol* 2000;120:380-5.

2659 Katsarkas A. Benign paroxysmal positional vertigo (BPPV): idiopathic versus post-traumatic.

2660 Acta Otolaryngol 1999;119:745-9.

2661 Katsarkas A. Dizziness in aging: the clinical experience. Geriatrics 2008; 63(11):18-20.

2662 Kayan A, Hood JD. Neuro-otological manifestations of migraine. Brain 1984;107 ( Pt 4):1123-  
2663 42.

2664 Kentala E, Laurikkala J, Pyykko I, et al. Discovering diagnostic rules from a neurotologic  
2665 database with genetic algorithms. Ann Otol Rhinol Laryngol 1999;108:948-54.

2666 Kentala E, Pyykko I. Vertigo in patients with benign paroxysmal positional vertigo. Acta  
2667 Otolaryngol Suppl 2000;543:20-2.

2668 Kentala E, Rauch SD. A practical assessment algorithm for diagnosis of dizziness. Otolaryngol  
2669 Head Neck Surg 2003;128:54-9.

2670 Kentala E. Characteristics of six otologic diseases involving vertigo. Am J Otol 1996;17:883-92.

2671 Kerber KA, *Benign paroxysmal positional vertigo: opportunities squandered*. Annals of the New  
2672 York Academy of Sciences, 2015. 1343(1): p. 106-112.

2673 Kerrigan MA, Costigan MF, Blatt KJ, Mathiason MA, Domroese ME. Prevalance of benign  
2674 paroxysmal positional vertigo in the young adult population. Phys Med Rehab. 2013; 5:778-785.

2675 Kim JS and Zee DS, *Benign paroxysmal positional vertigo*. N Engl J Med, 2014. 370: p. 1138-  
2676 47., p. 1140.

2677 Kim JS, Oh S-Y, Lee S-H, Kang JH, Kim DU, Jeong SH, Choi K-D, Moon IS, Kim BK, Kim  
2678 HJ. Randomized clinical trial for geotropic horizontal canal benign paroxysmal positional  
2679 vertigo. Neurology 2012; 79: 700-707.

2680 Kim JS, Oh S-Y, Lee S-H, Kang JH, Kim DU, Jeong SH, Choi K-D, Moon IS, Kim BK, Kim  
2681 HJ. Randomized clinical trial for apogeotropic horizontal canal benign paroxysmal positional  
2682 vertigo. Neurology 2012; 28:159-166. (2012b)

2683 Kollén L, Frändin K, Möller M, Fagevik Olsén M, Möller C. Benign paroxysmal positional  
 2684 vertigo is a common cause of dizziness and unsteadiness in a large population of 75-year-olds.  
 2685 Aging Clin Exp Res 2012;24(4):317-323

2686 Korres SG, Balatsouras DG. Diagnostic, pathophysiologic, and therapeutic aspects of benign  
 2687 paroxysmal positional vertigo. Otolaryngol Head Neck Surg 2004;131:438-44.

2688 Kumar A, Patni AH, Charbel F. The Chiari I malformation and the neurotologist. Otol Neurotol  
 2689 2002;23:727-35.

2690 Labuguen RH. Initial evaluation of vertigo. Am Fam Physician 2006;73:244-51.

2691 Landi F, Russo A, Liperoti R, et al. Anticholinergic drugs and physical function among frail  
 2692 elderly population. Clin Pharmacol Ther 2007;81:235-41.

2693 Lawson J, Johnson I, Bamiou DE, et al. Benign paroxysmal positional vertigo: clinical  
 2694 characteristics of dizzy patients referred to a Falls and Syncope Unit. QJM 2005;98:357-64.

2695 Lawson J, Johnson I, Bamiou DE, et al. Benign paroxysmal positional vertigo: clinical

2696 Lee JD, Park MK, Lee BD, Lee TK, Sung KB, Park JY. Abnormality of cervical vestibular-  
 2697 evoked myogenic potentials and ocular vestibular-evoked myogenic potentials in patients with  
 2698 recurrent benign paroxysmal positional vertigo. Acta Otolaryngol 2013;133(2):150-3.

2699 Lee SH, Choi KD, Jeong SH, et al. Nystagmus during neck flexion in the pitch plane in benign  
 2700 paroxysmal positional vertigo involving the horizontal canal. J Neurol Sci 2007;256:75–80.

2701 Lempert T, Tiel-Wilck K. A positional maneuver for treatment of horizontal-canal benign  
 2702 positional vertigo. Laryngoscope 1996;106:476-8.

2703 Lempert T, Wolsley C, Davies R, et al. Three hundred sixty-degree rotation of the posterior  
 2704 semicircular canal for treatment of benign positional vertigo: a placebo-controlled trial.  
 2705 Neurology 1997;49:729-33.

2706 Li JC, Li CJ, Epley J, et al. Cost-effective management of benign positional vertigo using  
2707 canalith repositioning. *Otolaryngol Head Neck Surg* 2000;122:334-9.

2708 Li JC. Mastoid oscillation: a critical factor for success in canalith repositioning procedure.  
2709 *Otolaryngol Head Neck Surg* 1995;112:670-5.

2710 Lin HW, Bhattacharyya N. Balance disorders in the elderly: epidemiology and functional impact.  
2711 *Laryngoscope* 2012; 122(8); 1858-61.

2712 Lin HW, Bhattacharyya N. Otologic diagnoses in the elderly: current utilization and predicted  
2713 workload increase. *Laryngoscope* 2011; 121(7):1504-7.

2714 Longo G, Onofri M, Pellicciari T, Quaranta N. Benign paroxysmal positional vertigo: is  
2715 vestibular evoked myogenic potential testing useful? *Acta Otolaryngol.* 2012;132(1):39-43.

2716 Lopez-Escamez J, Gonzalez-Sanchez M, Salinero J. Meta-analysis of the treatment of benign  
2717 paroxysmal positional vertigo by Epley and Semont maneuvers. *Acta Otorrinolaringol Esp*  
2718 1999;50:366-70.

2719 Lopez-Escamez JA, Gamiz MJ, Fernandez-Perez A, et al. Impact of treatment on health-related  
2720 quality of life in patients with posterior canal benign paroxysmal positional vertigo. *Otol*  
2721 *Neurotol* 2003;24:637-41.

2722 Lopez-Escamez JA, Gamiz MJ, Fernandez-Perez A, et al. Long-term outcome and health-related  
2723 quality of life in benign paroxysmal positional vertigo. *Eur Arch Otorhinolaryngol*  
2724 2005;262:507-11.

2725 Lopez-Escamez JA, Lopez-Nevot A, Gamiz MJ, et al. Diagnosis of common causes of vertigo  
2726 using a structured clinical history. *Acta Otorrinolaringol Esp* 2000;51:25-30.

2727 Lopez-Escamez JA, Molina MI, Gamiz MJ. Anterior semicircular canal benign paroxysmal  
2728 positional vertigo and positional bowbeating nystagmus. *Am J Otolaryngol* 2006;27:173-178

2729 Lui H. Presentation and outcome of post-traumatic BPPV. *Acta Oto-Laryngologica* 2012;  
 2730 132:803-806.

2731 Lüscher M, Theilgaard S, Edholm B1 (2014). Prevalence and characteristics of diagnostic groups  
 2732 amongst 1034 patients seen in ENT practices for dizziness. *J Laryngol Otol.* 2014  
 2733 Feb;128(2):128-33.

2734 Lynn S, Pool A, Rose D, Brey R, Suman V. Randomized trial of the canalith repositioning  
 2735 procedure. *Otolaryngol Head Neck Surg* 1995;113:712–720.

2736 Lynn S, Pool A, Rose D, et al. Randomized trial of the canalith repositioning procedure.  
 2737 *Otolaryngol Head Neck Surg* 1995;113:712-20.

2738 Macias JD, Lambert KM, Massingale S, et al. Variables affecting treatment in benign  
 2739 paroxysmal positional vertigo. *Laryngoscope* 2000;110:1921-4.

2740 Mandalà M1, Pepponi E, Santoro GP, et al. . Double-blind randomized trial on the efficacy of  
 2741 the Gufoni maneuver for treatment of lateral canal BPPV. *Laryngoscope.* 2013 Jul;123(7):1782-  
 2742 6.

2743 Marzo SJ, Leonetti JP, Raffin MJ, et al. Diagnosis and management of post-traumatic vertigo.  
 2744 *Laryngoscope* 2004;114:1720-3.

2745 Maslovara S, Soldo SB, Puksec M, Balaban B, Penavic IP..Benign paroxysmal positional vertigo  
 2746 (BPPV): influence of pharmacotherapy and rehabilitation therapy on patients' recovery rate and  
 2747 life quality. *NeuroRehabilitation.* 2012;31(4):435-41. doi: 10.3233/NRE-2012-00814

2748 Massoud EA, Ireland DJ. Post-treatment instructions in the nonsurgical management of benign  
 2749 paroxysmal positional vertigo. *J Otolaryngol* 1996;25:121-5.

2750 Mathias S, Nayak USL, Isaacs B. Balance in elderly patients: the “get-up and go”

2751 McClure JA, Willett JM. Lorazepam and diazepam in the treatment of benign paroxysmal

2752 vertigo. J Otolaryngol 1980;9:472-7

2753 McDonnell MN, Hillier SL. Vestibular rehabilitation for unilateral peripheral vestibular  
 2754 dysfunction. Cochrane Database Systematic Reviews, 2015 Jan 13:1: CD005397.

2755 Minor LB, Cremer PD, Carey JP, et al. Symptoms and signs in superior canal dehiscence  
 2756 syndrome. Annals of the New York Academy of Sciences 2001;942:259-73.

2757 Mizukoshi K, Kobayashi H, Ohashi N, et al. Quantitative analysis of the visual vestibulo-ocular  
 2758 reflex using sinusoidal rotation in patients with peripheral vestibular disorders. Acta Otolaryngol  
 2759 Suppl 1984;406:178-81.

2760 Monobe H, Sugawara K, Murofushi T. The outcome of the canalith repositioning procedure for  
 2761 benign paroxysmal positional vertigo: are there any characteristic features of treatment failure  
 2762 cases? Acta Otolaryngol Suppl 2001;545:38-40.

2763 Moon SY, Kim JS, Kim BK, et al. Clinical characteristics of benign paroxysmal positional  
 2764 vertigo in Korea: a multicenter study. J Korean Med Sci 2006;21:539-43.

2765 Motin M, Keren O, Groswasser Z, et al. Benign paroxysmal positional vertigo as the cause of  
 2766 dizziness in patients after severe traumatic brain injury: diagnosis and treatment. Brain Inj  
 2767 2005;19:693-7.

2768 Munoz JE, Micklea JT, Howard M, et al. Canalith repositioning maneuver for benign paroxysmal  
 2769 positional vertigo: randomized controlled trial in family practice. Can Fam Physician  
 2770 2007;53:1049-53, 48.

2771 Murdin L, Schilder AGM. Epidemiology of Balance Symptoms and Disorders in the  
 2772 Community: a Systematic Review. Otol Neurotol 36:387-392, 2015.

2773 Nedzelski JM, Barber HO, McIlmoyl L. Diagnoses in a dizziness unit. J Otolaryngol  
 2774 1986;15:101-4.

2775 Neuhauser HK, Lempert T. *Vertigo: epidemiologic aspects*. Seminars in Neurology, 2009.

2776 Neuhauser HK. Epidemiology of vertigo. *Curr Opin Neurol* 2007;20:40-6.

2777 Newman-Toker DE, Edlow JA. TiTrATE: A novel, evidence-based approach to diagnosing acute  
2778 dizziness and vertigo. *Neurol Clin* 2015;33:577-99.

2779 Newman-Toker DE, Hsieh YH, Camargo CA, Jr., Pelletier AJ, Butchy GT, Edlow JA. Spectrum  
2780 of dizziness visits to US emergency departments: cross-sectional analysis from a nationally  
2781 representative sample. *Mayo Clin Proc* 2008;83:765-75.

2782 Norre ME, Beckers A. Benign paroxysmal positional vertigo in the elderly. Treatment by  
2783 habituation exercises. *J Am Geriatr Soc* 1988;36:425-9.

2784 Norre ME. Diagnostic problems in patients with benign paroxysmal positional vertigo.  
2785 *Laryngoscope* 1994;104:1385-8.

2786 Norre ME. Reliability of examination data in the diagnosis of benign paroxysmal positional  
2787 vertigo. *Am J Otol* 1995;16:806-10.

2788 Nunez RA, Cass SP, Furman JM. Short- and long-term outcomes of canalith repositioning for  
2789 benign paroxysmal positional vertigo. *Otolaryngol Head Neck Surg* 2000;122:647-52.

2790 Nuti D, Agus G, Barbieri MT, et al. The management of horizontal-canal paroxysmal positional  
2791 vertigo. *Acta Otolaryngol* 1998;118:455-60.

2792 Oghalai JS, Manolidis S, Barth JL, et al. Unrecognized benign paroxysmal positional vertigo in  
2793 elderly patients. *Otolaryngol Head Neck Surg* 2000;122:630-4.

2794 Oghalai JS, Manolidis S, Barth JL, Stewart MG, Jenkins HA(2000) Unrecognized benign  
2795 paroxysmal positional vertigo in elderly patients. *Otolaryngol Head Neck Surg* 122:630–634

2796 Padoan S, Karlberg M, Fransson PA, et al. Passive sustained turning of the head induces  
2797 asymmetric gain of the vestibulo-ocular reflex in healthy subjects. *Acta Otolaryngol*

2798 1998;118:778-82.

2799 Parnes LS, Agrawal SK, Atlas J. Diagnosis and management of benign paroxysmal positional  
2800 vertigo (BPPV). CMAJ 2003;169:681-93.

2801 Parnes LS, McClure JA. Free-floating endolymph particles: a new operative finding during  
2802 posterior semicircular canal occlusion. Laryngoscope 1992;102:988-92.

2803 Phillips JS, FitzGerald JE, Bath AP. The role of the vestibular assessment. J Laryngol Otol.  
2804 2009;123(11):1212-5.

2805 Pit SW, Byles JE, Henry DA, et al. A Quality Use of Medicines program for general  
2806 practitioners and older people: a cluster randomised controlled trial. Med J Aust 2007;187:23-30.

2807 Pollak L, Davies RA, Luxon LL. Effectiveness of the particle repositioning maneuver in benign  
2808 paroxysmal positional vertigo with and without additional vestibular pathology. Otol Neurotol  
2809 2002;23:79-83.

2810 Prim-Espada MP, De Diego-Sastre JJ, Perez-Fernandez E. Meta-analysis on the efficacy of  
2811 Epley's manoeuvre in benign paroxysmal positional vertigo. Neurologia 2010; 25(5):295-299.

2812 Prokopakis EP, Chimona T, Tsagournisakis M, et al. Benign paroxysmal positional vertigo: 10-  
2813 year experience in treating 592 patients with canalith repositioning procedure. Laryngoscope  
2814 2005;115:1667-71.

2815 Radtke A, Neuhauser H, von Brevern M, et al. A modified Epley's procedure for self-treatment  
2816 of benign paroxysmal positional vertigo. Neurology 1999;53:1358-60.

2817 Radtke A, von Brevern M, Tiel-Wilck K, et al. Self-treatment of benign paroxysmal positional  
2818 vertigo: Semont maneuver vs Epley procedure. Neurology 2004;63:150-2.

2819 Reinink H, Wegner I, Stegeman I, Grolman W. Rapid Systematic Review of Repeated  
2820 Application of the Epley Maneuver for Treating Posterior BPPV. Otol HNS 2014; 151(3): 399-



2821 406.

2822 Reinink H, Wegner I, Stegeman I, Grolman W. Rapid Systematic Review of Repeated

2823 Application of the Epley Maneuver for Treating Posterior BPPV. *Otol HNS* 2014; 151(3): 399-

2824 406.

2825 Richardson JK. Factors associated with falls in older patients with diffuse polyneuropathy. *J Am*

2826 *Geriatr Soc* 2002;50:1767-73.

2827 Roberts RA, Abrams H, Sembach MK, Lister JJ, Gans RE, Chisolm TH. Utility measures of

2828 health-related quality of life in patients treated for benign paroxysmal positional vertigo. *Ear*

2829 *Hear* 2009; 30(3):369-76.

2830 Roberts RA, Gans RE, DeBoodt JL, et al. Treatment of benign paroxysmal positional vertigo:

2831 necessity of postmaneuver patient restrictions. *J Am Acad Audiol* 2005;16:357-66.

2832 Roberts RA, Gans RE, Kastner AH, et al. Prevalence of vestibulopathy in benign paroxysmal

2833 positional vertigo patients with and without prior otologic history. *Int J Audiol* 2005;44:191-6.

2834 Rosenfeld RM, Shiffman RN, Robertson P, et al. Clinical practice guideline development

2835 manual, third edition: a quality-driven approach for translating evidence into action. *Otolaryngol*

2836 *Head Neck Surg.* 2013;148(1 Suppl):S1-55.

2837 Rosowski JJ, Songer JE, Nakajima HH, et al. Clinical, experimental, and theoretical

2838 investigations of the effect of superior semicircular canal dehiscence on hearing mechanisms.

2839 *Otol Neurotol* 2004;25:323-32.

2840 Rubenstein LZ, Powers CM, MacLean CH. Quality indicators for the management and

2841 prevention of falls and mobility problems in vulnerable elders. *Ann Intern Med* 2001;135:686-

2842 93.

2843 Rubenstein LZ. Falls in older people: epidemiology, risk factors and strategies for prevention.

2844 *Age Ageing* 2006;35 Suppl 2:ii37-ii41.

2845 Ruckenstein MJ, Shepard NT. The canalith repositioning procedure with and without mastoid  
2846 oscillation for the treatment of benign paroxysmal positional vertigo. *ORL J Otorhinolaryngol*  
2847 *Relat Spec* 2007;69:295-8.

2848 Ruckenstein MJ. Therapeutic efficacy of the Epley canalith repositioning maneuver.  
2849 *Laryngoscope* 2001;111:940-5.

2850 Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic  
2851 Sacco RR, Burmeister DB, Rupp VA, Greenberg MR. Management of benign paroxysmal  
2852 positional vertigo: a randomized controlled trial. *J Emerg Med*. 2014 Apr;46(4):575-81. doi:  
2853 10.1016/j.jemermed.2013.08.116. Epub 2014 Jan 22.adverse effects in older persons. *Arch Intern*  
2854 *Med* 2008;168:508-13.

2855 Rupa V. Persistent vertigo following particle repositioning maneuvers: an analysis of causes.  
2856 *Arch Otolaryngol Head Neck Surg* 2004;130:436-9.

2857 Sakaida M, Takeuchi K, Ishinaga H, et al. Long-term outcome of benign paroxysmal positional  
2858 vertigo. *Neurology* 2003;60:1532-4.

2859 Salvinelli F, Casale M, Trivelli M, et al. Benign paroxysmal positional vertigo: a comparative  
2860 prospective study on the efficacy of Semont's maneuver and no treatment strategy. *Clin Ter*  
2861 2003;154:7-11.

2862 Salvinelli F, Trivelli M, Casale M, et al. Treatment of benign positional vertigo in the elderly: a  
2863 randomized trial. *Laryngoscope* 2004;114:827-31.

2864 Schappert SM. National Ambulatory Medical Care Survey: 1989 summary. *Vital Health Stat* 13  
2865 1992;1-80.

2866 Seemungal B, Kaski D, Lopez-Escamez JA. Early diagnosis and management of acute vertigo  
2867 from vestibular migraine and Ménière's disease. *Neurol Clin*. 2015 Aug;33(3):619-28,

2868 Sekine K, Imai T, Sato G, et al. Natural history of benign paroxysmal positional vertigo and  
 2869 efficacy of Epley and Lempert maneuvers. *Otolaryngol Head Neck Surg* 2006;135:529-33.

2870 Semont A, Freyss G, Vitte E. Curing Benign paroxysmal vertigo with a liberatory maneuver.  
 2871 *Adv Otorhinolaryngol.* 1988; 42: 290.

2872 Shaia WT, Zappia JJ, Bojrab DI, et al. Success of posterior semicircular canal occlusion and  
 2873 application of the dizziness handicap inventory. *Otolaryngol Head Neck Surg* 2006;134:424-30.

2874 Shepard NT, Telian SA. Programmatic vestibular rehabilitation. *Otolaryngol Head Neck Surg*  
 2875 1995; 112: 173-82.

2876 Shepard NT, Telian SA. Programmatic vestibular rehabilitation. *Otolaryngol Head Neck Surg*  
 2877 1995; 112: 173-82.

2878 Sherman D, Massoud EA. Treatment outcomes of benign paroxysmal positional vertigo. *Journal*  
 2879 *of Otolaryngology* 2001;30:295-9.

2880 Shiffman RN, Dixon J, Brandt C, et al. The guideline implementability appraisal (GLIA):  
 2881 development of an instrument to identify obstacles to guideline implementation. *BMC Med*  
 2882 *Inform Decis.* 2005;5: 23.

2883 Shiffman RN, Michel G, Rosenfeld RM, Davidson C. Building better guidelines with BRIDGE-  
 2884 Wiz: a software assistant to promote quality, transparency, and implementability. *J Amer Med*  
 2885 *Inform Assoc.* 2012; 19:94-101.

2886 Smouha EE, Roussos C. Atypical forms of paroxysmal positional nystagmus. *Ear Nose Throat J*  
 2887 1995;74:649-56.

2888 Soto Varela A, Bartual Magro J, Santos Perez S, et al. Benign paroxysmal vertigo: a comparative  
 2889 prospective study of the efficacy of Brandt and Daroff exercises, Semont and Epley maneuver.  
 2890 *Rev Laryngol Otol Rhinol (Bord)* 2001;122:179-83.

2891 Sridhar S, Panda N. Particle repositioning manoeuvre in benign paroxysmal positional vertigo: is  
 2892 it really safe? *J Otolaryngol* 2005;34:41-5.

2893 Staab JP Chronic Subjective Dizziness. *Continuum Lifelong Learning Neurol* 2012; 18 (5):  
 2894 1118-1141.

2895 Steenerson RL, Cronin GW, Marbach PM. Effectiveness of treatment techniques in 923 cases of  
 2896 benign paroxysmal positional vertigo. *Laryngoscope* 2005;115:226-31.

2897 Sundararajan I, Rangachari V, Sumathi V, Kumar K. Epley's manoeuvre versus Epley's  
 2898 manoeuvre plus labyrinthine sedative as management of benign paroxysmal positional vertigo:  
 2899 prospective, randomised study. *J Laryngol Otol.* 2011 Jun;125(6):572-5. doi:  
 2900 10.1017/S0022215110002781. Epub 2011 Jan 27.

2901 Teixeira LJ, Machado JN. Maneuvers for the treatment of benign positional paroxysmal vertigo:  
 2902 a systematic review. *Rev Bras Otorrinolaringol (Engl Ed)* 2006;72:130-9.

2903 Telian SA, Shepard NT. Update on vestibular rehabilitation therapy. *Otolaryngol Clin North Am*  
 2904 1996;29:359-71.

2905 test. *Arch Phys Med Rehabil.* 1986;67:387-389.

2906 Thorp MA, Shehab ZP, Bance ML, et al. The AAO-HNS Committee on Hearing and  
 2907 Equilibrium guidelines for the diagnosis and evaluation of therapy in Ménière's disease: have  
 2908 they been applied in the published literature of the last decade? *Clin Otolaryngol Allied Sci*  
 2909 2003;28:173-6.

2910 Tilling LM, Darawil K, Britton M. Falls as a complication of diabetes mellitus in older people. *J*  
 2911 *Diabetes Complications* 2006;20:158-62.

2912 Tinetti ME, Speechley M, Ginter SF: Risk factors for falls among elderly persons living in the  
 2913 community. *N Engl J med* 1988; 319: 1701-1707.

2914 Tinetti ME, Williams TF, Mayewski R, Fall Risk Index for elderly patients based on number of  
 2915 chronic disabilities. *Am J Med* 1986;80:429-434.

2916 Tirelli G, Russolo M. 360-Degree canalith repositioning procedure for the horizontal canal.  
 2917 Otolaryngol Head Neck Surg 2004;131:740-6.

2918 Toledo H, Cortes ML, Pane C, et al. Semont maneuver and vestibular rehabilitation exercises in  
 2919 the treatment of benign paroxysmal postural vertigo. A comparative study. Neurologia  
 2920 2000;15:152-7.

2921 Toupet M, Ferrary E, Bozorg Grayeli A. Effect of repositioning maneuver type and  
 2922 postmaneuver restrictions on vertigo and dizziness in benign paroxysmal positional vertigo.  
 2923 Scientific World Journal 2012;2012:162123.

2924 Turski P, Seidenwurm D, Davis P, et al. American College of Radiology: ACR appropriateness  
 2925 criteria: vertigo and hearing loss. In. Reston (VA): American College of Radiology; 1996. p. 8.

2926 Turski P, Seidenwurm D, Davis P, et al. American College of Radiology: Expert Panel on  
 2927 Neuroimaging: vertigo and hearing loss. In. Reston (VA): American College of Radiology; 2006.  
 2928 p. 8.

2929 Uneri A. Falling sensation in patients who undergo the Epley maneuver: a retrospective study.  
 2930 Ear Nose Throat J 2005;84:82, 84-5.

2931 Uneri A. Migraine and benign paroxysmal positional vertigo: an outcome study of 476 patients.  
 2932 Ear Nose Throat J 2004;83:814-5.

2933 van den broek EMJM, van der Zaag-Loonen HJ, Buintjes TD. Systematic Review: Efficacy of  
 2934 Gufoni Maneuver for Treatment of Laterl Canal BPPV with Geotropic Nystagmus. Otol HNS  
 2935 2014; 150 (6): 933-938.

2936 Van der Zaag-Loonen HJ, van Leeuwen RB, Buintjes, TD, van Munster BC. Prevalence of  
 2937 unrecognized benign paroxysmal positional vertigo in older patients. Eur Arch Otorhinolaryngol.  
 2938 2015;272:1521-1524.

2939 Van Duijn JG et al. Rapid Systematic Review of the Epley Maneuver for Treating Posterior  
 2940 Canal Benign Paroxysmal Positional Vertigo. *Otolaryngol Head Neck Surg*. 2014;15D(6):925-  
 2941 32.

2942 Vannucchi P, Giannoni B, Pagnini P. Treatment of horizontal semicircular canal benign  
 2943 paroxysmal positional vertigo. *J Vestib Res* 1997;7:1-6.

2944 Viirre E, Purcell I, Baloh RW. The Dix-Hallpike test and the canalith repositioning maneuver.  
 2945 *Laryngoscope* 2005;115:184-7.

2946 von Brevern M, Bertholon P, Brandt T, Fife T, Imai T, Nuti D, Newman-Toker D. Benign  
 2947 paroxysmal positional vertigo: Diagnostic criteria. *J Vestib Res* 2015;25:105-17.

2948 von Brevern M, Lezius F, Tiel-Wilck K, et al. Benign paroxysmal positional vertigo: current  
 2949 status of medical management. *Otolaryngol Head Neck Surg* 2004;130:381-2.

2950 von Brevern M, Radtke A, Lezius F, et al. Epidemiology of benign paroxysmal positional  
 2951 vertigo: a population based study. *J Neurol Neurosurg Psychiatry* 2007;78:710-5.

2952 von Brevern M, Seelig T, Radtke A, et al. Short-term efficacy of Epley's manoeuvre: a double-  
 2953 blind randomised trial. *J Neurol Neurosurg Psychiatry* 2006;77:980-2.

2954 Wang H, Yu D, Song N, Yin S. Delayed diagnosis and treatment of benign paroxysmal  
 2955 positional vertigo associated with current practice. *Eur Arch Otorhinolaryngol* 2014; 271(2):261-  
 2956 4.

2957 White J, Savvides P, Cherian N, et al. Canalith repositioning for benign paroxysmal positional  
 2958 vertigo. *Otol Neurotol* 2005;26:704-10.

2959 White JA, Coale KD, Catalano PJ, et al. Diagnosis and management of lateral semicircular canal  
 2960 benign paroxysmal positional vertigo. *Otolaryngol Head Neck Surg* 2005;133:278-84.

2961 Whitney SL, Marchetti GF, Morris LO. Usefulness of the dizziness handicap inventory in the

2962 screening for benign paroxysmal positional vertigo. *Otol Neurotol* 2005;26:1027-33.

2963 Whitney SL, Morris LO. Multisensory impairment in older adults: evaluation and intervention.

2964 In: *Geriatric Otolaryngology*. Calhoun KH, Eibling DE, editors. New York: Taylor and Francis;

2965 2006. p. 115.

2966 Whitney SL, Rossi MM. Efficacy of vestibular rehabilitation. *Otolaryngol Clin North Am*

2967 2000;33:659-72.

2968 Whitney SL, Sparto PJ. Principals of vestibular physical therapy rehabilitation.

2969 *NeuroRehabilitation* 2011; 29: 157-166.

2970 Wolf M, Hertanu T, Novikov I, et al. Epley's manoeuvre for benign paroxysmal positional

2971 vertigo: a prospective study. *Clin Otolaryngol Allied Sci* 1999;24:43-6.

2972 Woodworth BA, Gillespie MB, Lambert PR. The canalith repositioning procedure for benign

2973 positional vertigo: a meta-analysis. *Laryngoscope* 2004;114:1143-6.

2974 Yimtae K, Srirompotong S, Sae-Seaw P. A randomized trial of the canalith repositioning

2975 procedure. *Laryngoscope* 2003;113:828-32.

2976 Yu,S, Liu F, Cheng Z, Wang Q. Association between osteoporosis and benign paroxysmal

2977 positional vertigo: a systematic review. *BMC Neurology*. 2014. May 20;14:110.

2978 Doi10.1186/1471-2377-14-110.